<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Gut Microbes</journal-id><journal-id journal-id-type="iso-abbrev">Gut Microbes</journal-id><journal-id journal-id-type="pmc-domain-id">1365</journal-id><journal-id journal-id-type="pmc-domain">gmic</journal-id><journal-title-group><journal-title>Gut Microbes</journal-title></journal-title-group><issn pub-type="ppub">1949-0976</issn><issn pub-type="epub">1949-0984</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11332652</article-id><article-id pub-id-type="pmcid-ver">PMC11332652.1</article-id><article-id pub-id-type="pmcaid">11332652</article-id><article-id pub-id-type="pmcaiid">11332652</article-id><article-id pub-id-type="pmid">39150897</article-id><article-id pub-id-type="doi">10.1080/19490976.2024.2387400</article-id><article-id pub-id-type="publisher-id">2387400</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities</article-title><alt-title alt-title-type="left-running-head">F. MARTINELLI AND I. THIELE</alt-title><alt-title alt-title-type="right-running-head">GUT MICROBES</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6635-6793</contrib-id><name name-style="western"><surname>Martinelli</surname><given-names initials="F">Filippo</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8071-7110</contrib-id><name name-style="western"><surname>Thiele</surname><given-names initials="I">Ines</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref><xref rid="aff0005" ref-type="aff">
<sup>e</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>a</label>School of Medicine, <institution-wrap><institution>University of Galway</institution></institution-wrap>, <city>Galway</city>, <country>Ireland</country></aff><aff id="aff0002"><label>b</label>Digital Metabolic Twin Centre, <institution-wrap><institution>University of Galway</institution></institution-wrap>, <city>Galway</city>, <country>Ireland</country></aff><aff id="aff0003"><label>c</label>The Ryan Institute, <institution-wrap><institution>University of Galway</institution></institution-wrap>, <city>Galway</city>, <country>Ireland</country></aff><aff id="aff0004"><label>d</label>School of Microbiology, <institution-wrap><institution>University of Galway</institution></institution-wrap>, <city>Galway</city>, <country>Ireland</country></aff><aff id="aff0005"><label>e</label><institution-wrap><institution>APC Microbiome Ireland</institution></institution-wrap>, <city>Cork</city>, <country>Ireland</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Ines Thiele <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Ines.thiele@universityofgalway.ie">Ines.thiele@universityofgalway.ie</email> School of Medicine, University of Galway, <addr-line>Orbsen Building, University Rd, Galway City</addr-line>, <city>Galway</city><postal-code>H91TK33</postal-code>, <country>Ireland</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>8</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><volume>16</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">451333</issue-id><elocation-id seq="234">2387400</elocation-id><pub-history><event event-type="pmc-release"><date><day>16</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>19</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 23:25:35.897"><day>28</day><month>08</month><year>2024</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>14</day><month>8</month><year>2024</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>14</day><month>8</month><year>2024</year></date></event><event event-type="received"><date><day>31</day><month>1</month><year>2024</year></date></event><event event-type="revised"><date><day>22</day><month>7</month><year>2024</year></date></event><event event-type="accepted"><date><day>25</day><month>7</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="KGMI_16_2387400.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="KGMI_16_2387400.pdf"/><abstract><title>ABSTRACT</title><p>This comprehensive review elucidates the pivotal role of microbes in drug metabolism, synthesizing insights from an exhaustive analysis of over two hundred papers. Employing a structural classification system grounded in drug atom involvement, the review categorizes the microbiome-mediated drug-metabolizing capabilities of over 80 drugs. Additionally, it compiles pharmacodynamic and enzymatic details related to these reactions, striving to include information on encoding genes and specific involved microorganisms. Bridging biochemistry, pharmacology, genetics, and microbiology, this review not only serves to consolidate diverse research fields but also highlights the potential impact of microbial drug metabolism on future drug design and <italic toggle="yes">in silico</italic> studies. With a visionary outlook, it also lays the groundwork for personalized medicine interventions, emphasizing the importance of interdisciplinary collaboration for advancing drug development and enhancing therapeutic strategies.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Gut microbiome</kwd><kwd>microbiota</kwd><kwd>microbial drug metabolism</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>European Research Council</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100000781</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>Horizon 2020</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100007601</institution-id></institution-wrap></funding-source><award-id>757922</award-id></award-group><award-group><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="open-funder-registry">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>1RF1AG058942</award-id></award-group><award-group><funding-source><institution-wrap><institution>Science Foundation Ireland</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100001602</institution-id></institution-wrap></funding-source></award-group><funding-statement>This study was funded by the European Research Council (ERC) under the European Union&#8217;s Horizon 2020 Research and Innovation Programme (757922) to IT, by the National Institute on Aging grants [1RF1AG058942 and 1U19AG063744], and by the Science Foundation Ireland under Grant number 12/RC/2273-P2.</funding-statement></funding-group></support-group><counts><fig-count count="6"/><ref-count count="243"/><page-count count="1"/><word-count count="9949"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p>Microbial drug metabolism is a fascinating research field that explores the intricate relationship between microorganisms and pharmaceutical compounds. Microbes, including bacteria, fungi, and other microorganisms, possess remarkable abilities to metabolize various drugs, impacting their effectiveness, toxicity, and pharmacokinetics.<sup><xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref></sup></p><p>Human drug metabolism can be divided into phase I and phase II metabolic reactions. Phase I reactions typically involve the modification of the drug molecule through processes, such as oxidation, reduction, hydrolysis, or dealkylation. These reactions can introduce functional groups or alter the chemical structure of the drug, influencing its pharmacological properties. On the other hand, phase II reactions involve the conjugation of drug metabolites with endogenous molecules, such as glucuronic acid, sulfate, and amino acids. These conjugation reactions increase the water solubility of the drug and facilitate its elimination from the body.<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup></p><p>Similarly, microbial drug metabolism involves the biotransformation of drugs through enzymatic reactions, leading to the formation of metabolites that may have altered pharmacological properties compared to the parent drug.<sup><xref rid="cit0004" ref-type="bibr">4</xref></sup> The impact of microbial drug metabolism in medicine cannot be overstated. In some cases, microbial metabolism is essential for the activation of prodrugs, which are inactive or minimally active compounds that require metabolic conversion to exert their therapeutic effects.<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> Microbial metabolism can also lead to the inactivation or degradation of drugs, reducing their effectiveness, or to the reactivation of specific metabolites elongating the drug effect, or to the production of toxic metabolites.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup></p><p>Microbes have also the ability to indirectly influence drug metabolism by modifying the host&#8217;s metabolic processes.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> Understanding the direct and indirect interplay between drugs and microbial enzymes is crucial for predicting drug-drug interactions, identifying potential toxicities, designing drugs with enhanced microbial stability, optimizing drug dosing regimens and ensuring their therapeutic efficacy, and developing new therapeutic strategies. The interplay between the host, drug, and microbial factors can lead to significant variability in drug response and treatment outcomes.<sup><xref rid="cit0008" ref-type="bibr">8</xref></sup> Continued research in this field will undoubtedly unlock new avenues for drug discovery and personalized medicine.</p><p>Various methods have been employed to explore drug metabolism by the gut microbiota.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup>
<italic toggle="yes">In vitro</italic> culture incubation of the microbes with various drugs is a fundamental approach, in which the microorganism is grown in a controlled environment. This approach allows for the observation of metabolic activities and the identification of specific species involved in the investigated drug metabolic pathway.<sup><xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0010" ref-type="bibr">10</xref></sup>
<italic toggle="yes">Ex vivo</italic> incubation with fecal samples is another valuable technique, especially in studying gut microbiota. By introducing the fecal sample into a suitable culture medium, researchers can analyze the microbial metabolic product and infer their role in specific pathways.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup> Additionally, <italic toggle="yes">in vivo</italic> studies involving the administration of antibiotics or the comparison of the metabolism of germ-free and control animals allow for the investigation of microbial involvement in metabolic processes.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> Furthermore, <italic toggle="yes">in vivo</italic> studies utilizing different routes of drug administration<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> provide data, on how the microbial community can affect drug metabolism as different administration routes may result in distinct interactions with the microbiota, impacting the overall drug metabolism.</p><p>However, these methods have several limitations. <italic toggle="yes">In vitro</italic> cultures might not fully mimic the complex environment of the intestine, showing metabolic abilities that do not accurately represent what would happen <italic toggle="yes">in vivo</italic>. For example, <italic toggle="yes">in vivo</italic> differences in drug uptake and the intestinal milieu can affect outcomes. Oppositely, <italic toggle="yes">in vivo</italic> studies may reveal microbial involvement in metabolism but often fail to identify the specific microbial species and enzymes responsible. Moreover, host factors and interindividual variability can influence results. Consequently, these approaches provide valuable insights into microbial metabolic pathways but necessitate cautious interpretation due to their inherent constraints in representing the intricate <italic toggle="yes">in vivo</italic> conditions and accurately pinpointing the responsible microorganisms and enzymes. A combination of <italic toggle="yes">in vitro</italic>, <italic toggle="yes">ex vivo</italic>, and <italic toggle="yes">in vivo</italic> methods is essential for identifying the microbes responsible for specific metabolic pathways, providing crucial knowledge for advancing our understanding of host-microbe interactions and designing targeted therapeutic strategies.<sup><xref rid="cit0002" ref-type="bibr">2</xref></sup></p><p>In recent years, advances in sequencing technologies and bioinformatics have revolutionized the study of microbiome.<sup><xref rid="cit0014" ref-type="bibr">14</xref></sup> Metagenomic approaches have allowed researchers to explore the collective metabolic potential of microbial communities, providing valuable clinical insights into the role of the human microbiome on a larger scale.<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup> For instance, extensive comparative genomic analysis of 25 genes known to encode for 15 enzymes involved in drug metabolism has been performed for 5,438 bacterial strains covering the metabolism of 98 drugs.<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> The identified drug reactions and pathways were included in genome-scale metabolic reconstructions, which additionally cover comprehensively the biochemical transformation in each strain, as encoded by its genome. This work enabled, for the first time, a large-scale <italic toggle="yes">in silico</italic> investigation of gut microbes and microbial communities involved in drug metabolism. This resource of genome-scale metabolic reconstructions, deemed AGORA2, can also be integrated with organ-resolved, sex-specific, whole-body human metabolic reconstructions,<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> thereby allowing for future analysis on host-microbiota drug co-metabolism. Such <italic toggle="yes">in silico</italic> analyses, complementing existing <italic toggle="yes">in vitro</italic>, <italic toggle="yes">ex vivo</italic>, and <italic toggle="yes">in vivo</italic> methods, could enhance our understanding of host-microbe interactions, guiding the development of microbiome-modulating therapies to optimize drug outcomes and minimize adverse effects in diverse patient populations. Computational tools and predictive models have been developed to simulate and predict microbial drug metabolism,<sup><xref rid="cit0018" ref-type="bibr">18</xref></sup> possibly aiding in the design and optimization of drug candidates.</p><p>Our review, with its extensive collection of gene information based on the extensive comparative genome (re-)annotation work done for the AGORA2 resource,<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> aims to provide a substantial resource for genetic analysis, such as the BLAST (Basic Local Alignment Search Tool) and GSEA (Gene Set Enrichment Analysis) analysis conducted by Zimmermann,<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> facilitating the refinement of taxonomic and functional analyses on microbial drug metabolism. Additionally, our comprehensive examination of the drug-transforming reactions and known associated microbes provide a valuable tool for researchers aiming to enhance genomic-scale metabolic models, ensuring a more precise depiction of microbial drug metabolism, and empowering future <italic toggle="yes">in silico</italic> studies. Furthermore, this review seeks to establish a knowledge base for forthcoming drug development studies and interventions in personalized medicine, with a specific consideration of the individual microbiome. This review not only elucidates the current state of knowledge in microbial drug metabolism but also attempts to provide future research with the indispensable tools and insights necessary to advance understanding in the intricate field of drug microbial metabolism.</p></sec><sec disp-level="1" id="s0002"><title>Direct effect of microbial metabolism</title><p>Direct microbial drug metabolism encompasses a diverse array of reactions, which can be categorized in different ways. From a chemical standpoint, reactions can be classified as azoreduction, deamination, phosphorolysis, hydrolysis, reduction, oxidation, decarboxylation, dehydroxylation, and acetylation. Alternatively, from a pharmacodynamic perspective, the reactions can be classified as activation, modulation, deactivation, toxification, and reactivation, based on the difference in the intrinsic pharmacological activity of the reaction&#8217;s reagents and products. Definitions of the chemical and pharmacodynamics terms can be found in Table S1.</p><p>Regarding the chemical approach, microbial drug metabolism predominantly involves reduction and hydrolysis reactions, although exceptions exist.<sup><xref rid="cit0019" ref-type="bibr">19</xref></sup> Reductions can have different electron donors and act on various drug moieties, and in some cases, the precise mechanism may not be fully understood due to the absence of genetic and enzyme mechanistic studies.<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> On the pharmacodynamic side, accurately classifying the reactions is challenging without knowing the specific activity of each produced metabolite.</p><p>For this review, we have chosen to organize the reactions based on a univocal classification based on the atoms involved in the broken or formed bond. When possible, additional details regarding the specific chemical aspect and pharmacological activity of each reaction are provided. This classification aims at facilitating the identification of other drugs, whose microbial metabolism remains unexplored, but may undergo similar metabolic pathways, and aid in recognizing the drug moiety that is subject to microbial metabolism. Such insights could prove valuable in evaluating microbial drug metabolism in the development of future pharmaceuticals. A summary of all the reactions described in this section, with associated taxonomical and genetic information, can be found in Table S2.</p><sec disp-level="2" id="s0002-s2001"><title>C-C bonds</title><sec disp-level="3" id="s0002-s2001-s3001"><title>Dihydropyrimidine reduction</title><p>Sixty years ago, bacterial enzymes capable of reductively breaking down pyrimidine have been discovered in <italic toggle="yes">Clostridium uracilicum</italic>.<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> The first reaction in this catabolic pathway is catalyzed by a dihydropyrimidine dehydrogenase (DPD). Subsequently, researchers have demonstrated the presence of DPD activity in various bacterial strains, such as <italic toggle="yes">Alcaligenes eutrophus</italic><sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> and <italic toggle="yes">Escherichia coli B</italic>.<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup> Two <italic toggle="yes">Escherichia coli</italic> iron-sulfur proteins, PreT and PreA, have been found to have approximately 30% identity to the <italic toggle="yes">N</italic>- and C-terminal portions of mammalian DPD, respectively, and the <italic toggle="yes">preT</italic> and <italic toggle="yes">preA</italic> genes form an operon structure in the genomes.<sup><xref rid="cit0024" ref-type="bibr">24</xref></sup> The incubation of 5-fluorouracil (5-FU), a chemotherapy drug, with <italic toggle="yes">E. coli</italic> MG1655 and <italic toggle="yes">Salmonella enterica</italic> LT2 showed production of dihydrofluorouracil (DHFU) confirming that the microbial NADH-dependent DPD can also target substituted dihydropyrimidines, such as 5-FU. Additionally, measurements of tumor growth after capecitabine (CAP), a 5-FU prodrug, administration in gnotobiotic mice showed reduced efficacy of the drug in <italic toggle="yes">preTA</italic><sup><italic toggle="yes">++</italic></sup>
<italic toggle="yes">E. coli</italic> colonized mice compared to <italic toggle="yes">&#916;preTA</italic> colonized ones<sup><xref rid="cit0025" ref-type="bibr">25</xref></sup> (<xref rid="f0001" ref-type="fig">Figure 1(A)</xref>). In contrast, the activity and specificity of NADPH-dependent DPD of <italic toggle="yes">Pseudomonas aeruginosa</italic> correlated to the <italic toggle="yes">pydX-pydA</italic> genes,<sup><xref rid="cit0024" ref-type="bibr">24</xref></sup> has yet to be tested with the 5FU drug and related compound, such as 5FU prodrugs or compounds with similar structures. The comparative genomic analysis revealed that the DPD enzyme may be present in 935/5,451 distinct strains, spanning 85 species, 35 genera, and three phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup>
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Microbial drug metabolizing reactions involving a C-C bond.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0001_PB.jpg"/></alternatives></fig></p><p>In conclusion, the NADH-dependent <italic toggle="yes">E. coli</italic> DPD, which is encoded by the <italic toggle="yes">preA-preT</italic> genes, plays a role in 5-FU and capecitabine therapies, by deactivating the metabolite and reducing its cytotoxic effect. The potential implications of <italic toggle="yes">pydX-pydA</italic> NADH-dependent bacterial reductases in this context remain understudied. It is also possible that NADPH-dependent DPDs could also influence the therapies involving other 5-FU precursors, such as tegafur, doxifluridine, floxuridine, and 5-fluorocytosine.</p></sec><sec disp-level="3" id="s0002-s2001-s3002"><title>Cardiac glycosides reduction</title><p>Forty years ago, gastrointestinal bacteria was determined responsible for the reductive metabolism of digoxin to its inactive form dihydrodigoxin.<sup><xref rid="cit0026" ref-type="bibr">26</xref></sup>
<italic toggle="yes">Eggerthella lenta</italic> (previously known as <italic toggle="yes">Eubacterium lentum</italic>) has subsequently been identified as the exclusive species responsible for this reductive metabolism. However, the high fecal concentrations level of <italic toggle="yes">E. lenta</italic> alone were not sufficient for the <italic toggle="yes">in vitro</italic> inactivation of digoxin.<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup> Furthermore, <italic toggle="yes">E. lenta</italic> has also been found responsible for the similar reduction of digitoxigenin and its aglycone derivatives, such as digitoxin.<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup> Successive transcriptional profiling, comparative genomics, and culture-based assays revealed a cytochrome-encoding two-gene operon: the cardiac glycoside reductase (<italic toggle="yes">cgr</italic>). This operon is upregulated by digoxin, inhibited by arginine, absent in non-metabolizing <italic toggle="yes">E. lenta</italic> strains, and predictive of digoxin inactivation by the human gut microbiome.<sup><xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0030" ref-type="bibr">30</xref></sup> Further investigation revealed an expanded 8-gene-cgr associated gene cluster with <italic toggle="yes">cgr2</italic> being sufficient for digoxin activation. The enzyme requires FADH and anaerobic conditions and has been found to reduce other cardiac glycosides, such as digitoxin, digoxigenin the aglycon of digoxin, ouabain and ouabagenin<sup><xref rid="cit0031" ref-type="bibr">31</xref></sup> (<xref rid="f0001" ref-type="fig">Figure 1(B)</xref>). The comparative genomic analysis confirmed <italic toggle="yes">E. lenta</italic> as the exclusive microbe having the cgr operon (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec><sec disp-level="3" id="s0002-s2001-s3003"><title>Other C=C reduction</title><p>The microbiota can also reduce deleobuvir, an experimental drug for the treatment of hepatitis C, into its main metabolite CD 6168 (<xref rid="f0001" ref-type="fig">Figure 1(C)</xref>).<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup> When the drug was incubated with liver microsomes or cytosol, the CD 6168 was not produced, but incubation with rat and human feces resulted in its formation. Furthermore, pseudo-germ-free (pGF) rat models showed a lower rate of reduction metabolism for deleobuvir compared to control rats.<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup> Although the specific microbe or enzyme responsible has not yet been identified, it is crucial to note that this reduction shares similarities with previously described alkene reductions, particularly the presence of an &#945;-&#946; unsaturated carbonylic compound. This similarity suggests that microbes might metabolize drugs with this common moiety through different enzymatic reactions involving electron donors, such as NADH or FADH. Further investigations on microbial reductions on drugs presenting an &#945;-&#946; unsaturated carboxylic acid moiety are essential to evaluate the drugs&#8217; efficacy and for future drug design purposes. Additionally, microbes from the <italic toggle="yes">Clostridium</italic> genera have been found capable of reducing the 4,5 double bond in progesterone<sup><xref rid="cit0033" ref-type="bibr">33</xref></sup> and cortisol<sup><xref rid="cit0034" ref-type="bibr">34</xref></sup> through the action of stereospecific ketosteroid reductases (<xref rid="f0001" ref-type="fig">Figure 1(C)</xref>). So far, the responsible genes have not been identified.</p></sec><sec disp-level="3" id="s0002-s2001-s3004"><title>Dianthrone reduction</title><p>It has been shown that different species, such as <italic toggle="yes">Clostridium sphenoides, Clostridium, butyricum, Bifidobacterium adolescentis, Eubacterium rectale, Eubacterium limosum, Egghertella lenta</italic>, and <italic toggle="yes">Peptostreptococcus intermedius</italic> can activate sennosides and sennidins, converting them to rheinanthrone (<xref rid="f0001" ref-type="fig">Figure 1(D)</xref>).<sup><xref rid="cit0035" ref-type="bibr">35&#8211;37</xref></sup> This activation occurs through an enzymatic reduction carried by sennidin reductase, first isolated from <italic toggle="yes">P. intermedius</italic>.<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup> This enzyme requires NADH as an electron donor and FAD or FMN as electron carriers. However, genes encoding the identified enzyme have yet to be discovered.</p></sec><sec disp-level="3" id="s0002-s2001-s3005"><title>Aromatic amino acid decarboxylation and degradation</title><p>The primary treatment for Parkinson&#8217;s disease, the second most common neurodegenerative disease, is levodopa (L-3,4,dihydroxyphenylalanine or L-DOPA). It has been already noted 50&#8201;years ago that the gut microflora can decarboxylate L-DOPA.<sup><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0040" ref-type="bibr">40</xref></sup> The gene and structure of the enzyme involved in tyrosine decarboxylation have been identified: the enzyme is coded by the <italic toggle="yes">tyrDC</italic> gene, is a pyridoxal-5-phosphate (PLP) dependent tyrosine decarboxylase (TyrDC) and is found in the genome of various bacteria, such as <italic toggle="yes">Lactobacillus</italic> and <italic toggle="yes">Enterococcus</italic><sup><xref rid="cit0041" ref-type="bibr">41&#8211;43</xref></sup> (<xref rid="f0001" ref-type="fig">Figure 1(E)</xref>). TyrDC can also decarboxylate levodopa.<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup> Studies linking fecal microbial tyrosine decarboxylases to levodopa levels, clinical variables, and treatment response in Parkinson&#8217;s disease<sup><xref rid="cit0044" ref-type="bibr">44&#8211;46</xref></sup> prove that the activity of gut microbiota&#8217;s TyrDC may interfere with L-DOPA availability and therapeutic efficacy.</p><p>Carbidopa, a decarboxylase inhibitor, is commonly used in combination with L-DOPA to reduce decarboxylation of the drug by human enzymes to increase L-DOPA availability,<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup> but it was ineffective against <italic toggle="yes">Enterococcus faecalis</italic> TyrDC.<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup> Instead, (S)-&#945;-fluoromethyltyrosine (AFMT), a tyrosine mimic, has been found to prevent decarboxylation by <italic toggle="yes">E. faecalis&#8217;</italic> TyrDC.<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup></p><p>Based on comparative genomics, 475/5,451 microbial genomes, encode for the TyrDC enzyme, spanning 20 species, 7 genera, and one phylum, identifying Firmicutes as the exclusive phylum harboring this drug metabolizing capabilities (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p><p>Additionally, two enzymes from <italic toggle="yes">Clostridium sporogenes</italic> and <italic toggle="yes">Ruminococcus gnavus</italic>, respectively encoded by <italic toggle="yes">CLOSPO_02083</italic> and <italic toggle="yes">RUMGNA_01526</italic> genes, can decarboxylate a different aromatic amino acid, tryptophan, to form the &#946;-arylamine neurotransmitter tryptamine<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup> (<xref rid="f0001" ref-type="fig">Figure 1(E)</xref>). Similarly, to the inhibition of TyrDC, (S)-&#945;-fluoromethyltryptophan can inhibit <italic toggle="yes">R. gnavus</italic> tryptophan decarboxylase.<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup> A different degradation of tryptophan is performed by the bacterial enzyme tryptophanase encoded by the gene <italic toggle="yes">tnaA</italic>. The enzyme was first purified from <italic toggle="yes">E. coli</italic>. It is pyridoxal phosphate (PLP) dependent and catalyzes the degradation of tryptophan into indole, pyruvate, and ammonia via &#945;,&#946;-elimination and &#946;-replacement<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> (<xref rid="f0001" ref-type="fig">Figure 1(E)</xref>). No comparative genomic analysis has been carried out for these genes.</p></sec><sec disp-level="3" id="s0002-s2001-s3006"><title>Side-chain cleavage</title><p>Forty years ago, it was recognized that human feces can remove the side chain of cortisol.<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup> Later, <italic toggle="yes">Clostridium scindens</italic> was identified as one of the microbes capable of performing this reaction, with its activity relying on manganese ion and NAD<sup>+</sup> or NADH.<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup> More recently, the genes <italic toggle="yes">desA</italic> and <italic toggle="yes">desB</italic> have been identified in <italic toggle="yes">C. scindens</italic> as responsible for encoding the corresponding enzyme.<sup><xref rid="cit0052" ref-type="bibr">52</xref></sup> Furthermore, <italic toggle="yes">Propionimicrobium lymphophilum</italic>, a bacterium found in the urinary tract, also carries these genes and has the demonstrated ability to remove the side chain of prednisone, prednisolone, dexamethasone, and fludrocortisone, synthetic pharmaceutical derivatives of cortisol, by releasing glycolaldehyde<sup><xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0052" ref-type="bibr">52</xref></sup> (<xref rid="f0001" ref-type="fig">Figure 1(F)</xref>). Note that the comparative genomics study did not include these gene. This pathway may have implications for glucocorticoid therapy and diseases, such as prostate cancer, as it could potentially contribute as a source of androgens.<sup><xref rid="cit0053" ref-type="bibr">53</xref></sup></p></sec></sec><sec disp-level="2" id="s0002-s2002"><title>C-N bonds</title><sec disp-level="3" id="s0002-s2002-s3001"><title>Lactam hydrolysis</title><p>Over 80&#8201;years ago, it was recognized that a bacterial enzyme was responsible for breaking down penicillin preparations.<sup><xref rid="cit0054" ref-type="bibr">54</xref>,<xref rid="cit0055" ref-type="bibr">55</xref></sup> To-date, we have a deeper understanding that microbial &#946;-lactamases play a significant role in hydrolyzing the amide bond of the four-membered &#946;-lactam ring.<sup><xref rid="cit0056" ref-type="bibr">56</xref></sup> These enzymes are the primary culprits behind the resistance to beta-lactam antibiotics, including penicillins, cephalosporins, carbapenems, and monobactams<sup><xref rid="cit0056" ref-type="bibr">56</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2(A)</xref>). &#946;-lactamases are categorized into four classes: active-site serine &#946;-lactamases (classes A, C, and D) and zinc-dependent or metallo-&#946;-lactamases (MBLs; class B) and different genes (<italic toggle="yes">bla, ctx, tem, ampC, shv, kpc, vim, cmy, adc, oxa</italic>) encode these enzymes, leading to varying substrate specificity.<sup><xref rid="cit0057" ref-type="bibr">57</xref></sup>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Microbial drug metabolizing reactions involving an amide bond. *&#946;-lactamases activity varies from drug to drug. 2A shows only the core structures of drugs that can be modified by &#946;-lactamases.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0002_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0002_PB.jpg"/></alternatives></fig></p><p>To combat antimicrobial resistance and broaden the efficacy of antibiotics, a common approach is to co-administer beta-lactam antibiotics with microbial beta-lactamase inhibitors, such as clavulanic acid.<sup><xref rid="cit0058" ref-type="bibr">58</xref></sup> This strategy helps to prevent the degradation of the antibiotics by &#946;-lactamases, thereby extending their spectrum of activity against resistant bacteria.<sup><xref rid="cit0059" ref-type="bibr">59</xref></sup> New microbial MBL inhibitors are constantly investigated and developed to overcome antibiotic resistance.<sup><xref rid="cit0060" ref-type="bibr">60</xref></sup></p></sec><sec disp-level="3" id="s0002-s2002-s3002"><title>Bile acid amino acid conjugate hydrolysis</title><p>Bile acids are natural compounds produced in the liver and stored in the gallbladder. They aid in the digestion and absorption of lipophilic nutrients and drugs in the small intestine.<sup><xref rid="cit0061" ref-type="bibr">61</xref></sup> They play essential roles in cholesterol metabolism and the elimination of waste products from the body.<sup><xref rid="cit0062" ref-type="bibr">62</xref></sup> Bile acid therapy is used for gallstones, but it has also been proven useful in the treatment of primary biliary cholangitis, liver diseases, and liver-associated metabolic diseases.<sup><xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0064" ref-type="bibr">64</xref></sup></p><p>Microbial bile salt hydrolases (BSHs), which catalyze the deconjugation of C-24 amino acid conjugated bile acids, have been isolated and/or characterized from several species of intestinal bacteria<sup><xref rid="cit0065" ref-type="bibr">65</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2(B)</xref>). Homologs and putative <italic toggle="yes">bsh</italic> genes, such as <italic toggle="yes">cbh</italic>, have also been identified.<sup><xref rid="cit0066" ref-type="bibr">66</xref></sup> It has been hypothesized that deconjugation may be a mechanism of the detoxification of bile salts due to their antimicrobial activity.<sup><xref rid="cit0067" ref-type="bibr">67</xref></sup></p><p>In a recent study, bile salt hydrolases (BSHs) in the human microbiota have been investigated for their diversity and activity levels across 11 different human populations revealing a widespread presence of BSH protein sequences among intestinal bacteria, with significant variations observed across the populations.<sup><xref rid="cit0068" ref-type="bibr">68</xref></sup> Moreover, Song et al. identified distinct phylotypes of the BSH enzyme in these populations with different activity and distribution, highlighting the diversity and potential functional implications of these microbial enzymes in human health.<sup><xref rid="cit0068" ref-type="bibr">68</xref></sup> Accordingly, the comparative genomic analysis identified the presence of the <italic toggle="yes">bsh</italic> gene in 530/5,451 microbial genomes, spanning 178 species, 62 genera, and six phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0069" ref-type="bibr">69</xref></sup></p></sec><sec disp-level="3" id="s0002-s2002-s3003"><title>Glutathione conjugates amide bond hydrolysis</title><p>Glutathione (GSH) conjugation is a common process for many drugs. Both human and microbial enzymes can degrade glutathione conjugate compounds and also glutathione.<sup><xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0071" ref-type="bibr">71</xref></sup> Studies on gnotobiotic rats and mice have shown the involvement of the microbiota in this process.<sup><xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0073" ref-type="bibr">73</xref></sup> In this catabolic pathway, the initial two reactions lead to the release of glutamic acid and glycine from the GSH residue. The first reaction is facilitated by the &#947;-glutamyltransferase enzyme (GGT), encoded by the <italic toggle="yes">ggt</italic> gene, with homologues found in <italic toggle="yes">E. coli, Helicobacter pylori</italic>, and <italic toggle="yes">Bacillus subtilis</italic>.<sup><xref rid="cit0073" ref-type="bibr">73&#8211;76</xref></sup> The second reaction involves hydrolysis catalyzed by peptidases with cysteinylglycinase activity.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup> Peptidase A, B, D, and N of <italic toggle="yes">E. coli</italic>, encoded, respectively, by the <italic toggle="yes">pepA, pepB, pepD</italic>, and <italic toggle="yes">pepN</italic> genes, have shown cysteinylglycinase activity, but no study was conducted on cysteinylglycine drug conjugated compounds.<sup><xref rid="cit0077" ref-type="bibr">77</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2(C)</xref>). No comparative genomic analysis has been carried out for these genes.</p></sec><sec disp-level="3" id="s0002-s2002-s3004"><title>Other amide bond hydrolysis</title><p>Other hydrolysis reactions of amide bonds that are not part of the glutathione degradation pathway can also be performed by gut bacteria. For instance, protein therapeutics, such as azetirelin,<sup><xref rid="cit0078" ref-type="bibr">78</xref></sup> insulin,<sup><xref rid="cit0079" ref-type="bibr">79</xref></sup> and calcitonin,<sup><xref rid="cit0080" ref-type="bibr">80</xref></sup> can be degraded by the intestinal microflora. To avoid microbial degradation, protein drugs are administered intravenously. However, smaller drugs that are administered orally and that have an amide bond can be affected by microbial metabolism. For example, the succinylsulfathiazole prodrug needs to be activated by amidases into sulfathiazole, an antimicrobial for the gastrointestinal tract, with the release of the succinyl group<sup><xref rid="cit0081" ref-type="bibr">81</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2(D)</xref>). Other examples of drugs having an amide bond are methotrexate, which is deactivated with the release of a pteroic acid derivative and glutamic acid;<sup><xref rid="cit0082" ref-type="bibr">82</xref>,<xref rid="cit0083" ref-type="bibr">83</xref></sup> and chloramphenicol, which can be deactivated by <italic toggle="yes">E. coli</italic><sup><xref rid="cit0084" ref-type="bibr">84</xref></sup> by the gene estDL136<sup><xref rid="cit0085" ref-type="bibr">85</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2(D)</xref>). No comparative genomic analysis has been performed for this gene.</p><p>Microbes have also been found to degrade drug molecules that have an amide bond between a carboxylic acid and an aniline as is the case for paracetamol, phenacetin, bucetin, and other acetanilide derivatives<sup><xref rid="cit0086" ref-type="bibr">86</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2(D)</xref>). The breakage of the amide bond occurred in many N-acyl aniline derivatives, although N-benzoyl substituted anilines were not as well deacylated as was the case for anilines para-substituted with aromatic compound or halide groups.<sup><xref rid="cit0086" ref-type="bibr">86</xref></sup> The responsible enzymes involved in this degradation are currently understudied.</p></sec><sec disp-level="3" id="s0002-s2002-s3005"><title>Nitrile hydration</title><p>Nitrile hydratase (NHase) belongs to a class of metalloenzymes that catalyze the transformation of a nitrile compound by acting on its triple bond, converting it first into an amide and then into a carboxylic acid with the release of ammonia (<xref rid="f0002" ref-type="fig">Figure 2(E)</xref>). The initial identification of this enzyme occurred in the bacterium <italic toggle="yes">Rhodococcus rhodochrous J1</italic>.<sup><xref rid="cit0087" ref-type="bibr">87</xref></sup> After the discovery, many other microbes, including gut commensals, such as <italic toggle="yes">Enterococcus faecalis</italic> and <italic toggle="yes">Pseudomonas spp</italic>., have been found able to perform similar reactions<sup><xref rid="cit0088" ref-type="bibr">88</xref></sup> and additionally, two different enzymes encoded by the nitrilase (nit) and the nitrile hydratase (nthAB) genes have been found responsible for catalyzing this reaction.<sup><xref rid="cit0089" ref-type="bibr">89</xref></sup> While these enzymes are of great interest for industrial application, their involvement in the metabolism of drugs containing a nitrile group, such as anastrozole, citalopram, and vildagliptin, remains understudied.<sup><xref rid="cit0090" ref-type="bibr">90</xref></sup> No comparative genomic analysis has been carried out for these genes.</p></sec><sec disp-level="3" id="s0002-s2002-s3006"><title>Cytosine deamination</title><p>Flucytosine, a nucleotide analogue, is an antifungal medication that excerpts its activity after being converted into its cytostatic metabolite 5-fluorouracil after absorption into microorganism cells. The cytosine deaminase enzyme responsible for this amido hydrolyzation was purified from <italic toggle="yes">Saccharomyces cerevisiae</italic>.<sup><xref rid="cit0091" ref-type="bibr">91</xref></sup> Its species-specific metabolism is essential for its antifungal action, but gut microbes can also perform the reaction. The corresponding gene <italic toggle="yes">codA</italic> has been identified in <italic toggle="yes">Escherichia coli</italic><sup><xref rid="cit0092" ref-type="bibr">92</xref></sup> (<xref rid="f0003" ref-type="fig">Figure 3(A)</xref>), and this microbial activity could lead to possible side effects of the drugs.<sup><xref rid="cit0093" ref-type="bibr">93</xref></sup> Novel findings have shown that bacterial deaminases are less efficient in degrading 5-fluoroisocytosine rather than flucytosine, and hence, it is hypothesized that the use of fluoro-isocytosine would produce fewer side effects.<sup><xref rid="cit0094" ref-type="bibr">94</xref></sup> Interestingly, the discovery of cytosine deaminase as a drug-metabolizing enzyme improved cancer therapies. Using purified cytosine deaminase in combination with flucytosine in anticancer treatment instead of 5-fluorouracil by itself led to the reduction of toxic effects, improving the specificity of the toxic metabolite action. Exploring the biochemical properties of the cytosine deaminase and its isoforms could lead to further improvement in cancer therapy.<sup><xref rid="cit0095" ref-type="bibr">95</xref></sup> The comparative genomic analysis identified the cytosine deaminase enzyme across 2,317/5,451 distinct strains, spanning 239 species, 109 genera, and nine phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup>
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><p>Microbial drug metabolising reactions involving C-N bonds.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0003_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0003_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="3" id="s0002-s2002-s3007"><title>Cytidine deamination</title><p>Microbial deamination can also happen on nucleoside analogues, such as gemcitabine. <italic toggle="yes">Mycoplasma hyorhinis&#8217;</italic> cytidine deaminase is more catalytically active than its human equivalent in the deamination of gemcitabine.<sup><xref rid="cit0096" ref-type="bibr">96</xref></sup> Additionally, deactivation of gemcitabine has been found in incubation with human faces or <italic toggle="yes">Escherichia coli</italic> suspension<sup><xref rid="cit0097" ref-type="bibr">97</xref></sup> (<xref rid="f0003" ref-type="fig">Figure 3(A)</xref>). Finally, a study on colon cancer mice showed that Gammaproteobacterial cytidine deaminase expression, encoded by the <italic toggle="yes">cdd</italic> gene, induced gemcitabine resistance showing that intratumor bacteria can contribute to the therapy efficacy.<sup><xref rid="cit0098" ref-type="bibr">98</xref></sup> Based on comparative genomics, 660/5,451 microbial genomes, spanning 660 species, 224 genera, and 12 phyla, carry the <italic toggle="yes">cdd</italic> gene (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec><sec disp-level="3" id="s0002-s2002-s3008"><title>Pyrimidine-nucleosidase phosphorolysis</title><p>Nucleoside analogues can also undergo phosphorolysis with the breaking of the bond between the nucleoside and the sugar. This reaction is catalyzed by pyrimidine-nucleosidase phosphorylase, encoded by the <italic toggle="yes">pdp</italic> gene and present in <italic toggle="yes">Escherichia coli</italic> and many <italic toggle="yes">Bacteroides</italic> species, and has been found involved in the metabolism of sorivudine<sup><xref rid="cit0099" ref-type="bibr">99</xref></sup> and brivudine<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> (<xref rid="f0003" ref-type="fig">Figure 3(B)</xref>), with both drugs leading to the formation of the toxic compound bromovinyluracil. While interesting, no study on the bacterial-driven phosphorolysis of other oral-administered nucleoside analogues, such as zidovudine or tegafur, has been performed yet. Overall, the brivudine/sorivudine hydrolyzing enzyme has been found in 189/5,451 distinct strains, spanning 127 species, 18 genera, all belonging exclusively to the Bacteroidetes phylum (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec><sec disp-level="3" id="s0002-s2002-s3009"><title>Ring-opening (benzodiazepine and imidazole)</title><p>Incubation with human feces has suggested the ability of the microbiome to hydrolyze the benzodiazepine ring of diazepam and bromazepam, two drugs used in the treatment of anxiety<sup><xref rid="cit0100" ref-type="bibr">100</xref></sup> (<xref rid="f0003" ref-type="fig">Figure 3(C)</xref>). Additionally, degradation metabolites of the imidazole ring of metronidazole and misonidazole have been found in the feces of conventional rats while being not detectable in the excretion of germ-free rats.<sup><xref rid="cit0101" ref-type="bibr">101</xref>,<xref rid="cit0102" ref-type="bibr">102</xref></sup> Through an unspecified mechanism, metronidazole is degraded into <italic toggle="yes">N</italic>-(2-hydroxyethyl)-oxamic acid with the probable release of acetamide.<sup><xref rid="cit0102" ref-type="bibr">102</xref></sup> Misonidazole instead is degraded into acetic acid derivatives and urea after the initial reduction of the nitro group to obtain the aminoimidazole (AIM)<sup><xref rid="cit0101" ref-type="bibr">101</xref></sup> (<xref rid="f0003" ref-type="fig">Figure 3(C)</xref>). None of the responsible genes or microbes have been identified so far.</p></sec><sec disp-level="3" id="s0002-s2002-s3010"><title>N-demethylation</title><p>N-demethylation by bacteria has been observed for methamphetamine and imipramine showing that N-demethylase activity is common among bacteria<sup><xref rid="cit0103" ref-type="bibr">103</xref>,<xref rid="cit0104" ref-type="bibr">104</xref></sup> (<xref rid="f0003" ref-type="fig">Figure 3(D)</xref>). Additionally, demethylation of different purine alkaloids, including caffeine has been observed in <italic toggle="yes">Pseudomonas putida</italic>, and it is attributed to the activity of methylxanthine N-demethylases encoded by <italic toggle="yes">ndm(A/B/C/D)</italic> genes<sup><xref rid="cit0105" ref-type="bibr">105</xref></sup> (<xref rid="f0003" ref-type="fig">Figure 3(D)</xref>). No comparative genomic analysis has been performed for this gene. While this transformation has little consequences when the drugs are rapidly absorbed, it could still be of interest for less rapidly absorbed drugs.</p></sec></sec><sec disp-level="2" id="s0002-s2003"><title>C-O bonds</title><sec disp-level="3" id="s0002-s2003-s3001"><title>Glycosides hydrolysis</title><p>Gut bacteria are known to metabolize non-digestible dietary carbohydrates<sup><xref rid="cit0106" ref-type="bibr">106</xref></sup> and these capabilities can imply the metabolism of glycosidic drugs. Many drugs undergo glucuronidation by human UDP-glucuronosyltransferases to be deactivated and excreted.<sup><xref rid="cit0107" ref-type="bibr">107</xref></sup> Microbes, through the action of &#946;-glucuronidase enzymes, can remove the glucuronide moiety reactivating the drugs and altering their excretion rate (<xref rid="f0004" ref-type="fig">Figure 4(A)</xref>). The involvement of the microbe is known in the case of morphine,<sup><xref rid="cit0108" ref-type="bibr">108</xref></sup> camptothecin,<sup><xref rid="cit0109" ref-type="bibr">109</xref></sup> and estrogens.<sup><xref rid="cit0110" ref-type="bibr">110</xref></sup> Moreover, the inhibition of microbial &#946;-glucuronidase by antibiotics or specific inhibitors has been suggested for regorafenib and irinotecan to increase their therapeutic efficacy and reduce their side effects.<sup><xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0112" ref-type="bibr">112</xref></sup> The microbial gene <italic toggle="yes">uidA</italic>, encoding a &#946;-glucuronidase enzyme, has been first identified in <italic toggle="yes">Escherichia coli</italic>.<sup><xref rid="cit0113" ref-type="bibr">113</xref></sup> Successively, a study on bacterial glucuronidase orthologs identified other genes and microbes that remove the glucuronide moiety from drugs with different substrate efficiency.<sup><xref rid="cit0114" ref-type="bibr">114</xref></sup> Accordingly, comparative genomics analysis identified the uidA gene across 1,553/5,451 microbial genomes, spanning 148 species, 47 genera, and six phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup>
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><p>Microbial drug metabolizing reactions involving C-O and C-S bonds. *epimerase activity shown in the picture represents the 7-epimerases acting on cholic acid and the 20-epimerase acting on cortisol. Other epimerases are known to act on hydroxy residues attached to carbon 3,12,17, and 20 of different steroid compounds.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0004_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0004_PB.jpg"/></alternatives></fig></p><p>Gut microbes can also metabolize lactulose, a prebiotic drug that stimulates the growth of beneficial bifidobacteria and lactobacilli used in the treatment of constipation, degrading it into fructose and glucose. A study involving 453 strains of bacteria commonly found in the human gut identified the gene for lactulose metabolism in 222 of them.<sup><xref rid="cit0115" ref-type="bibr">115</xref></sup> Additionally, the galactosidase could be identified in 2,663/5,451 distinct strains, spanning 505 species, 159 genera, and ten phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p><p>Other examples of glycosides hydrolysis include the removal of the rhamnosyl moiety of hesperidin by microbial rhamnosidases<sup><xref rid="cit0116" ref-type="bibr">116</xref></sup> as well as other flavonoid rhamnoglucosides, such as narcissin and rutin.<sup><xref rid="cit0117" ref-type="bibr">117</xref></sup> Microbial rhamnosidase structures were isolated from <italic toggle="yes">Clostridium stercorarium</italic><sup><xref rid="cit0118" ref-type="bibr">118</xref></sup> and <italic toggle="yes">Bacillus sp. GL1</italic><sup><xref rid="cit0119" ref-type="bibr">119</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(A)</xref>).</p><p>While microbial deglucuronidation could affect the metabolism of all the drugs that are glucuronidated by the host to increase their excretion, the other glycoside hydrolyses are mostly involved in the metabolism of herbal glycosidic drugs, such as sennosides,<sup><xref rid="cit0036" ref-type="bibr">36</xref></sup> rutin, known also as quercetin-glycoside,<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0121" ref-type="bibr">121</xref></sup> and calycosin-glycoside,<sup><xref rid="cit0122" ref-type="bibr">122</xref></sup> and their effect on the efficacy of herbal medicines should be considered.</p></sec><sec disp-level="3" id="s0002-s2003-s3002"><title>Lactone hydrolysis</title><p>The microbiome has been found responsible for the lactone ring opening of lovastatin after incubation with human and rat feces while the formation of the active hydroxy acid metabolite decreased in the antibiotic-treated rat<sup><xref rid="cit0123" ref-type="bibr">123</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(B)</xref>). Other statins, such as mevastatin and simvastatin, are also administered as lactone-ring prodrugs and their activation also requires the opening of the lactone ring and could be influenced by the gut microbiota<sup><xref rid="cit0124" ref-type="bibr">124</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(B)</xref>). To-date, the responsible genes and microbes have not been identified.</p></sec><sec disp-level="3" id="s0002-s2003-s3003"><title>Ester bond hydrolysis</title><p>The esterase activity of the gut microbiota was already known 50&#8201;years ago. By comparing the metabolism of carbenoxolone, a drug used for peptic ulcer disease, in rats between oral and intraperitoneal administration and also by incubating the drug with rat feces, it has been concluded that the gut microflora is responsible for the hydrolysis to glycyrrhetic acid<sup><xref rid="cit0125" ref-type="bibr">125</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(C)</xref>). However, the responsible genes and microbes remain unknown.</p><p>Furthermore, a study on aspirin has shown a prolonged antithrombotic activity in mice when administered with ampicillin, an antibiotic, and human feces incubation of the drug showed the production of its deacetylated derivative, salicylic acid<sup><xref rid="cit0126" ref-type="bibr">126</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(C)</xref>). While this reaction may be catalyzed by esterases, with aspirin being a phenolic compound, we cannot exclude also the possible involvement of O-acetyltransferases present in many microbes part of the <italic toggle="yes">Staphylococcus, Enterococcus</italic>, and <italic toggle="yes">Lactobacillus</italic> genera.<sup><xref rid="cit0127" ref-type="bibr">127</xref></sup></p><p>In the case of diltiazem, a calcium channel blocker, it has been shown that its deacetylation is performed by <italic toggle="yes">Bacteroides thetaiotaomicron</italic> with the <italic toggle="yes">bt4096</italic> gene being responsible for the specific metabolic capability.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup></p></sec><sec disp-level="3" id="s0002-s2003-s3004"><title>O-demethylation</title><p>O-demethylation by gut microbes has been already evaluated 50&#8201;years ago. Through the incubation of different possible substrates with rat cecal microflora, it has been observed that methoxylated benzenoid compounds were demethylated. It has also been noted that compounds resistant to demethylation by the microflora were characterized by the absence of oxy-substitution in positions ortho to the methoxy group.<sup><xref rid="cit0086" ref-type="bibr">86</xref></sup> Successively, many acetogenic bacteria, such as <italic toggle="yes">Eubacterium limosum</italic> and <italic toggle="yes">Blautia producta</italic>, have been identified as responsible for this pathway,<sup><xref rid="cit0128" ref-type="bibr">128</xref></sup> but also non-acetogenic ones, such as <italic toggle="yes">Desulfitobacterium hafniense</italic> DCB-2<sup><xref rid="cit0129" ref-type="bibr">129</xref></sup> and their enzymes were identified as molybdenum-dependent O-methyltransferase.<sup><xref rid="cit0130" ref-type="bibr">130</xref></sup> Interestingly, 3-methoxytyramine has also been identified as a possible substrate of these enzymes, discovering an alternative pathway of acetogenic bacteria to produce dopamine<sup><xref rid="cit0131" ref-type="bibr">131</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(D)</xref>). Additionally, microbial O-demethylation was also observed for fostamatinib, but only after its initial para-O-demethylation by CYP enzymes suggesting that the presence of the free para-hydroxyl group is a structural requirement for meta-O-demethylation.<sup><xref rid="cit0132" ref-type="bibr">132</xref></sup> Lignans<sup><xref rid="cit0133" ref-type="bibr">133</xref></sup> are also demethylated by gut microbes and we may further hypothesize that this microbial driven O-demethylation may also occur in oral administered etoposide, a chemotherapy drug, due to its lignan-like structure.<sup><xref rid="cit0134" ref-type="bibr">134</xref></sup> None of the responsible genes have been identified so far.</p></sec><sec disp-level="3" id="s0002-s2003-s3005"><title>Catechol dehydroxylation</title><p>The demethylation of a methoxylated benzenoid, which presents an oxy-substitution in ortho to the methoxy group, generates pyrocatechols. These compounds are further metabolized by microbes via catechol dihydroxylation, as is the case for dopamine, a metabolite of levodopa,<sup><xref rid="cit0135" ref-type="bibr">135</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(D)</xref>), caffeic acid,<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup> fostamatinib,<sup><xref rid="cit0132" ref-type="bibr">132</xref></sup> and lignans.<sup><xref rid="cit0133" ref-type="bibr">133</xref></sup> It has been found that <italic toggle="yes">Eggerthella lenta</italic> molybdenum-dependent dopamine dehydroxylase is responsible for the conversion of dopamine into tyramine<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup> while there are currently no additional insights into the other compounds metabolism. Based on comparative genomics, the dopamine dehydroxylase enzyme could only be found in three distinct strains of two different species: <italic toggle="yes">E. lenta</italic> and <italic toggle="yes">Eggerthella sp. 1_3_56FAA</italic> (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec><sec disp-level="3" id="s0002-s2003-s3006"><title>Other dehydroxylation</title><p><italic toggle="yes">E</italic>. <italic toggle="yes">lenta</italic> also harbors a 21-dehydroxylase,<sup><xref rid="cit0136" ref-type="bibr">136</xref></sup> which can metabolize corticoids, such as cortisol and corticosterone but no responsible enzymes or genes have been identified so far<sup><xref rid="cit0137" ref-type="bibr">137</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(E)</xref>). Another important dihydroxylation performed by the microbes is the 7a-dehydroxylation of free bile acids. The ability is attributed to the <italic toggle="yes">Clostridium</italic> genera<sup><xref rid="cit0138" ref-type="bibr">138</xref></sup> and <italic toggle="yes">E. lenta</italic>,<sup><xref rid="cit0139" ref-type="bibr">139</xref></sup> which express the bile acid-inducible (<italic toggle="yes">bai</italic>) operon.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> In contrast to the straight-forward dopamine dihydroxylation, this specific conversion involves eight different reactions that compose a microbiome-derived pathway that has been recently shown to be able to be expressed and controlled heterologously<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(E)</xref>). Preliminary comparative genomic analysis on 693 microbial genomes revealed the presence of the bai operon in seven of the analyzed genomes.<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> The study has also identified new genes belonging to the same cluster and metabolic pathway. <italic toggle="yes">Clostridium scindens&#8217;s CLOSCI_00522 and CLOSCI_01264</italic>, respectively ortholog of <italic toggle="yes">E. lenta&#8217;s Elen_108</italic> and <italic toggle="yes">Elen_1016</italic> gene, have been suggested to be renamed <italic toggle="yes">baiO</italic> and <italic toggle="yes">baiP</italic>.<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> In a subsequent comparative genomics analysis, the gene has been identified in 33/5,451 microbial genomes, spanning 18 species, and 14 genera belonging to the Firmicutes and Actinobacteria phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec><sec disp-level="3" id="s0002-s2003-s3007"><title>Hydroxysteroid epimerisation</title><p>Microbes can also epimerize hydroxysteroids in a position-specific manner. Two hydroxysteroid dehydrogenases (HSDH) catalyze the oxidation of a specific hydroxy moiety followed by its reduction to generate the correspondent epimer.<sup><xref rid="cit0065" ref-type="bibr">65</xref></sup> Multiple microbes have been identified as producers of 3-, 7-, and 12(&#945;/&#946;)-HSDH responsible for the production of secondary bile acids<sup><xref rid="cit0141" ref-type="bibr">141</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(E)</xref>). While it has been previously believed that these enzymes could only act on non-conjugated bile acids, a recent study has shown that recombinant HSDHs from a novel identified gene cluster of <italic toggle="yes">E. lenta</italic> were able to utilize taurine and glycine conjugate bile acids as substrates.<sup><xref rid="cit0142" ref-type="bibr">142</xref></sup> The HSDH are position specific and cortisol, a steroid hormone, is a substrate of microbial 3(&#945;/&#946;)-HSDH as well of 17- and 20- (&#945;/&#946;)-HSDH, the latest known also as DesC/E<sup><xref rid="cit0034" ref-type="bibr">34</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(E)</xref>). Preliminary comparative genomic analysis on 693 microbial genomes revealed the presence of the 7&#945;-, 12&#945;-, 3&#945;-, 3&#946;-, and 7&#946;-HSDHs, respectively, in 46, 39, 17, 12, and three different genomes.<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> Successive more extensive analysis encompassing 5,451 microbial genomes, confirmed 7&#945;-HSDH to be the most widespread being found in 1,006 distinct strains, spanning 44 species, 18 genera, and six phyla, followed by 12&#945;-HSDH found in 18 species from four different phyla, 3&#945;-HSDH found in 17 species from two different phyla, 3&#946;-HSDH found in 10 species from four different phyla, confirming 7&#946;-HSDH as the rarest, found exclusively in C<italic toggle="yes">ollinsella aerofaciens</italic> and <italic toggle="yes">Mediterraneibacter gnavus</italic> (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec><sec disp-level="3" id="s0002-s2003-s3008"><title>C = O reduction</title><p>Microbial drug ketone reduction has been recently observed in the case of tacrolimus, with the reduced metabolite being 15-fold less potent than the immunosuppressant parent drug.<sup><xref rid="cit0143" ref-type="bibr">143</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(F)</xref>). <italic toggle="yes">Faecalibacterium prausnitzii</italic> was the first bacteria found with this metabolic capability and further screening of other bacteria species has shown that different microbes belonging to the <italic toggle="yes">Clostridiales</italic> or <italic toggle="yes">Bacteroidales</italic> order are also able to metabolize tacrolimus.<sup><xref rid="cit0143" ref-type="bibr">143</xref></sup> Additionally, nabumetone, a nonsteroidal anti-inflammatory drug (NSAID), is reduced and inactivated by gut microbes (<xref rid="f0004" ref-type="fig">Figure 4(F)</xref>), in particular by <italic toggle="yes">E. coli, Lactobacillus plantarum, Lactobacillus casei</italic>, and <italic toggle="yes">Parabacteroides distasonis</italic>.<sup><xref rid="cit0144" ref-type="bibr">144</xref></sup> However, the responsible genes remain unknown.</p></sec></sec><sec disp-level="2" id="s0002-s2004"><title>C-S bonds</title><sec disp-level="3" id="s0002-s2004-s3001"><title>Cysteine-S-conjugate degradation</title><p>Numerous drugs undergo detoxification through conjugation with glutathione (GSH), followed by microbial-mediated hydrolyses, to produce glycine conjugates. These hydrolyses have already been presented in the C-N bond section. Cysteine conjugates can be additionally metabolized into thiol conjugates through the action of cysteine S-conjugate &#946;-lyases that are also present in microbes, such as <italic toggle="yes">Eubacterium limosum</italic><sup><xref rid="cit0145" ref-type="bibr">145</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(G)</xref>). This enzyme degrades the cysteine conjugate into a thiol conjugate with the release of pyruvic acid and ammonia, similar to the tryptophanase described in the C-C bond section (<xref rid="f0001" ref-type="fig">Figure 1(E)</xref>). The remaining sulfur-containing fragments are normally more reactive than their parent compound, with the reaction representing a bioactivation or toxification mechanism. However, the host can deactivate and eliminate these active compounds through processes, such as methylation or glucuronidation.<sup><xref rid="cit0146" ref-type="bibr">146</xref></sup> The corresponding gene has yet to be identified.</p></sec><sec disp-level="3" id="s0002-s2004-s3002"><title>Ring-opening (imidazothiazole)</title><p>The microbiome can also cleave the C-S bond in the imidazothiazole ring, as in the case of levamisole, resulting in the production of the lactam derivative 2-oxo-3-(2-mercaptoethyl)-5-phenylimidazolidi (OMPI), which may be its active form<sup><xref rid="cit0147" ref-type="bibr">147</xref></sup> (<xref rid="f0004" ref-type="fig">Figure 4(H)</xref>). The incubation with individual bacterial strains has shown that the major metabolizing microbes were anaerobic bacteria from the <italic toggle="yes">Bacteroides</italic> and <italic toggle="yes">Clostridium</italic> genera.<sup><xref rid="cit0147" ref-type="bibr">147</xref></sup> The enzyme and mechanism of this reaction are still unclear and while the authors proposed the involvement of an oxidative pathway, due to its activity being seemingly more prevalent in anaerobic bacteria, we would suggest the possible involvement of a substrate-specific hydrolase instead.</p></sec></sec><sec disp-level="2" id="s0002-s2005"><title>N-N bonds</title><sec disp-level="3" id="s0002-s2005-s3001"><title>Azo compounds and hydrazones reduction</title><p>Gingell et al. have found that rats receiving prontosil or neoprontosil produced less sulfanilamide, a metabolite generated from the azo-bond reduction, when they were treated with antibiotics.<sup><xref rid="cit0148" ref-type="bibr">148</xref></sup> Furthermore, these results were more evident for neoprontosil, as it was more water-soluble and less rapidly absorbed in the gut.<sup><xref rid="cit0148" ref-type="bibr">148</xref></sup> While these two drugs are not commonly used anymore, other drugs containing an azo bond are still on the market. For instance, sulphasalazine is still used to treat autoimmune conditions, such as rheumatoid arthritis and inflammatory bowel disease.<sup><xref rid="cit0149" ref-type="bibr">149</xref></sup> Peppercorn et al. found that while germ-free rats did not metabolize sulphasalazine, conventional rats completely degraded the drug into sulphapyridine and mesalazine, the two products of the azo bond reduction<sup><xref rid="cit0150" ref-type="bibr">150</xref></sup> (<xref rid="f0005" ref-type="fig">Figure 5(A)</xref>). Additionally, the finding that gnotobiotic rats infected with four microbial species could degrade the drug further supports the hypothesis that microbes are responsible for the azo-bond reduction.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup> Subsequently, the crystal structure of the azoreductase (AzoR) isolated from <italic toggle="yes">Escherichia coli</italic> has been obtained, which suggested the requirement of NADH as an electron donor.<sup><xref rid="cit0151" ref-type="bibr">151</xref></sup> Furthermore, its similarity with quinone oxidoreductases suggested that the actual reduction site is not the azo bond itself, but the quinonimine moiety of mesalazine.<sup><xref rid="cit0152" ref-type="bibr">152</xref></sup> While this finding can be extended to other azo-bonded prodrugs, such as balsalazide (<xref rid="f0005" ref-type="fig">Figure 5(A)</xref>) and olsalazine,<sup><xref rid="cit0153" ref-type="bibr">153</xref>,<xref rid="cit0154" ref-type="bibr">154</xref></sup> there are still uncertainties about the substrate specificity and the pH sensibility of the enzyme and its isoforms.<sup><xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0156" ref-type="bibr">156</xref></sup>
<fig position="float" id="f0005" fig-type="figure" orientation="portrait"><label>Figure 5.</label><caption><p>Microbial drug metabolizing reactions involving N-N and N-O bonds.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0005_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0005_PB.jpg"/></alternatives></fig></p><p>Additionally, eltrombopag, a drug with a hydrazine bond linked to a quinonimine, can also be metabolized by gut microbes (<xref rid="f0005" ref-type="fig">Figure 5(A)</xref>).<sup><xref rid="cit0157" ref-type="bibr">157</xref></sup> We hypothesize that microbial azoreductases are responsible for this degradation. While the azo or hydrazine bond with a linked quinonimine seems important for the substrate specificity of the enzyme, the <italic toggle="yes">E. coli</italic> AzoR can also reduce nitro groups.<sup><xref rid="cit0158" ref-type="bibr">158</xref></sup> Furthermore, the levosimendan hydrazine-bond, even lacking a linked quinonimine moiety, can be reduced by bacteria, with the responsible enzyme being located in the lower parts of the gastrointestinal tract (<xref rid="f0005" ref-type="fig">Figure 5(A)</xref>).<sup><xref rid="cit0159" ref-type="bibr">159</xref></sup> The importance of microbial azoreductases does not stop at drug compounds because azo compounds are common in synthetic chemicals, particularly in food dyes and tattoo pigments.<sup><xref rid="cit0157" ref-type="bibr">157</xref></sup></p><p>So far, azoreductase has been identified in 78/5,451 microbial genomes spanning 22 species, 15 genera, and three phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec></sec><sec disp-level="2" id="s0002-s2006"><title>N-O bonds</title><sec disp-level="3" id="s0002-s2006-s3001"><title>Nitroreduction</title><p>The high levels of nitroreductase activity in intestinal bacteria are well-documented.<sup><xref rid="cit0160" ref-type="bibr">160</xref></sup> When clonazepam and nitrazepam were exposed to rat intestinal contents under both aerobic and anaerobic conditions, they were rapidly reduced to their amino derivatives.<sup><xref rid="cit0161" ref-type="bibr">161</xref>,<xref rid="cit0162" ref-type="bibr">162</xref></sup> Additionally, pretreatment of the animals with antibiotics decreased nitrazepam-induced teratogenicity, suggesting that the teratogenic effects of nitrazepam are dependent on nitroreduction by the intestinal microflora.<sup><xref rid="cit0161" ref-type="bibr">161</xref>,<xref rid="cit0162" ref-type="bibr">162</xref></sup> The reduction of nitrazepam has been first identified in <italic toggle="yes">Clostridium leptum</italic>.<sup><xref rid="cit0163" ref-type="bibr">163</xref></sup> A successive study of purified <italic toggle="yes">Escherichia coli</italic> recombinant nitroreductase (NfsB) revealed that flunitrazepam, nitrazepam, and clonazepam were all subject to nitroreduction mediated by NfsB (<xref rid="f0005" ref-type="fig">Figure 5(B)</xref>). Additionally, two other nitroreductases, from <italic toggle="yes">E. cloacae</italic> NR and from <italic toggle="yes">S. typhimurium</italic> cnr, could also perform the nitroreduction of flunitrazepam.<sup><xref rid="cit0164" ref-type="bibr">164</xref></sup></p><p>Nitrobenzodiazepines are not the only drugs that undergo nitroreduction. The inactivation of chloramphenicol through the reduction of its nitro group to an amino group by <italic toggle="yes">E. coli</italic> was identified 70&#8201;years ago (<xref rid="f0005" ref-type="fig">Figure 5(B)</xref>).<sup><xref rid="cit0165" ref-type="bibr">165</xref></sup> Subsequently, chloramphenicol has also been found to be reduced by <italic toggle="yes">Haemophilus influenzae</italic>&#8217;s nitroreductase.<sup><xref rid="cit0166" ref-type="bibr">166</xref></sup> This nitroreductase can confer bacterial resistance to chloramphenicol and perform incomplete reduction of metronidazole (<xref rid="f0005" ref-type="fig">Figure 5(B)</xref>) and nitrofurantoin antibiotics.<sup><xref rid="cit0167" ref-type="bibr">167</xref></sup></p><p>Taken together, microbial nitroreductases reduce the nitro group of different drugs to an amino group proceeding through a hydroxylamine derivative. The hydroxylamine derivatives are responsible for the antibiotic activity in the case of metronidazole and nitrofurantoin, and the teratogenic activity in the case of nitrobenzodiazepines. The amino derivatives are inactive and this complete reduction lowers the efficacy of the therapies.</p><p>Additionally, ranitidine and nizatidine, two H2-receptor antagonists containing a nitro group, are metabolized when incubated with human feces: UV and mass spectrometry analysis indicated that metabolism occurs via cleavage of an N-oxide bond within the molecules with the loss of an oxygen atom.<sup><xref rid="cit0168" ref-type="bibr">168</xref>,<xref rid="cit0169" ref-type="bibr">169</xref></sup> We hypothesize that microbial nitroreductases may be involved in this process.</p><p>Notably, microbial nitroreductases have applications beyond drug efficacy evaluation. They are used in gene-directed enzyme prodrug therapy, also known as suicide gene therapy.<sup><xref rid="cit0170" ref-type="bibr">170</xref></sup> By expressing the microbial gene exclusively in cancer cells, the location toxicity of the administered nitro pro-drug can be controlled.<sup><xref rid="cit0171" ref-type="bibr">171&#8211;173</xref></sup></p><p>Overall, nitroreductases could be identified in 4,206/5,451 microbial genomes, spanning 548 species, 187 genera, and 13 phyla (Table S3),<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> highlighting their broad distribution in human-associated microbes.</p></sec><sec disp-level="3" id="s0002-s2006-s3002"><title>N-oxide reduction</title><p>Microbes can also perform reduction on N-oxide moieties to produce their respective amines. Loperamide oxide is a prodrug which requires gut microbes to undergo reduction to loperamide, an effective antidiarrheic medication (<xref rid="f0005" ref-type="fig">Figure 5(C)</xref>).<sup><xref rid="cit0174" ref-type="bibr">174</xref></sup> Similarly, chlorpromazine N-oxide, an inactive metabolite of chlorpromazine, a psycholeptic drug, can be reactivated by microbes present in the intestinal and urinary tracts of rats (<xref rid="f0005" ref-type="fig">Figure 5(C)</xref>).<sup><xref rid="cit0175" ref-type="bibr">175</xref></sup></p><p>This pathway may also be relevant in phytotherapy because many alkaloids can have or be metabolized into N-oxide compounds, such as the case of indicine<sup><xref rid="cit0176" ref-type="bibr">176</xref></sup> or nicotine<sup><xref rid="cit0177" ref-type="bibr">177</xref></sup> and its derivatives 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).<sup><xref rid="cit0178" ref-type="bibr">178</xref></sup> Additionally, sorafenib (SRF) undergoes activation by CYP3A4, resulting in the formation of sorafenib N-oxide (SRF-Nox), which is utilized as a treatment for renal cell carcinoma.<sup><xref rid="cit0179" ref-type="bibr">179</xref></sup> One can hypothesize that the potential bacterial reduction of the N-oxide in the urinary tract may lead to a decrease in its effectiveness. No specific enzyme has been identified for the reduction of the aforementioned drugs, but we hypothesize an involvement of N-oxide reductases from the same family as the trimethylamine-N-oxide reductase and dimethyl sulfoxide reductase, encoded by <italic toggle="yes">torA</italic> and <italic toggle="yes">dmsA</italic>, respectively, in <italic toggle="yes">Escherichia coli</italic>.<sup><xref rid="cit0180" ref-type="bibr">180</xref>,<xref rid="cit0181" ref-type="bibr">181</xref></sup> No comparative genomic analysis has been carried out for these two genes.</p></sec><sec disp-level="3" id="s0002-s2006-s3003"><title>Nitrates degradation</title><p>Organic nitrates, such as nitroglycerin (glyceryl trinitrate) and isosorbide dinitrate, are used to improve angina pectoris symptoms and can be metabolized into their complete and incomplete alcoholic derivatives by mixed cultures of rat cecal contents (<xref rid="f0005" ref-type="fig">Figure 5(D)</xref>).<sup><xref rid="cit0182" ref-type="bibr">182</xref>,<xref rid="cit0183" ref-type="bibr">183</xref></sup> While no specific mechanism has been identified so far, some studies observed that the nitro group was liberated as nitrite, not nitrate, indicating a possible reductive mechanism.<sup><xref rid="cit0184" ref-type="bibr">184</xref>,<xref rid="cit0185" ref-type="bibr">185</xref></sup> The liberated nitrite is recycled in blood and tissue to form nitric oxide (NO) that retains the pharmacological action of the drugs,<sup><xref rid="cit0186" ref-type="bibr">186</xref></sup> so the microbial involvement could be significant for the activation of these drugs and their efficacy. The responsible microbial genes remain unknown.</p></sec><sec disp-level="3" id="s0002-s2006-s3004"><title>Ring-opening (benzisoxazole)</title><p>Zonisamide is metabolized through benzisoxazole ring reduction to form 2-sulphamoylacetylphenol.<sup><xref rid="cit0187" ref-type="bibr">187</xref></sup> A study involving antibiotic-treated rats suggested the involvement of intestinal bacteria in this reductive conversion. Using cell-free extracts of <italic toggle="yes">Clostridium sporogenes</italic>, significant drug-metabolizing activity has been observed and NADH or NADPH-dependent reduction of zonisamide has been demonstrated (<xref rid="f0005" ref-type="fig">Figure 5(E)</xref>).<sup><xref rid="cit0187" ref-type="bibr">187</xref></sup> Risperidone and paliperidone, two antipsychotics with a benzisoxazole moiety, also undergo benzisoxazole ring scission in their metabolic pathway in humans.<sup><xref rid="cit0188" ref-type="bibr">188</xref></sup> Bacterial involvement in their metabolism has been proven through a stability experiment, in which the drugs were incubated with sterile and bacterially inoculated porcine blood. While the drugs were stable in the sterile culture, they were degraded into their 2-hydroxybenzoyl derivatives in the bacterial culture (<xref rid="f0005" ref-type="fig">Figure 5(E)</xref>).<sup><xref rid="cit0189" ref-type="bibr">189</xref></sup> The responsible genes are currently not known.</p></sec></sec><sec disp-level="2" id="s0002-s2007"><title>S-O bonds</title><sec disp-level="3" id="s0002-s2007-s3001"><title>S-oxide reduction</title><p>Forty years ago, through a study of the metabolism of sulfinpyrazone in germ-free and antibiotic-treated rats, the involvement of the gut microbiota in the reduction of the S-oxide moiety of the drug was suggested.<sup><xref rid="cit0190" ref-type="bibr">190</xref></sup> Bacterial culture proved that <italic toggle="yes">Arthrobacter sp</italic>. ATCC 19,140 was able to reduce sulindac S-oxide moiety to sulfide (<xref rid="f0006" ref-type="fig">Figure 6(A)</xref>).<sup><xref rid="cit0191" ref-type="bibr">191</xref></sup> Further confirmation of the reductive metabolism was obtained through the incubation of sulfinpyrazone with human feces. It has been observed that the formation of sulindac and sulfinpyrazone sulfides was reduced in patients treated with metronidazole, an antibiotic and antiprotozoal medication. Additionally, screening of over 200 strains of bacteria isolated from human faces showed different reductive potential for the two drugs with both being reduced by mostly aerobic microbes (<xref rid="f0006" ref-type="fig">Figure 6(A)</xref>).<sup><xref rid="cit0192" ref-type="bibr">192</xref></sup> A study on <italic toggle="yes">Escherichia coli</italic> reductive potential showed the presence of different sulfoxide reductase systems with different substrate specificity and different cofactor requirements.<sup><xref rid="cit0193" ref-type="bibr">193</xref></sup> By testing different members of the thioredoxin-dependent methionine sulfoxide reductase (Msr) family, MsrA has been found to reduce sulindac to its active sulfide,<sup><xref rid="cit0194" ref-type="bibr">194</xref></sup> but other enzymes that are part of the molybdenum family can also reduce S-oxides and they have yet to been evaluated regarding their drug S-oxides reduction potential.<sup><xref rid="cit0195" ref-type="bibr">195</xref></sup> No comparative genomics analysis has been carried out for MsrA.
<fig position="float" id="f0006" fig-type="figure" orientation="portrait"><label>Figure 6.</label><caption><p>Microbial drug metabolizing reactions involving S-O, P-O bonds, and conjugations.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0006_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KGMI_A_2387400_F0006_PB.jpg"/></alternatives></fig></p><p>Other drugs, such as omeprazole, as well as other prazoles containing the S-oxide moiety, may also undergo S-oxide reduction by gut microbiota (<xref rid="f0006" ref-type="fig">Figure 6(A)</xref>).<sup><xref rid="cit0196" ref-type="bibr">196</xref></sup> The importance of this metabolic pathway is not only limited to the activation of S-oxide drugs but encompasses all the drugs that contain a sulfide group, which can undergo oxidation by CYP enzymes. The restoration of the initial sulfide group through reduction by gut microbiota has the potential to extend the activity of the drugs.</p></sec><sec disp-level="3" id="s0002-s2007-s3002"><title>Sulphate transfer</title><p>Sodium picosulphate undergoes conversion into 4,4&#8217;-dihydroxydiphenyl-(2-pyridyl)methane (DPM), a crucial component of the laxative (<xref rid="f0006" ref-type="fig">Figure 6(B)</xref>). Incubation with rat faces revealed the necessity of phenol for this transformation, indicating the involvement of a sulphotransferase enzyme that requires phenolic acceptors. In support of this finding, the reaction has been successfully catalyzed by a purified sulphotransferase from <italic toggle="yes">Eubacterium</italic> A-44.<sup><xref rid="cit0197" ref-type="bibr">197</xref></sup> Sulphotransferases have been identified in <italic toggle="yes">Streptomyces sp</italic>. MK730-62F2<sup><xref rid="cit0198" ref-type="bibr">198</xref></sup> and <italic toggle="yes">Salmonella enterica</italic> serovar Typhi IMSS-1,<sup><xref rid="cit0199" ref-type="bibr">199</xref></sup> with the <italic toggle="yes">assT</italic> gene encoding it in the latter. While the sulfate moiety is not common, many drugs undergo sulfation by the host to improve their hydrophilicity and subsequent elimination. The microbial reaction is significant for the activation of picosulphate and can also potentially modify the excretion pattern of drugs undergoing host sulfation, as it affects their hydrophilicity and elimination. No comparative genomics has been performed for the assT gene.</p></sec></sec><sec disp-level="2" id="s0002-s2008"><title>P-O bonds</title><sec disp-level="3" id="s0002-s2008-s3001"><title>Phosphate hydrolysis</title><p>Fostamatinib is rapidly hydrolyzed into its active metabolite R406 by the alkaline phosphatase in the gut (<xref rid="f0006" ref-type="fig">Figure 6(C)</xref>).<sup><xref rid="cit0132" ref-type="bibr">132</xref></sup> Alkaline phosphatases occur widely in nature, including in humans and bacteria.<sup><xref rid="cit0200" ref-type="bibr">200</xref></sup> While no specific microbes have been experimentally shown to activate fostamatinib, the alkaline phosphatase, encoded by microbial gene <italic toggle="yes">phoA</italic>, could be identified in 2,618/5,451 microbial genomes, spanning 325 species, 115 genera, and 12 phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec></sec><sec disp-level="2" id="s0002-s2009"><title>Conjugations</title><p>The microbial involvement in phase II reactions of the overall drug metabolism is an important aspect of microbial drug metabolism.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup> Human phase II reactions typically involve the conjugation of drugs or their metabolites with endogenous compounds, such as glucuronic acid, sulfate, amino acids, or glutathione.<sup><xref rid="cit0201" ref-type="bibr">201</xref></sup> Some bacteria possess sulphotransferases or acetyltransferases that can catalyze the addition of sulfate or acetyl groups to drugs or their metabolites, respectively.<sup><xref rid="cit0202" ref-type="bibr">202</xref>,<xref rid="cit0203" ref-type="bibr">203</xref></sup> The microbial involvement in phase II metabolism affects the clearance rate and bioavailability of drugs. Hence, this microbial drug metabolism can have significant implications for drug effectiveness, toxicity, and overall pharmacokinetics.</p><sec disp-level="3" id="s0002-s2009-s3001"><title>Acetylation</title><p>Acetylation of sulphapyridine and mesalazine (5-aminosalicylic acid, 5-ASA) has been observed in the feces of rats, guinea pigs, dogs, and humans (<xref rid="f0006" ref-type="fig">Figure 6(D)</xref>).<sup><xref rid="cit0204" ref-type="bibr">204</xref></sup> The N-acetyltransferases enzyme (NAT) encoded by the <italic toggle="yes">nat</italic> gene has been identified and investigated in different bacterial species. It has been found that bacterial NAT activities are comparable to the human NAT1 with both having higher catalytic efficiency with 5-ASA than its isomer 4-ASA.<sup><xref rid="cit0205" ref-type="bibr">205</xref></sup> NAT from <italic toggle="yes">Pseudomonas aeruginosa</italic> showed additional activity on the anti-tubercular drug, isoniazid, as well as on p-aminobenzoic acid (PABA), a folate precursor.<sup><xref rid="cit0206" ref-type="bibr">206</xref></sup> Recently, a novel acetyltransferase, encoded by the gene <italic toggle="yes">nhoA</italic>, has been identified in <italic toggle="yes">Enterobacter sp</italic>. strain CZ-1.<sup><xref rid="cit0207" ref-type="bibr">207</xref></sup> Bacterial N-acetyltransferases are also responsible for the acetylation of other substituted anilines, such as the eltrombopag reduction metabolite, SB-611855, whose acetylated form has been found after incubations with both rodent cecal contents and human feces.<sup><xref rid="cit0157" ref-type="bibr">157</xref></sup> Moreover, the comparative genomics analysis identified NAT encoding genes in 2,165/5,451 distinct strains, spanning 100 species, 32 genera, and four phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p><p>Taken together, bacterial NATs influence drug metabolism within the gut microbiota, affecting drug activity. Understanding these interactions may lead to personalized medicine advancements and improved therapeutic strategies for various clinical conditions.</p><p>Additionally, microbial enzymes can perform O-acetylation. For example, the chloramphenicol acetyltransferase (CAT) encoded by the <italic toggle="yes">cat</italic> gene in <italic toggle="yes">E. coli</italic> and other Gram-negative bacteria has been shown to catalyze the acetyl-S-CoA-dependent acetyl at the 3-hydroxyl group (<xref rid="f0006" ref-type="fig">Figure 6(D)</xref>).<sup><xref rid="cit0203" ref-type="bibr">203</xref></sup> No comparative genomics has been carried out for this gene.</p><p>Finally, gene <italic toggle="yes">bt_2367</italic> has recently been shown to have acyltransferase properties converting periciazine to acetyl- and proprionylpericiazine.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup></p></sec><sec disp-level="3" id="s0002-s2009-s3002"><title>Bile acids amino acid conjugation</title><p>Microbes do not only perform hydrolysis on the glycine and taurine-conjugated bile acids produced by the host, but they are also able to conjugate bile acids with other amino acids. Phenylalanine, tyrosine, and leucine conjugates have been identified in a study comparing metabolomics data from germ-free and specific pathogen-free mice (<xref rid="f0006" ref-type="fig">Figure 6(E)</xref>).<sup><xref rid="cit0208" ref-type="bibr">208</xref></sup> More recently, through a synthesis-based reverse metabolomics approach, further amino acid conjugates and bile acids have been identified in human feces additionally showing a difference in their level in Crohn&#8217;s disease compared to healthy controls.<sup><xref rid="cit0209" ref-type="bibr">209</xref></sup> However, the responsible genes have yet to be identified. This significant expansion of bile acid conjugates has the potential to revolutionize our view on the role of microbial metabolism in host-related diseases.</p></sec><sec disp-level="3" id="s0002-s2009-s3003"><title>Sulphation</title><p>We already discussed sulphotransferases for their involvement in the removal of the sulfate group from sodium picosulphate (<xref rid="f0006" ref-type="fig">Figure 6(B)</xref>). They may also induce the sulfation of drugs that have phenolic moieties. Drugs, such as paracetamol, can act as a substrate acceptor of microbial sulphotransferases.<sup><xref rid="cit0197" ref-type="bibr">197</xref></sup> While sulfation is already performed by the host, it cannot be excluded that the microbes could also perform the same reaction thereby further increasing the excretion rate of the drug and reducing its bioavailability.</p></sec></sec></sec><sec disp-level="1" id="s0003"><title>Indirect effect of microbial metabolism</title><p>The microbiome also has the potential to indirectly influence drug metabolism by modifying the conditions within the gut. The presence of gut microbes leads to the production of metabolites that can affect the integrity of the intestinal barrier, influence drug transporters, and interact with drug-metabolizing enzymes.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> As a result, the way drugs are processed in the body, known as pharmacokinetics, is impacted. Additionally, the microbiome plays a role in altering gut pH<sup><xref rid="cit0210" ref-type="bibr">210</xref></sup> and engaging in competition for nutrients,<sup><xref rid="cit0211" ref-type="bibr">211</xref></sup> which, in turn, can affect the solubility, bioavailability, and stability of drugs.</p><sec disp-level="2" id="s0003-s2001"><title>Alteration of drug metabolism</title><p>The microbiome can indirectly affect drug metabolism by producing metabolites that inhibit drug-metabolizing enzymes. For instance, p-cresol is produced by <italic toggle="yes">Clostridium difficile</italic> through the fermentation of tyrosine.<sup><xref rid="cit0212" ref-type="bibr">212</xref></sup> The metabolite is then sulfated by human sulphurtransferases, thereby acting as a competitive inhibitor for the sulfonation of other metabolites.<sup><xref rid="cit0213" ref-type="bibr">213</xref></sup> Many drugs undergo sulfonation and in the case of paracetamol, p-cresol sulfate levels in urine could be correlated to the paracetamol-sulfate/paracetamol-glucuronide ratio suggesting a microbial-driven metabolic switch in the drug metabolism.<sup><xref rid="cit0214" ref-type="bibr">214</xref></sup> Overall, the 4-hydroxyphenylacetate decarboxylase, the enzyme producing p-cresol, has been found in 32/5,451 distinct strains, spanning seven species, six genera, and three phyla (Table S3).<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup></p><p>Similarly, the microbiome can influence drug-drug interaction, as is the case for the production of bromovinyluracil (BVU) from the antiviral drugs sorivudine and brivudine.<sup><xref rid="cit0099" ref-type="bibr">99</xref></sup> BVU is an inhibitor of the human dihydropyridine dehydrogenase acting on 5-fluorouracil (5FU).<sup><xref rid="cit0215" ref-type="bibr">215</xref>,<xref rid="cit0216" ref-type="bibr">216</xref></sup> This interaction was responsible for the death of 18 patients that received sorivudine during chemotherapy with tegafur, a 5FU prodrug<sup><xref rid="cit0217" ref-type="bibr">217</xref>,<xref rid="cit0218" ref-type="bibr">218</xref></sup> as well as the death of a patient who received brivudine while being treated for metastatic colorectal cancer with capecitabine, another 5FU prodrug.<sup><xref rid="cit0219" ref-type="bibr">219</xref></sup> BVU can be produced by both host and microbial metabolism. Their contribution has recently been disentangled showing that microbial activity accounts for nearly all the serum BVU measures at later timepoints (&gt;3&#8201;h), and 71% of total BVU exposure in the serum of mice. These results strongly suggest a leading role of the microbiome in deathly outcomes.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup></p></sec><sec disp-level="2" id="s0003-s2002"><title>Alteration of bioavailability</title><p>The microbiome can also affect drug bioavailability without modifying the drug structure by altering the solubility, absorption, and transport of drug compounds.<sup><xref rid="cit0220" ref-type="bibr">220</xref></sup> As described in the previous sections, the gut microbiome produces secondary bile acids and can hydrolyze conjugated bile acids into their free form.<sup><xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0221" ref-type="bibr">221</xref></sup> In particular, gut microbiome modulation of drug pharmacokinetics through regulation of P-gp has been demonstrated in the case of tacrolimus.<sup><xref rid="cit0222" ref-type="bibr">222</xref></sup> The microbiome can also affect OATP2B1, a transporter that mediates the absorption of different drugs including statins,<sup><xref rid="cit0223" ref-type="bibr">223</xref></sup> limiting the transporter food-induced inhibition, and rescuing intestinal drug absorption.<sup><xref rid="cit0224" ref-type="bibr">224</xref></sup> Additionally, gut microbiota can produce short-chain fatty acids (SCFA),<sup><xref rid="cit0225" ref-type="bibr">225</xref></sup> which are known to increase transepithelial resistance (TER) in Caco-2 cells<sup><xref rid="cit0226" ref-type="bibr">226</xref></sup> and are a potential supplementation therapy to restore gut permeability in people with liver disease.<sup><xref rid="cit0227" ref-type="bibr">227</xref></sup> This permeability alteration could affect drugs&#8217; passive absorption in the intestinal epithelial cells. Finally, gut microbes can bioaccumulate drugs, such as duloxetine, altering their availability.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> All these alterations could participate in pharmacokinetics, impacting drug response, and possibly causing adverse side reactions or therapy failure.</p></sec></sec><sec disp-level="1" id="s0004"><title>Therapeutical inhibition of microbial drug-metabolizing capabilities</title><p>Beta-lactamase inhibitors are crucial in combating antibiotic resistance by blocking bacterial enzymes that degrade beta-lactam antibiotics. They were introduced into therapy almost 50&#8201;years ago with clavulanic acid being the first beta-lactamase inhibitor,<sup><xref rid="cit0228" ref-type="bibr">228</xref></sup> and they restore antibiotic efficacy, broaden their spectrum, and preserve their usefulness against resistant strains, thus, representing a vital tool in the fight against drug-resistant infections.<sup><xref rid="cit0057" ref-type="bibr">57</xref></sup></p><p>Beta-glucuronidase inhibitors play a significant role in pharmacology and drug development. These enzymes are responsible for cleaving glucuronic acid conjugates, thereby reactivating drugs or metabolites excreted into the gut. By inhibiting beta-glucuronidases, the recycling of drugs could be minimized, reducing potential toxicity and drug reabsorption.<sup><xref rid="cit0229" ref-type="bibr">229</xref>,<xref rid="cit0230" ref-type="bibr">230</xref></sup> Understanding and utilizing beta-glucuronidase inhibitors offer promising avenues for improving drug safety, efficacy, and precision in therapeutic interventions.<sup><xref rid="cit0231" ref-type="bibr">231</xref></sup> In particular, in the case of irinotecan, microbial beta-glucuronidases have been proposed as a possible biomarker to predict irinotecan-induced diarrhea.<sup><xref rid="cit0232" ref-type="bibr">232</xref></sup> Both probiotics and bacterial beta-glucuronidase inhibitors have been shown to reduce the drug&#8217;s gastrointestinal toxicity<sup><xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0233" ref-type="bibr">233</xref>,<xref rid="cit0234" ref-type="bibr">234</xref></sup></p><p>Additionally, carbidopa plays a crucial role in Parkinson&#8217;s disease therapy. It is a peripheral decarboxylase inhibitor that prevents the conversion of levodopa to dopamine in the bloodstream, allowing more levodopa to reach the brain. Unfortunately, carbidopa fails to prevent L-dopa decarboxylation by <italic toggle="yes">E. faecalis;</italic> therefore, new specific molecules, such as (S)-&#945;-fluoromethyltyrosine,<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup> are required to inhibit gut microbial L-dopa metabolism.</p></sec><sec disp-level="1" id="s0005"><title>Conclusion</title><p>Personalized therapies that assess microbial drug-metabolizing capabilities hold immense potential to reduce variability in treatment outcomes. By understanding an individual&#8217;s gut microbiota and its enzymatic capabilities, clinicians could tailor drug treatments to address an additional layer of individual variability in drug response (IVDR) to reduce adverse drug reactions (ADR) and optimize drug efficacy.<sup><xref rid="cit0235" ref-type="bibr">235</xref></sup> Recognizing the role of microbial metabolism holds paramount importance in preempting potentially lethal drug-related repercussions, as illuminated by instances such as the co-administration of brivudine and fluorouracil. The microbial transformation of brivudine into bromovinyluracil, a dihydropyrimidine dehydrogenase (DPD) inhibitor, accentuates the toxic impact of fluorouracil, exemplifying life-threatening ramifications.<sup><xref rid="cit0236" ref-type="bibr">236</xref></sup> Additionally, the co-administration of cytochrome inhibitors to increase clinical exposure of drugs that undergo cytochrome degradation could lead to metabolic switching and generation of currently understudied microbial products.<sup><xref rid="cit0237" ref-type="bibr">237</xref></sup> Grasping the intricate interplay between drug metabolism and the gut microbiota is pivotal for customizing treatment regimens, sidestepping unwarranted drug interactions, and mitigating the peril of adverse outcomes or therapy failure.<sup><xref rid="cit0235" ref-type="bibr">235</xref></sup> Infusing microbiome analysis into drug development or clinical protocols holds the potential for upholding patient safety and optimizing treatment efficacy.<sup><xref rid="cit0238" ref-type="bibr">238</xref></sup></p><p>An <italic toggle="yes">in silico</italic> analysis across 616 microbiomes, using the AGORA2 resource, has illustrated the interpersonal variation of microbial drug metabolism as a function of the microbial composition.<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> While most drugs could be converted by the studied microbiomes, quantitative differences have been predicted and could be correlated to BMI, age, and sex. Furthermore, the microbial activity against balsalazide, digoxin, and levodopa was dependent on the presence of <italic toggle="yes">E. lenta</italic> in the microbiomes and thus these drug conversions were only present in a subset of the studied microbes.<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> Such <italic toggle="yes">in silico</italic> investigation, particularly when human drug metabolism is also simulated using whole-body models of human metabolism,<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> could be used to identify candidate subsets of patients, harboring specific microbes, for optimal trial design, for identifying <italic toggle="yes">in silico</italic> patients suitable for a particular drug treatment where alternatives exist, as well as predicting consequences of multi-drug treatment and drug-diet interactions.<sup><xref rid="cit0239" ref-type="bibr">239</xref></sup> As such, the enumeration of drug-metabolizing capabilities and their addition to computational models represents a pivotal step toward personalized medicine.</p><p>This review highlights the impact of the microbiome on drug metabolism. However, it&#8217;s essential to recognize the bidirectional nature of these interactions as drugs can also influence the composition of the microbiota.<sup><xref rid="cit0240" ref-type="bibr">240</xref>,<xref rid="cit0241" ref-type="bibr">241</xref></sup> For instance, chemotherapy, proton pump inhibitors, and immunomodulatory drugs have demonstrated such effects.<sup><xref rid="cit0242" ref-type="bibr">242</xref></sup> These alterations can affect drug efficacy, toxicity, and patient responses. Understanding these bidirectional relationships between drugs and the microbiome is thus crucial for optimizing therapeutic outcomes.<sup><xref rid="cit0243" ref-type="bibr">243</xref></sup></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM7766" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplemental Material</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="KGMI_A_2387400_SM7766.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec sec-type="COI-statement" disp-level="1" id="s0006"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec disp-level="1" id="s0007"><title>Author contributions</title><p>I.T and F.M conceived the concept and design of the article. F.M. conducted the literature investigation, gathered information, and wrote the initial draft of the manuscript. I.T provided critical revisions to the article and contributed to the shaping of the final version. Our gratitude extends to Joanne Cooney and Natalia Makosa for their meticulous grammar and readability check.</p></sec><sec sec-type="data-availability" disp-level="1" id="s0008"><title>Data availability statement</title><p>This is a literature review</p></sec><sec sec-type="supplementary-material" disp-level="1" id="s0009"><title>Supplementary material</title><p>Supplemental data for this article can be accessed online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1080/19490976.2024.2387400" ext-link-type="uri">https://doi.org/10.1080/19490976.2024.2387400</ext-link></p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsunoda</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Gonzales</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jarmusch</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Momper</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>JD.</given-names></string-name></person-group><article-title>Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability</article-title>. <source>Clin Pharmacokinet</source>. <year>2021</year>;<volume>60</volume>(<issue>8</issue>):<fpage>971</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40262-021-01032-y</pub-id>.<pub-id pub-id-type="pmid">33959897</pub-id><pub-id pub-id-type="pmcid">PMC8332605</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Auster</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Dissecting the human gut microbiome to better decipher drug liability: a once-forgotten organ takes center stage</article-title>. <source>J Adv Res</source>. <year>2023</year>;<volume>52</volume>:<fpage>171</fpage>&#8211;<lpage>201</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jare.2023.07.002</pub-id>.<pub-id pub-id-type="pmid">37419381</pub-id><pub-id pub-id-type="pmcid">PMC10555929</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iversen</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Dalg&#229;rd Dunvald</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Potteg&#229;rd</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stage</surname><given-names>TB</given-names></string-name></person-group>. <article-title>Drug metabolism and drug transport of the 100 most prescribed oral drugs</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2022</year>;<volume>131</volume>(<issue>5</issue>):<fpage>311</fpage>&#8211;<lpage>324</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcpt.13780</pub-id>.<pub-id pub-id-type="pmid">35972991</pub-id><pub-id pub-id-type="pmcid">PMC9804310</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>W</given-names></string-name></person-group>. <article-title>The influence of gut microbiota on drug metabolism and toxicity</article-title>. <source>Expert Opin Drug Metab Toxicol</source>. <year>2016</year>;<volume>12</volume>(<issue>1</issue>):<fpage>31</fpage>&#8211;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1517/17425255.2016.1121234</pub-id>.<pub-id pub-id-type="pmid">26569070</pub-id><pub-id pub-id-type="pmcid">PMC5683181</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice</article-title>. <source>Saudi Pharm J</source>. <year>2019</year>;<volume>27</volume>(<issue>8</issue>):<fpage>1146</fpage>&#8211;<lpage>1156</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsps.2019.09.011</pub-id>.<pub-id pub-id-type="pmid">31885474</pub-id><pub-id pub-id-type="pmcid">PMC6921184</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dhurjad</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dhavaliker</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sonti</surname><given-names>R</given-names></string-name></person-group>. <article-title>Exploring drug metabolism by the gut microbiota: modes of metabolism and experimental approaches</article-title>. <source>Drug Metab Dispos</source>. <year>2022</year>;<volume>50</volume>(<issue>3</issue>):<fpage>224</fpage>&#8211;<lpage>234</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.121.000669</pub-id>.<pub-id pub-id-type="pmid">34969660</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pant</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Maiti</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Mahajan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>B</given-names></string-name></person-group>. <article-title>Human Gut Microbiota and Drug Metabolism</article-title>. <source>Microb Ecol</source>. <year>2023</year>;<volume>86</volume>(<issue>1</issue>):<fpage>97</fpage>&#8211;<lpage>111</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00248-022-02081-x</pub-id>.<pub-id pub-id-type="pmid">35869999</pub-id><pub-id pub-id-type="pmcid">PMC9308113</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weersma</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Zhernakova</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>J</given-names></string-name></person-group>. <article-title>Interaction between drugs and the gut microbiome</article-title>. <source>Gut</source>. <year>2020</year>;<volume>69</volume>(<issue>8</issue>):<fpage>1510</fpage>&#8211;<lpage>1519</lpage>. doi:<pub-id pub-id-type="doi">10.1136/gutjnl-2019-320204</pub-id>.<pub-id pub-id-type="pmid">32409589</pub-id><pub-id pub-id-type="pmcid">PMC7398478</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kl&#252;nemann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andrejev</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Blasche</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mateus</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Phapale</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Devendran</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vappiani</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Kafkia</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Bioaccumulation of therapeutic drugs by human gut bacteria</article-title>. <source>Nature</source>. <year>2021</year>;<volume>597</volume>(<issue>7877</issue>):<fpage>533</fpage>&#8211;<lpage>538</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-021-03891-8</pub-id>.<pub-id pub-id-type="pmid">34497420</pub-id><pub-id pub-id-type="pmcid">PMC7614428</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zimmermann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wegmann</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>AL</given-names></string-name></person-group>. <article-title>Mapping human microbiome drug metabolism by gut bacteria and their genes</article-title>. <source>Nature</source>. <year>2019</year>;<volume>570</volume>(<issue>7762</issue>):<fpage>462</fpage>&#8211;<lpage>467</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-019-1291-3</pub-id>.<pub-id pub-id-type="pmid">31158845</pub-id><pub-id pub-id-type="pmcid">PMC6597290</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Javdan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Chankhamjon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Hull</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chatterjee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Donia</surname><given-names>MS</given-names></string-name></person-group>. <article-title>Personalized mapping of drug metabolism by the human gut microbiome</article-title>. <source>Cell</source>. <year>2020</year>;<volume>181</volume>(<issue>7</issue>):<fpage>1661</fpage>&#8211;<lpage>1679.e22</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.05.001</pub-id>.<pub-id pub-id-type="pmid">32526207</pub-id><pub-id pub-id-type="pmcid">PMC8591631</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kennedy</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Baldridge</surname><given-names>MT</given-names></string-name></person-group>. <article-title>Mouse microbiota models: comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria</article-title>. <source>Front Physiol</source>. <year>2018</year>;<volume>9</volume>:<fpage>1534</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphys.2018.01534</pub-id>.<pub-id pub-id-type="pmid">30429801</pub-id><pub-id pub-id-type="pmcid">PMC6220354</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turner</surname><given-names>PV</given-names></string-name>, <string-name name-style="western"><surname>Brabb</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pekow</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vasbinder</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Administration of substances to laboratory animals: routes of administration and factors to consider</article-title>. <source>J Am Assoc Lab Anim Sci</source>. <year>2011</year>;<volume>50</volume>(<issue>5</issue>):<fpage>600</fpage>&#8211;<lpage>613</lpage>.<pub-id pub-id-type="pmid">22330705</pub-id><pub-id pub-id-type="pmcid">PMC3189662</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malla</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Dubey</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hashem</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abd Allah</surname><given-names>EF</given-names></string-name></person-group>. <article-title>Exploring the human microbiome: the potential future role of next-generation sequencing in disease diagnosis and treatment</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>2868</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2018.02868</pub-id>.<pub-id pub-id-type="pmid">30666248</pub-id><pub-id pub-id-type="pmcid">PMC6330296</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wensel</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Pluznick</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Sears</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Next-generation sequencing: insights to advance clinical investigations of the microbiome</article-title>. <source>J Clin Invest</source>. <year>2022</year>;<volume>132</volume>(<issue>7</issue>). doi:<pub-id pub-id-type="doi">10.1172/JCI154944</pub-id>.<pub-id pub-id-type="pmcid">PMC8970668</pub-id><pub-id pub-id-type="pmid">35362479</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heinken</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hertel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Acharya</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ravcheev</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Nyga</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Okpala</surname><given-names>OE</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Magn&#250;sd&#243;ttir</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Martinelli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nap</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine</article-title>. <source>Nat Biotechnol</source>. <year>2023</year>;<volume>41</volume>(<issue>9</issue>):<fpage>1320</fpage>&#8211;<lpage>1331</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41587-022-01628-0</pub-id>.<pub-id pub-id-type="pmid">36658342</pub-id><pub-id pub-id-type="pmcid">PMC10497413</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thiele</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sahoo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Heinken</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hertel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heirendt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Aurich</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>RM</given-names></string-name></person-group>. <article-title>Personalized whole&#8208;body models integrate metabolism, physiology, and the gut microbiome</article-title>. <source>Mol Syst Biol</source>. <year>2020</year>;<volume>16</volume>(<issue>5</issue>):<fpage>e8982</fpage>. doi:<pub-id pub-id-type="doi">10.15252/msb.20198982</pub-id>.<pub-id pub-id-type="pmid">32463598</pub-id><pub-id pub-id-type="pmcid">PMC7285886</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McCoubrey</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Thomaidou</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Elbadawi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gaisford</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Orlu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Basit</surname><given-names>AW</given-names></string-name></person-group>. <article-title>Machine learning predicts drug metabolism and bioaccumulation by intestinal microbiota</article-title>. <source>Pharmaceutics</source>. <year>2021</year>;<volume>13</volume>(<issue>12</issue>). doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics13122001</pub-id>.<pub-id pub-id-type="pmcid">PMC8707855</pub-id><pub-id pub-id-type="pmid">34959282</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname><given-names>H</given-names></string-name></person-group>. <article-title>Gut microbiota in reductive drug metabolism</article-title>. <source>Prog Mol Biol Transl Sci</source>. <year>2020</year>;<volume>171</volume>:<fpage>61</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">32475528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2020.04.002</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name></person-group>. <article-title>Application of cofactors in the regulation of microbial metabolism: a state of the art review</article-title>. <source>Front Microbiol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1145784</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2023.1145784</pub-id>.<pub-id pub-id-type="pmid">37113222</pub-id><pub-id pub-id-type="pmcid">PMC10126289</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Campbell</surname><given-names>LL</given-names><suffix>Jr.</suffix></string-name></person-group><article-title>Reductive degradation of pyrimidines. III. Purification and properties of dihydrouracil dehydrogenase</article-title>. <source>J Biol Chem</source>. <year>1957</year>;<volume>227</volume>(<issue>2</issue>):<fpage>693</fpage>&#8211;<lpage>700</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0021-9258(18)70749-7</pub-id>.<pub-id pub-id-type="pmid">13462991</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmitt</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Jahnke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rosenbaum</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Schnackerz</surname><given-names>KD</given-names></string-name></person-group>. <article-title>Purification and characterization of dihydropyrimidine dehydrogenase from Alcaligenes eutrophus</article-title>. <source>Arch Biochem Biophys</source>. <year>1996</year>;<volume>332</volume>(<issue>1</issue>):<fpage>175</fpage>&#8211;<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.1006/abbi.1996.0330</pub-id>.<pub-id pub-id-type="pmid">8806723</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>West</surname><given-names>TP</given-names></string-name></person-group>. <article-title>Isolation and characterization of an Escherichia coli B mutant strain defective in uracil catabolism</article-title>. <source>Can J Microbiol</source>. <year>1998</year>;<volume>44</volume>(<issue>11</issue>):<fpage>1106</fpage>&#8211;<lpage>1109</lpage>. doi:<pub-id pub-id-type="doi">10.1139/w98-102</pub-id>.<pub-id pub-id-type="pmid">10030006</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hidese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mihara</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kurihara</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Esaki</surname><given-names>N</given-names></string-name></person-group>. <article-title>Escherichia coli dihydropyrimidine dehydrogenase is a novel nad-dependent heterotetramer essential for the production of 5,6-dihydrouracil</article-title>. <source>J Bacteriol</source>. <year>2011</year>;<volume>193</volume>(<issue>4</issue>):<fpage>989</fpage>&#8211;<lpage>993</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.01178-10</pub-id>.<pub-id pub-id-type="pmid">21169495</pub-id><pub-id pub-id-type="pmcid">PMC3028684</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spanogiannopoulos</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kyaw</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Guthrie</surname><given-names>BGH</given-names></string-name>, <string-name name-style="western"><surname>Bradley</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Melamed</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Malig</surname><given-names>YNA</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Gempis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sandy</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism</article-title>. <source>Nat Microbiol</source>. <year>2022</year>;<volume>7</volume>(<issue>10</issue>):<fpage>1605</fpage>&#8211;<lpage>1620</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41564-022-01226-5</pub-id>.<pub-id pub-id-type="pmid">36138165</pub-id><pub-id pub-id-type="pmcid">PMC9530025</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lindenbaum</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rund</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>VP</given-names><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Tse-Eng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>JR</given-names></string-name></person-group>. <article-title>Inactivation of digoxin by the gut flora: reversal by antibiotic therapy</article-title>. <source>N Engl J Med</source>. <year>1981</year>;<volume>305</volume>(<issue>14</issue>):<fpage>789</fpage>&#8211;<lpage>794</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM198110013051403</pub-id>.<pub-id pub-id-type="pmid">7266632</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saha</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>VP</given-names><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Neu</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Lindenbaum</surname><given-names>J</given-names></string-name></person-group>. <article-title>Digoxin-inactivating bacteria: identification in human gut flora</article-title>. <source>Science</source>. <year>1983</year>;<volume>220</volume>(<issue>4594</issue>):<fpage>325</fpage>&#8211;<lpage>327</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.6836275</pub-id>.<pub-id pub-id-type="pmid">6836275</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chandrasekaran</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>Reuning</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Reductive inactivation of digitoxin by eubacterium lentum cultures</article-title>. <source>Appl Environ Microbiol</source>. <year>1987</year>;<volume>53</volume>(<issue>4</issue>):<fpage>901</fpage>&#8211;<lpage>904</lpage>. doi:<pub-id pub-id-type="doi">10.1128/aem.53.4.901-904.1987</pub-id>.<pub-id pub-id-type="pmid">3579289</pub-id><pub-id pub-id-type="pmcid">PMC203778</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haiser</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Gootenberg</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Chatman</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sirasani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta</article-title>. <source>Science</source>. <year>2013</year>;<volume>341</volume>(<issue>6143</issue>):<fpage>295</fpage>&#8211;<lpage>298</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1235872</pub-id>.<pub-id pub-id-type="pmid">23869020</pub-id><pub-id pub-id-type="pmcid">PMC3736355</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haiser</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Seim</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics</article-title>. <source>Gut Microbes</source>. <year>2014</year>;<volume>5</volume>(<issue>2</issue>):<fpage>233</fpage>&#8211;<lpage>238</lpage>. doi:<pub-id pub-id-type="doi">10.4161/gmic.27915</pub-id>.<pub-id pub-id-type="pmid">24637603</pub-id><pub-id pub-id-type="pmcid">PMC4063850</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koppel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bisanz</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Pandelia</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></string-name></person-group>. <article-title>Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins</article-title>. <source>Elife</source>. <year>2018</year>;<volume>7</volume>. doi:<pub-id pub-id-type="doi">10.7554/eLife.33953</pub-id>.<pub-id pub-id-type="pmcid">PMC5953540</pub-id><pub-id pub-id-type="pmid">29761785</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McCabe</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sane</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Keith-Luzzi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Whitcher-Johnstone</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Johnstone</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tweedie</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Defining the role of gut bacteria in the metabolism of deleobuvir: In Vitro and in vivo studies</article-title>. <source>Drug Metab Dispos</source>. <year>2015</year>;<volume>43</volume>(<issue>10</issue>):<fpage>1612</fpage>&#8211;<lpage>1618</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.115.064477</pub-id>.<pub-id pub-id-type="pmid">26068924</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stokes</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></string-name></person-group>. <article-title>Characterization of &#8224;4-3-ketosteroid-5&#946;-reductase and 3&#946;-hydroxysteroid dehydrogenase in cell extracts of clostridium innocuum</article-title>. <source>Biochim et Biophys Acta (BBA) - Lipids Lipid Metab</source>. <year>1985</year>;<volume>836</volume>(<issue>2</issue>):<fpage>255</fpage>&#8211;<lpage>261</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0005-2760(85)90073-6</pub-id>.<pub-id pub-id-type="pmid">3861198</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ly</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Doden</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Ridlon</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Gut feelings about bacterial steroid-17,20-desmolase</article-title>. <source>Mol Cellular Endocrinol</source>. <year>2021</year>;<volume>525</volume>:<fpage>111174</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mce.2021.111174</pub-id>.<pub-id pub-id-type="pmid">33503463</pub-id><pub-id pub-id-type="pmcid">PMC8886824</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hattori</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Motoike</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kobashi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Namba</surname><given-names>T</given-names></string-name></person-group>. <article-title>Metabolism of sennosides by intestinal flora</article-title>. <source>Chem Pharm Bull (Tokyo)</source>. <year>1982</year>;<volume>30</volume>(<issue>4</issue>):<fpage>1338</fpage>&#8211;<lpage>1346</lpage>. doi:<pub-id pub-id-type="doi">10.1248/cpb.30.1338</pub-id>.<pub-id pub-id-type="pmid">7105255</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hattori</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Namba</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Akao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kobashi</surname><given-names>K</given-names></string-name></person-group>. <article-title>Metabolism of sennosides by human intestinal bacteria</article-title>. <source>Pharmacology</source>. <year>1988</year>;<volume>36</volume>(<issue>Suppl 1</issue>):<fpage>172</fpage>&#8211;<lpage>179</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000138437</pub-id>.<pub-id pub-id-type="pmid">3368516</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kobashi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nishimura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kusaka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hattori</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Namba</surname><given-names>T</given-names></string-name></person-group>. <article-title>Metabolism of sennosides by human intestinal bacteria</article-title>. <source>Planta Med</source>. <year>1980</year>;<volume>40</volume>(<issue>3</issue>):<fpage>225</fpage>&#8211;<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-2008-1074963</pub-id>.<pub-id pub-id-type="pmid">7443842</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mibu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Erabi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hattori</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Namba</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kobashi</surname><given-names>K</given-names></string-name></person-group>. <article-title>Non-enzymatic reduction of sennidins and sennosides by reduced flavin</article-title>. <source>Chem Pharm Bull (Tokyo)</source>. <year>1987</year>;<volume>35</volume>(<issue>5</issue>):<fpage>1998</fpage>&#8211;<lpage>2003</lpage>. doi:<pub-id pub-id-type="doi">10.1248/cpb.35.1998</pub-id>.<pub-id pub-id-type="pmid">3664804</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bakke</surname><given-names>OM</given-names></string-name></person-group>. <article-title>Degradation of DOPA by intestinal microorganisms in vitro</article-title>. <source>Acta Pharmacol Toxicol (Copenh)</source>. <year>1971</year>;<volume>30</volume>(<issue>1</issue>):<fpage>115</fpage>&#8211;<lpage>121</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1600-0773.1971.tb00640.x</pub-id>.<pub-id pub-id-type="pmid">5171345</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goldin</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Peppercorn</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>P</given-names></string-name></person-group>. <article-title>Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1973</year>;<volume>186</volume>(<issue>1</issue>):<fpage>160</fpage>&#8211;<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0016-5085(19)33139-7</pub-id>.<pub-id pub-id-type="pmid">4723308</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Connil</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Le Breton</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dousset</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Auffray</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rinc&#233;</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pr&#233;vost</surname><given-names>H</given-names></string-name></person-group>. <article-title>Identification of the Enterococcus faecalis tyrosine decarboxylase operon involved in tyramine production</article-title>. <source>Appl Environ Microbiol</source>. <year>2002</year>;<volume>68</volume>(<issue>7</issue>):<fpage>3537</fpage>&#8211;<lpage>3544</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.68.7.3537-3544.2002</pub-id>.<pub-id pub-id-type="pmid">12089039</pub-id><pub-id pub-id-type="pmcid">PMC126796</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maini Rekdal</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bess</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Bisanz</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></string-name></person-group>. <article-title>Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism</article-title>. <source>Science</source>. <year>2019</year>;<volume>364</volume>(<issue>6445</issue>). doi:<pub-id pub-id-type="doi">10.1126/science.aau6323</pub-id>.<pub-id pub-id-type="pmcid">PMC7745125</pub-id><pub-id pub-id-type="pmid">31196984</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Crystal structure of tyrosine decarboxylase and identification of key residues involved in conformational swing and substrate binding</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>27779</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep27779</pub-id>.<pub-id pub-id-type="pmid">27292129</pub-id><pub-id pub-id-type="pmcid">PMC4904194</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Kessel</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Frye</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>El-Gendy</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Castejon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Keshavarzian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>van Dijk</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>El Aidy</surname><given-names>S</given-names></string-name></person-group>. <article-title>Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson&#8217;s disease</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>310</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-08294-y</pub-id>.<pub-id pub-id-type="pmid">30659181</pub-id><pub-id pub-id-type="pmcid">PMC6338741</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Kessel</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Auvinen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Scheperjans</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>El Aidy</surname><given-names>S</given-names></string-name></person-group>. <article-title>Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinson's disease</article-title>. <source>Npj Parkinson&#8217;s Disease</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>115</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41531-021-00260-0</pub-id>.<pub-id pub-id-type="pmcid">PMC8674283</pub-id><pub-id pub-id-type="pmid">34911958</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients with Parkinson disease</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>99</volume>(<issue>22</issue>):<fpage>e2443</fpage>&#8211;<lpage>e2453</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000201204</pub-id>.<pub-id pub-id-type="pmid">36240098</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Durso</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Josephs</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Szabo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Browne</surname><given-names>TR</given-names></string-name></person-group>. <article-title>Variable absorption of carbidopa affects both peripheral and central levodopa metabolism</article-title>. <source>J Clin Pharmacol</source>. <year>2000</year>;<volume>40</volume>(<issue>8</issue>):<fpage>854</fpage>&#8211;<lpage>860</lpage>. doi:<pub-id pub-id-type="doi">10.1177/00912700022009585</pub-id>.<pub-id pub-id-type="pmid">10934669</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Williams</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Van Benschoten</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Cimermancic</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Donia</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Zimmermann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Taketani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ishihara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kashyap</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Fraser</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Fischbach</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine</article-title>. <source>Cell Host Microbe</source>. <year>2014</year>;<volume>16</volume>(<issue>4</issue>):<fpage>495</fpage>&#8211;<lpage>503</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2014.09.001</pub-id>.<pub-id pub-id-type="pmid">25263219</pub-id><pub-id pub-id-type="pmcid">PMC4260654</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rety</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Deschamps</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Leulliot</surname><given-names>N</given-names></string-name></person-group>. <article-title>Structure of Escherichia coli tryptophanase purified from an alkaline-stressed bacterial culture</article-title>. <source>Acta Crystallogr F Struct Biol Commun</source>. <year>2015</year>;<volume>71</volume>(<issue>Pt 11</issue>):<fpage>1378</fpage>&#8211;<lpage>1383</lpage>. doi:<pub-id pub-id-type="doi">10.1107/S2053230X15017549</pub-id>.<pub-id pub-id-type="pmid">26527264</pub-id><pub-id pub-id-type="pmcid">PMC4631586</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cerone-McLernon</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mosbach</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Bokkenheuser</surname><given-names>VD</given-names></string-name></person-group>. <article-title>Side-chain cleavage of cortisol by fecal flora</article-title>. <source>Biochim Biophys Acta</source>. <year>1981</year>;<volume>666</volume>(<issue>3</issue>):<fpage>341</fpage>&#8211;<lpage>347</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0005-2760(81)90292-7</pub-id>.<pub-id pub-id-type="pmid">7326247</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krafft</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bokkenheuser</surname><given-names>VD</given-names></string-name>, <string-name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></string-name></person-group>. <article-title>Cofactor requirements of steroid-17-20-desmolase and 20 alpha-hydroxysteroid dehydrogenase activities in cell extracts of clostridium scindens</article-title>. <source>J Steroid Biochem</source>. <year>1987</year>;<volume>28</volume>(<issue>1</issue>):<fpage>49</fpage>&#8211;<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0022-4731(87)90123-3</pub-id>.<pub-id pub-id-type="pmid">3475510</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Devendran</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mythen</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Ridlon</surname><given-names>JM</given-names></string-name></person-group>. <article-title>The desA and desB genes from Clostridium scindens ATCC 35704 encode steroid-17,20-desmolase</article-title>. <source>J Lipid Res</source>. <year>2018</year>;<volume>59</volume>(<issue>6</issue>):<fpage>1005</fpage>&#8211;<lpage>1014</lpage>. doi:<pub-id pub-id-type="doi">10.1194/jlr.M083949</pub-id>.<pub-id pub-id-type="pmid">29572237</pub-id><pub-id pub-id-type="pmcid">PMC5983398</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ly</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Rowles</surname><given-names>JL</given-names><suffix>3rd</suffix></string-name>, <string-name name-style="western"><surname>Paul</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Alves</surname><given-names>JMP</given-names></string-name>, <string-name name-style="western"><surname>Yemm</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wolf</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Devendran</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Erdman</surname><given-names>JW</given-names><suffix>Jr.</suffix></string-name>, et al</person-group>. <article-title>Bacterial steroid-17,20-desmolase is a taxonomically rare enzymatic pathway that converts prednisone to 1,4-androstanediene-3,11,17-trione, a metabolite that causes proliferation of prostate cancer cells</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2020</year>;<volume>199</volume>:<fpage>105567</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsbmb.2019.105567</pub-id>.<pub-id pub-id-type="pmid">31870912</pub-id><pub-id pub-id-type="pmcid">PMC7333170</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abraham</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Chain</surname><given-names>E</given-names></string-name></person-group>. <article-title>An enzyme from bacteria able to destroy penicillin</article-title>. <source>Nature</source>. <year>1940</year>;<volume>146</volume>(<issue>3713</issue>):<fpage>837</fpage>&#8211;<lpage>837</lpage>. doi:<pub-id pub-id-type="doi">10.1038/146837a0</pub-id>.<pub-id pub-id-type="pmid">3055168</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abraham</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Chain</surname><given-names>E</given-names></string-name></person-group>. <article-title>An enzyme from bacteria able to destroy penicillin. 1940</article-title>. <source>Rev Infect Dis</source>. <year>1988</year>;<volume>10</volume>(<issue>4</issue>):<fpage>677</fpage>&#8211;<lpage>678</lpage>.<pub-id pub-id-type="pmid">3055168</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Russ</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Glaser</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shaer Tamar</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yelin</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Baym</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kelsic</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Zampaloni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Haldimann</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kishony</surname><given-names>R</given-names></string-name></person-group>. <article-title>Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>2029</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-15666-2</pub-id>.<pub-id pub-id-type="pmid">32332717</pub-id><pub-id pub-id-type="pmcid">PMC7181632</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tooke</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Hinchliffe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bragginton</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Colenso</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Hirvonen</surname><given-names>VHA</given-names></string-name>, <string-name name-style="western"><surname>Takebayashi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>J</given-names></string-name></person-group>. <article-title>&#946;-lactamases and &#946;-lactamase inhibitors in the 21st Century</article-title>. <source>J Mol Biol</source>. <year>2019</year>;<volume>431</volume>(<issue>18</issue>):<fpage>3472</fpage>&#8211;<lpage>3500</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmb.2019.04.002</pub-id>.<pub-id pub-id-type="pmid">30959050</pub-id><pub-id pub-id-type="pmcid">PMC6723624</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Castle</surname><given-names>SS</given-names></string-name></person-group>. <source>Beta-lactamase inhibitors. xPharm: the comprehensive pharmacology reference</source>. <person-group person-group-type="editor"><string-name name-style="western"><given-names>S. J.</given-names><surname>Enna</surname></string-name> and <string-name name-style="western"><given-names>D. B.</given-names><surname>Bylund</surname></string-name></person-group>, editors. <publisher-loc>New York</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2007</year>. p. <fpage>1</fpage>&#8211;<lpage>3</lpage>.</mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Geddes</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Klugman</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Rolinson</surname><given-names>GN</given-names></string-name></person-group>. <article-title>Introduction: historical perspective and development of amoxicillin/clavulanate</article-title>. <source>Int J Antimicrob Agents</source>. <year>2007</year>;<volume>30</volume>(<issue>Suppl 2</issue>):<fpage>S109</fpage>&#8211;<lpage>112</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.07.015</pub-id>.<pub-id pub-id-type="pmid">17900874</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brem</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Panduwawala</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>JU</given-names></string-name>, <string-name name-style="western"><surname>Hewitt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liepins</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Donets</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Espina</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Farley</surname><given-names>AJM</given-names></string-name>, <string-name name-style="western"><surname>Shubin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Campillos</surname><given-names>GG</given-names></string-name>, et al</person-group>. <article-title>Imitation of &#946;-lactam binding enables broad-spectrum metallo-&#946;-lactamase inhibitors</article-title>. <source>Nat Chem</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>15</fpage>&#8211;<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41557-021-00831-x</pub-id>.<pub-id pub-id-type="pmid">34903857</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Macierzanka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Torcello-G&#243;mez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jungnickel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maldonado-Valderrama</surname><given-names>J</given-names></string-name></person-group>. <article-title>Bile salts in digestion and transport of lipids</article-title>. <source>Adv Colloid Interface Sci</source>. <year>2019</year>;<volume>274</volume>:<fpage>102045</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cis.2019.102045</pub-id>.<pub-id pub-id-type="pmid">31689682</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Staels</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Fonseca</surname><given-names>VA</given-names></string-name></person-group>. <article-title>Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration</article-title>. <source>Diabetes Care</source>. <year>2009</year>;<volume>32</volume>(<issue>Suppl 2</issue>):<fpage>S237</fpage>&#8211;<lpage>245</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc09-S355</pub-id>.<pub-id pub-id-type="pmid">19875558</pub-id><pub-id pub-id-type="pmcid">PMC2811459</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>&#208;ani&#263;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stanimirov</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pavlovi&#263;</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Golo&#269;orbin-Kon</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Al-Salami</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Stankov</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mikov</surname><given-names>M</given-names></string-name></person-group>. <article-title>Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome</article-title>. <source>Front Pharmacol</source>. <year>2018</year>;<volume>9</volume>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2018.01382</pub-id>.<pub-id pub-id-type="pmcid">PMC6287190</pub-id><pub-id pub-id-type="pmid">30559664</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karpen</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Novel bile acid therapies for liver disease</article-title>. <source>Gastroenterol Hepatol (N Y)</source>. <year>2018</year>;<volume>14</volume>(<issue>2</issue>):<fpage>117</fpage>&#8211;<lpage>119</lpage>.<pub-id pub-id-type="pmid">29606923</pub-id><pub-id pub-id-type="pmcid">PMC5866303</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ridlon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></string-name></person-group>. <article-title>Bile salt biotransformations by human intestinal bacteria</article-title>. <source>J Lipid Res</source>. <year>2006</year>;<volume>47</volume>(<issue>2</issue>):<fpage>241</fpage>&#8211;<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1194/jlr.R500013-JLR200</pub-id>.<pub-id pub-id-type="pmid">16299351</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Christiaens</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Leer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Pouwels</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Verstraete</surname><given-names>W</given-names></string-name></person-group>. <article-title>Cloning and expression of a conjugated bile acid hydrolase gene from Lactobacillus plantarum by using a direct plate assay</article-title>. <source>Appl Environ Microbiol</source>. <year>1992</year>;<volume>58</volume>(<issue>12</issue>):<fpage>3792</fpage>&#8211;<lpage>3798</lpage>. doi:<pub-id pub-id-type="doi">10.1128/aem.58.12.3792-3798.1992</pub-id>.<pub-id pub-id-type="pmid">1476424</pub-id><pub-id pub-id-type="pmcid">PMC183183</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>An</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chon</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ku</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Eom</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Seok</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Koo</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Bile acids: major regulator of the gut microbiome</article-title>. <source>Microorganisms</source>. <year>2022</year>;<volume>10</volume>(<issue>9</issue>):<fpage>1792</fpage>. doi:<pub-id pub-id-type="doi">10.3390/microorganisms10091792</pub-id>.<pub-id pub-id-type="pmid">36144395</pub-id><pub-id pub-id-type="pmcid">PMC9502002</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kalavagunta</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome</article-title>. <source>Microbiome</source>. <year>2019</year>;<volume>7</volume>(<issue>1</issue>):<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40168-019-0628-3</pub-id>.<pub-id pub-id-type="pmid">30674356</pub-id><pub-id pub-id-type="pmcid">PMC6345003</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heinken</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ravcheev</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Baldini</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Heirendt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>RMT</given-names></string-name>, <string-name name-style="western"><surname>Thiele</surname><given-names>I</given-names></string-name></person-group>. <article-title>Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease</article-title>. <source>Microbiome</source>. <year>2019</year>;<volume>7</volume>(<issue>1</issue>):<fpage>75</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40168-019-0689-3</pub-id>.<pub-id pub-id-type="pmid">31092280</pub-id><pub-id pub-id-type="pmcid">PMC6521386</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bachhawat</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>A</given-names></string-name></person-group>. <article-title>Glutathione Degradation</article-title>. <source>Antioxid Redox Signal</source>. <year>2017</year>;<volume>27</volume>(<issue>15</issue>):<fpage>1200</fpage>&#8211;<lpage>1216</lpage>. doi:<pub-id pub-id-type="doi">10.1089/ars.2017.7136</pub-id>.<pub-id pub-id-type="pmid">28537416</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Cooper</surname><given-names>AJL</given-names></string-name>, <string-name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></string-name></person-group>. <source>10.17 -metabolism of glutathione S-Conjugates: multiple pathways. Comprehensive toxicology</source>. <edition>Third</edition> ed. <person-group person-group-type="editor"><string-name name-style="western"><given-names>C. A.</given-names><surname>McQueen</surname></string-name></person-group>, editor. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2018</year>. p. <fpage>363</fpage>&#8211;<lpage>406</lpage>.</mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mikov</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Caldwell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dolphin</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>RL</given-names></string-name></person-group>. <article-title>The role of intestinal microflora in the formation of the methylthio adduct metabolites of paracetamol. Studies in neomycin-pretreated and germ-free mice</article-title>. <source>Biochem Pharmacol</source>. <year>1988</year>;<volume>37</volume>(<issue>8</issue>):<fpage>1445</fpage>&#8211;<lpage>1449</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0006-2952(88)90005-6</pub-id>.<pub-id pub-id-type="pmid">3358777</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peppercorn</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>P</given-names></string-name></person-group>. <article-title>Caffeic acid metabolism by gnotobiotic rats and their intestinal bacteria</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1972</year>;<volume>69</volume>(<issue>6</issue>):<fpage>1413</fpage>&#8211;<lpage>1415</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.69.6.1413</pub-id>.<pub-id pub-id-type="pmid">4504351</pub-id><pub-id pub-id-type="pmcid">PMC426714</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morrow</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sand</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Boanca</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Barycki</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Characterization of Helicobacter pylori gamma-glutamyltranspeptidase reveals the molecular basis for substrate specificity and a critical role for the tyrosine 433-containing loop in catalysis</article-title>. <source>Biochemistry</source>. <year>2007</year>;<volume>46</volume>(<issue>46</issue>):<fpage>13407</fpage>&#8211;<lpage>13414</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bi701599e</pub-id>.<pub-id pub-id-type="pmid">17960917</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Okada</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wada</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kumagai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fukuyama</surname><given-names>K</given-names></string-name></person-group>. <article-title>Crystal structures of gamma-glutamyltranspeptidase from Escherichia coli, a key enzyme in glutathione metabolism, and its reaction intermediate</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2006</year>;<volume>103</volume>(<issue>17</issue>):<fpage>6471</fpage>&#8211;<lpage>6476</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0511020103</pub-id>.<pub-id pub-id-type="pmid">16618936</pub-id><pub-id pub-id-type="pmcid">PMC1458908</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wada</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Irie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fukuyama</surname><given-names>K</given-names></string-name></person-group>. <article-title>Crystal structure of the halotolerant &#947;-glutamyltranspeptidase from Bacillus subtilis in complex with glutamate reveals a unique architecture of the solvent-exposed catalytic pocket</article-title>. <source>FEBS J</source>. <year>2010</year>;<volume>277</volume>(<issue>4</issue>):<fpage>1000</fpage>&#8211;<lpage>1009</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07543.x</pub-id>.<pub-id pub-id-type="pmid">20088880</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kamatani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Kumagai</surname><given-names>H</given-names></string-name></person-group>. <article-title>Aminopeptidases A, B, and N and dipeptidase D are the four cysteinylglycinases of Escherichia coli K-12</article-title>. <source>J Bacteriol</source>. <year>2001</year>;<volume>183</volume>(<issue>4</issue>):<fpage>1489</fpage>&#8211;<lpage>1490</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.183.4.1489-1490.2001</pub-id>.<pub-id pub-id-type="pmid">11157967</pub-id><pub-id pub-id-type="pmcid">PMC95028</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sasaki</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Tamura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shibakawa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fujita</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Murakami</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Muranishi</surname><given-names>S</given-names></string-name></person-group>. <article-title>Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganisms</article-title>. <source>Pharm Res</source>. <year>1997</year>;<volume>14</volume>(<issue>8</issue>):<fpage>1004</fpage>&#8211;<lpage>1007</lpage>. doi:<pub-id pub-id-type="doi">10.1023/A:1012141025938</pub-id>.<pub-id pub-id-type="pmid">9279880</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leader</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baca</surname><given-names>QJ</given-names></string-name>, <string-name name-style="western"><surname>Golan</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Protein therapeutics: a summary and pharmacological classification</article-title>. <source>Nat Rev Drug Discov</source>. <year>2008</year>;<volume>7</volume>(<issue>1</issue>):<fpage>21</fpage>&#8211;<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd2399</pub-id>.<pub-id pub-id-type="pmid">18097458</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tozaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Emi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Horisaka</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fujita</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Muranishi</surname><given-names>S</given-names></string-name></person-group>. <article-title>Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon</article-title>. <source>J Pharm Pharmacol</source>. <year>1997</year>;<volume>49</volume>(<issue>2</issue>):<fpage>164</fpage>&#8211;<lpage>168</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.2042-7158.1997.tb06773.x</pub-id>.<pub-id pub-id-type="pmid">9055189</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scheline</surname><given-names>RR</given-names></string-name></person-group>. <article-title>The metabolism of drugs and other organic compounds by the intestinal microflora</article-title>. <source>Acta Pharmacol Toxicol (Copenh)</source>. <year>1968</year>;<volume>26</volume>(<issue>4</issue>):<fpage>332</fpage>&#8211;<lpage>342</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1600-0773.1968.tb00453.x</pub-id>.<pub-id pub-id-type="pmid">5755481</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Valerino</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Johns</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Zaharko</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Oliverio</surname><given-names>VT</given-names></string-name></person-group>. <article-title>Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid</article-title>. <source>Biochem Pharmacol</source>. <year>1972</year>;<volume>21</volume>(<issue>6</issue>):<fpage>821</fpage>&#8211;<lpage>831</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0006-2952(72)90125-6</pub-id>.<pub-id pub-id-type="pmid">5014749</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zaharko</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Bruckner</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Oliverio</surname><given-names>VT</given-names></string-name></person-group>. <article-title>Antibiotics alter methotrexate metabolism and excretion</article-title>. <source>Science</source>. <year>1969</year>;<volume>166</volume>(<issue>3907</issue>):<fpage>887</fpage>&#8211;<lpage>888</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.166.3907.887</pub-id>.<pub-id pub-id-type="pmid">5345205</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Holt</surname><given-names>R</given-names></string-name></person-group>. <article-title>The bacterial degradation of chloramphenicol</article-title>. <source>Lancet</source>. <year>1967</year>;<volume>289</volume>(<issue>7502</issue>):<fpage>1259</fpage>&#8211;<lpage>1260</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(67)92720-1</pub-id>.<pub-id pub-id-type="pmid">4165044</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SW</given-names></string-name></person-group>. <article-title>Inactivation of chloramphenicol and florfenicol by a novel chloramphenicol hydrolase</article-title>. <source>Appl Environ Microbiol</source>. <year>2012</year>;<volume>78</volume>(<issue>17</issue>):<fpage>6295</fpage>&#8211;<lpage>6301</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.01154-12</pub-id>.<pub-id pub-id-type="pmid">22752166</pub-id><pub-id pub-id-type="pmcid">PMC3416615</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Griffiths</surname><given-names>LA</given-names></string-name></person-group>. <article-title>Metabolism of N-acylated and O-alkylated drugs by the intestinal microflora during anaerobic incubation in vitro</article-title>. <source>Xenobiotica</source>. <year>1974</year>;<volume>4</volume>(<issue>8</issue>):<fpage>477</fpage>&#8211;<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498257409052100</pub-id>.<pub-id pub-id-type="pmid">4418213</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Asano</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tani</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yamada</surname><given-names>H</given-names></string-name></person-group>. <article-title>A new enzyme &#8220;Nitrile Hydratase&#8221; which degrades acetonitrile in combination with Amidase</article-title>. <source>Agric Biol Chem</source>. <year>1980</year>;<volume>44</volume>(<issue>9</issue>):<fpage>2251</fpage>&#8211;<lpage>2252</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00021369.1980.10864311</pub-id>.</mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malaka</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Akkaya</surname><given-names>A</given-names></string-name></person-group>. <article-title>Optimization of growth for nitrilase producing bacteria</article-title>. <source>Catalysis Lett</source>. <year>2023</year>;<volume>154</volume>(<issue>3</issue>):<fpage>1232</fpage>&#8211;<lpage>1241</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10562-023-04377-0</pub-id>.</mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duca</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Glick</surname><given-names>BR</given-names></string-name></person-group>. <article-title>Characterization of a nitrilase and a nitrile hydratase from Pseudomonas sp. strain UW4 that converts indole-3-acetonitrile to indole-3-acetic acid</article-title>. <source>Appl Environ Microbiol</source>. <year>2014</year>;<volume>80</volume>(<issue>15</issue>):<fpage>4640</fpage>&#8211;<lpage>4649</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.00649-14</pub-id>.<pub-id pub-id-type="pmid">24837382</pub-id><pub-id pub-id-type="pmcid">PMC4148799</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Recent advances and promises in nitrile hydratase: from mechanism to industrial applications</article-title>. <source>Front Bioeng Biotechnol</source>. <year>2020</year>;<volume>8</volume>. doi:<pub-id pub-id-type="doi">10.3389/fbioe.2020.00352</pub-id>.<pub-id pub-id-type="pmcid">PMC7193024</pub-id><pub-id pub-id-type="pmid">32391348</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hayden</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Linsley</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Marquardt</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kerr</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Cloning, overexpression, and purification of cytosine deaminase from Saccharomyces cerevisiae</article-title>. <source>Protein Expr Purif</source>. <year>1998</year>;<volume>12</volume>(<issue>2</issue>):<fpage>173</fpage>&#8211;<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1006/prep.1997.0839</pub-id>.<pub-id pub-id-type="pmid">9518458</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Austin</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname><given-names>BE</given-names></string-name></person-group>. <article-title>Localization of the codA gene on the Escherichia coli chromosome</article-title>. <source>J Bacteriol</source>. <year>1993</year>;<volume>175</volume>(<issue>11</issue>):<fpage>3685</fpage>&#8211;<lpage>3686</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jb.175.11.3685-3686.1993</pub-id>.<pub-id pub-id-type="pmid">8501074</pub-id><pub-id pub-id-type="pmcid">PMC204774</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harris</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Manning</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Federle</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Diasio</surname><given-names>RB</given-names></string-name></person-group>. <article-title>Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1986</year>;<volume>29</volume>(<issue>1</issue>):<fpage>44</fpage>&#8211;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.29.1.44</pub-id>.<pub-id pub-id-type="pmid">3729334</pub-id><pub-id pub-id-type="pmcid">PMC180361</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Au&#269;ynait&#279;</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rutkien&#279;</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Taurait&#279;</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Me&#353;kys</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Urbonavi&#269;ius</surname><given-names>J</given-names></string-name></person-group>. <article-title>Discovery of bacterial deaminases that convert 5-fluoroisocytosine into 5-fluorouracil</article-title>. <source>Front Microbiol</source>. <year>2018</year>;<volume>9</volume>:<fpage>2375</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2018.02375</pub-id>.<pub-id pub-id-type="pmid">30349513</pub-id><pub-id pub-id-type="pmcid">PMC6186785</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>El-Sayed</surname><given-names>ASA</given-names></string-name>, <string-name name-style="western"><surname>Mohamed</surname><given-names>NZ</given-names></string-name>, <string-name name-style="western"><surname>Yassin</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Amer</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>El-Sharkawy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>El-Sayed</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>MG</given-names></string-name></person-group>. <article-title>Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy</article-title>. <source>Heliyon</source>. <year>2022</year>;<volume>8</volume>(<issue>9</issue>):<fpage>e10660</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e10660</pub-id>.<pub-id pub-id-type="pmid">36164544</pub-id><pub-id pub-id-type="pmcid">PMC9508425</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vande Voorde</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vervaeke</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liekens</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Balzarini</surname><given-names>J</given-names></string-name></person-group>. <article-title>Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs</article-title>. <source>FEBS Open Bio</source>. <year>2015</year>;<volume>5</volume>:<fpage>634</fpage>&#8211;<lpage>639</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fob.2015.07.007</pub-id><pub-id pub-id-type="pmcid">PMC4541722</pub-id><pub-id pub-id-type="pmid">26322268</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vermes</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kuijper</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Guchelaar</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Dankert</surname><given-names>J</given-names></string-name></person-group>. <article-title>An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora</article-title>. <source>Chemotherapy</source>. <year>2003</year>;<volume>49</volume>(<issue>1&#8211;2</issue>):<fpage>17</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000069784</pub-id>.<pub-id pub-id-type="pmid">12714804</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Geller</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Barzily-Rokni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Danino</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jonas</surname><given-names>OH</given-names></string-name>, <string-name name-style="western"><surname>Shental</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nejman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gavert</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zwang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cooper</surname><given-names>ZA</given-names></string-name>, <string-name name-style="western"><surname>Shee</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine</article-title>. <source>Science</source>. <year>2017</year>;<volume>357</volume>(<issue>6356</issue>):<fpage>1156</fpage>&#8211;<lpage>1160</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aah5043</pub-id>.<pub-id pub-id-type="pmid">28912244</pub-id><pub-id pub-id-type="pmcid">PMC5727343</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nakayama</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kinouchi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kataoka</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Akimoto</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Matsuda</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ohnishi</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(e)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil</article-title>. <source>Pharmacogenetics</source>. <year>1997</year>;<volume>7</volume>(<issue>1</issue>):<fpage>35</fpage>&#8211;<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00008571-199702000-00005</pub-id>.<pub-id pub-id-type="pmid">9110360</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fujii</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Inotsume</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nakano</surname><given-names>M</given-names></string-name></person-group>. <article-title>Degradation of bromazepam by the intestinal microflora</article-title>. <source>Chem Pharm Bull (Tokyo)</source>. <year>1987</year>;<volume>35</volume>(<issue>10</issue>):<fpage>4338</fpage>&#8211;<lpage>4341</lpage>. doi:<pub-id pub-id-type="doi">10.1248/cpb.35.4338</pub-id>.<pub-id pub-id-type="pmid">2893665</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koch</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Beaulieu</surname><given-names>BB</given-names><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>P</given-names></string-name></person-group>. <article-title>Role of the intestinal flora in the metabolism of misonidazole</article-title>. <source>Biochem Pharmacol</source>. <year>1980</year>;<volume>29</volume>(<issue>24</issue>):<fpage>3281</fpage>&#8211;<lpage>3284</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0006-2952(80)90304-4</pub-id>.<pub-id pub-id-type="pmid">6260109</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koch</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>P</given-names></string-name></person-group>. <article-title>The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1979</year>;<volume>208</volume>(<issue>3</issue>):<fpage>406</fpage>&#8211;<lpage>410</lpage>.<pub-id pub-id-type="pmid">430360</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Caldwell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hawksworth</surname><given-names>GM</given-names></string-name></person-group>. <article-title>The demethylation of methamphetamine by intestinal microflora</article-title>. <source>J Pharm Pharmacol</source>. <year>1973</year>;<volume>25</volume>(<issue>5</issue>):<fpage>422</fpage>&#8211;<lpage>424</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.2042-7158.1973.tb10043.x</pub-id>.<pub-id pub-id-type="pmid">4146404</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clark</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Clinton</surname><given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Hufford</surname><given-names>CD</given-names></string-name></person-group>. <article-title>Demethylation of imipramine by enteric bacteria</article-title>. <source>J Pharm Sci</source>. <year>1983</year>;<volume>72</volume>(<issue>11</issue>):<fpage>1288</fpage>&#8211;<lpage>1290</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jps.2600721113</pub-id>.<pub-id pub-id-type="pmid">6644589</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Summers</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Louie</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Gakhar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Louie</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Subramanian</surname><given-names>M</given-names></string-name></person-group>. <article-title>Novel, highly specific N-demethylases enable bacteria to live on caffeine and related purine alkaloids</article-title>. <source>J Bacteriol</source>. <year>2012</year>;<volume>194</volume>(<issue>8</issue>):<fpage>2041</fpage>&#8211;<lpage>2049</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.06637-11</pub-id>.<pub-id pub-id-type="pmid">22328667</pub-id><pub-id pub-id-type="pmcid">PMC3318484</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flint</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Duncan</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Louis</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Forano</surname><given-names>E</given-names></string-name></person-group>. <article-title>Microbial degradation of complex carbohydrates in the gut</article-title>. <source>Gut Microbes</source>. <year>2012</year>;<volume>3</volume>(<issue>4</issue>):<fpage>289</fpage>&#8211;<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.4161/gmic.19897</pub-id>.<pub-id pub-id-type="pmid">22572875</pub-id><pub-id pub-id-type="pmcid">PMC3463488</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rowland</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Miners</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Mackenzie</surname><given-names>PI</given-names></string-name></person-group>. <article-title>The udp-glucuronosyltransferases: their role in drug metabolism and detoxification</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2013</year>;<volume>45</volume>(<issue>6</issue>):<fpage>1121</fpage>&#8211;<lpage>1132</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biocel.2013.02.019</pub-id>.<pub-id pub-id-type="pmid">23500526</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walsh</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>RR</given-names></string-name></person-group>. <article-title>Studies of the enterohepatic circulation of morphine in the rat</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1975</year>;<volume>195</volume>(<issue>2</issue>):<fpage>303</fpage>&#8211;<lpage>310</lpage>.<pub-id pub-id-type="pmid">1185599</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Takasuna</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hagiwara</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hirohashi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nomura</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nagai</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kamataki</surname><given-names>T</given-names></string-name></person-group>. <article-title>Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>(<issue>16</issue>):<fpage>3752</fpage>&#8211;<lpage>3757</lpage>.<pub-id pub-id-type="pmid">8706020</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ervin</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Redinbo</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Gut microbial &#946;-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens</article-title>. <source>J Biol Chem</source>. <year>2019</year>;<volume>294</volume>(<issue>49</issue>):<fpage>18586</fpage>&#8211;<lpage>18599</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.RA119.010950</pub-id>.<pub-id pub-id-type="pmid">31636122</pub-id><pub-id pub-id-type="pmcid">PMC6901331</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bhatt</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Pellock</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Biernat</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Walton</surname><given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Creekmore</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Letertre</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Swann</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>ID</given-names></string-name>, <string-name name-style="western"><surname>Roques</surname><given-names>JR</given-names></string-name>, et al</person-group>. <article-title>Targeted inhibition of gut bacterial &#946;-glucuronidase activity enhances anticancer drug efficacy</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>(<issue>13</issue>):<fpage>7374</fpage>&#8211;<lpage>7381</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1918095117</pub-id>.<pub-id pub-id-type="pmid">32170007</pub-id><pub-id pub-id-type="pmcid">PMC7132129</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ervin</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Hanley</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Walton</surname><given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Pearce</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>LI</given-names></string-name>, <string-name name-style="western"><surname>Redinbo</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Targeting regorafenib-induced toxicity through inhibition of gut microbial &#946;-glucuronidases</article-title>. <source>ACS Chem Biol</source>. <year>2019</year>;<volume>14</volume>(<issue>12</issue>):<fpage>2737</fpage>&#8211;<lpage>2744</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acschembio.9b00663</pub-id>.<pub-id pub-id-type="pmid">31663730</pub-id><pub-id pub-id-type="pmcid">PMC7254866</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lum</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>GW</given-names></string-name></person-group>. <article-title>Identification of uidA gene sequences in beta-D-glucuronidase-negative Escherichia coli</article-title>. <source>Appl Environ Microbiol</source>. <year>1991</year>;<volume>57</volume>(<issue>1</issue>):<fpage>320</fpage>&#8211;<lpage>323</lpage>. doi:<pub-id pub-id-type="doi">10.1128/aem.57.1.320-323.1991</pub-id>.<pub-id pub-id-type="pmid">2036018</pub-id><pub-id pub-id-type="pmcid">PMC182706</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Biernat</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Pellock</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Bivins</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Walton</surname><given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>BNT</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Snider</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Cesmat</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Tripathy</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Structure, function, and inhibition of drug reactivating human gut microbial &#946;-glucuronidases</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>825</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-36069-w</pub-id>.<pub-id pub-id-type="pmid">30696850</pub-id><pub-id pub-id-type="pmcid">PMC6351562</pub-id></mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YQ</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name></person-group>. <article-title>In vitro fermentation of lactulose by human gut bacteria</article-title>. <source>J Agric Food Chem</source>. <year>2014</year>;<volume>62</volume>(<issue>45</issue>):<fpage>10970</fpage>&#8211;<lpage>10977</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jf503484d</pub-id>.<pub-id pub-id-type="pmid">25340538</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DH</given-names></string-name></person-group>. <article-title>Antiallergic activity of hesperidin is activated by intestinal microflora</article-title>. <source>Pharmacology</source>. <year>2004</year>;<volume>71</volume>(<issue>4</issue>):<fpage>174</fpage>&#8211;<lpage>180</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000078083</pub-id>.<pub-id pub-id-type="pmid">15240993</pub-id></mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mueller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zartl</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schleritzko</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stenzl</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Viernstein</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Unger</surname><given-names>FM</given-names></string-name></person-group>. <article-title>Rhamnosidase activity of selected probiotics and their ability to hydrolyse flavonoid rhamnoglucosides</article-title>. <source>Bioprocess Biosyst Eng</source>. <year>2018</year>;<volume>41</volume>(<issue>2</issue>):<fpage>221</fpage>&#8211;<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00449-017-1860-5</pub-id>.<pub-id pub-id-type="pmid">29124335</pub-id><pub-id pub-id-type="pmcid">PMC5773629</pub-id></mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zverlov</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Hertel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bronnenmeier</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hroch</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kellermann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schwarz</surname><given-names>WH</given-names></string-name></person-group>. <article-title>The thermostable alpha-L-rhamnosidase RamA of clostridium stercorarium: biochemical characterization and primary structure of a bacterial alpha-L-rhamnoside hydrolase, a new type of inverting glycoside hydrolase</article-title>. <source>Mol Microbiol</source>. <year>2000</year>;<volume>35</volume>(<issue>1</issue>):<fpage>173</fpage>&#8211;<lpage>179</lpage>.<pub-id pub-id-type="pmid">10632887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2958.2000.01691.x</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cui</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Maruyama</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mikami</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hashimoto</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Murata</surname><given-names>K</given-names></string-name></person-group>. <article-title>Crystal structure of glycoside hydrolase family 78 alpha-L-Rhamnosidase from Bacillus sp. GL1</article-title>. <source>J Mol Biol</source>. <year>2007</year>;<volume>374</volume>(<issue>2</issue>):<fpage>384</fpage>&#8211;<lpage>398</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmb.2007.09.003</pub-id>.<pub-id pub-id-type="pmid">17936784</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahn</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Choe</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Johnston</surname><given-names>TV</given-names></string-name>, <string-name name-style="western"><surname>Ku</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>GE</given-names></string-name></person-group>. <article-title>Microbial biocatalysis of quercetin-3-glucoside and isorhamnetin-3-glucoside in Salicornia herbacea and their contribution to improved anti-inflammatory activity</article-title>. <source>RSC Adv</source>. <year>2020</year>;<volume>10</volume>(<issue>9</issue>):<fpage>5339</fpage>&#8211;<lpage>5350</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C9RA08059G</pub-id>.<pub-id pub-id-type="pmid">35498283</pub-id><pub-id pub-id-type="pmcid">PMC9049170</pub-id></mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schneider</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Simmering</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hartmann</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pforte</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Blaut</surname><given-names>M</given-names></string-name></person-group>. <article-title>Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria</article-title>. <source>J Appl Microbiol</source>. <year>2000</year>;<volume>89</volume>(<issue>6</issue>):<fpage>1027</fpage>&#8211;<lpage>1037</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2672.2000.01209.x</pub-id>.<pub-id pub-id-type="pmid">11123476</pub-id></mixed-citation></ref><ref id="cit0122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruan</surname><given-names>JQ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>YP</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>R</given-names></string-name></person-group>. <article-title>The Presystemic interplay between gut microbiota and orally administered calycosin-7-O-&#946;-D-Glucoside</article-title>. <source>Drug Metab Dispos</source>. <year>2015</year>;<volume>43</volume>(<issue>10</issue>):<fpage>1601</fpage>&#8211;<lpage>1611</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.115.065094</pub-id>.<pub-id pub-id-type="pmid">26101224</pub-id></mixed-citation></ref><ref id="cit0123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yoo</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Van Le</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DH</given-names></string-name></person-group>. <article-title>Gut microbiota-mediated drug interactions between lovastatin and antibiotics</article-title>. <source>Drug Metab Dispos</source>. <year>2014</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1508</fpage>&#8211;<lpage>1513</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.114.058354</pub-id>.<pub-id pub-id-type="pmid">24947972</pub-id></mixed-citation></ref><ref id="cit0124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Preta</surname><given-names>G</given-names></string-name></person-group>. <article-title>Role of lactone and acid forms in the pleiotropic effects of statins</article-title>. <source>Pharmaceutics</source>. <year>2022</year>;<volume>14</volume>(<issue>9</issue>). doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics14091899</pub-id>.<pub-id pub-id-type="pmcid">PMC9503516</pub-id><pub-id pub-id-type="pmid">36145647</pub-id></mixed-citation></ref><ref id="cit0125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iveson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lindup</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Parke</surname><given-names>DV</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>RT</given-names></string-name></person-group>. <article-title>The metabolism of carbenoxolone in the rat</article-title>. <source>Xenobiotica</source>. <year>1971</year>;<volume>1</volume>(<issue>1</issue>):<fpage>79</fpage>&#8211;<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498257109044381</pub-id>.<pub-id pub-id-type="pmid">5163178</pub-id></mixed-citation></ref><ref id="cit0126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>ON</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DH</given-names></string-name></person-group>. <article-title>Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin</article-title>. <source>Biochem Pharmacol</source>. <year>2016</year>;<volume>122</volume>:<fpage>72</fpage>&#8211;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bcp.2016.09.023</pub-id>.<pub-id pub-id-type="pmid">27687643</pub-id></mixed-citation></ref><ref id="cit0127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Sychantha</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Structural basis for the O-acetyltransferase function of the extracytoplasmic domain of OatA from staphylococcus aureus</article-title>. <source>J Biol Chem</source>. <year>2020</year>;<volume>295</volume>(<issue>24</issue>):<fpage>8204</fpage>&#8211;<lpage>8213</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.RA120.013108</pub-id>.<pub-id pub-id-type="pmid">32350117</pub-id><pub-id pub-id-type="pmcid">PMC7294091</pub-id></mixed-citation></ref><ref id="cit0128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cocaign</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wilberg</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lindley</surname><given-names>ND</given-names></string-name></person-group>. <article-title>Sequential demethoxylation reactions during methylotrophic growth of methoxylated aromatic substrates with eubacterium limosum</article-title>. <source>Archiv Microbiol</source>. <year>1991</year>;<volume>155</volume>(<issue>5</issue>):<fpage>496</fpage>&#8211;<lpage>499</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00244968</pub-id>.</mixed-citation></ref><ref id="cit0129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Studenik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Diekert</surname><given-names>G</given-names></string-name></person-group>. <article-title>Characterization of an O-demethylase of desulfitobacterium hafniense DCB-2</article-title>. <source>J Bacteriol</source>. <year>2012</year>;<volume>194</volume>(<issue>13</issue>):<fpage>3317</fpage>&#8211;<lpage>3326</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.00146-12</pub-id>.<pub-id pub-id-type="pmid">22522902</pub-id><pub-id pub-id-type="pmcid">PMC3434752</pub-id></mixed-citation></ref><ref id="cit0130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maini Rekdal</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nol Bernadino</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Luescher</surname><given-names>MU</given-names></string-name>, <string-name name-style="western"><surname>Kiamehr</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bisanz</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Bess</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></string-name></person-group>. <article-title>A widely distributed metalloenzyme class enables gut microbial metabolism of host- and diet-derived catechols</article-title>. <source>Elife</source>. <year>2020</year>;<volume>9</volume>. doi:<pub-id pub-id-type="doi">10.7554/eLife.50845</pub-id>.<pub-id pub-id-type="pmcid">PMC7028382</pub-id><pub-id pub-id-type="pmid">32067637</pub-id></mixed-citation></ref><ref id="cit0131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rich</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>de Ora</surname><given-names>LO</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>ZG</given-names></string-name>, <string-name name-style="western"><surname>Uyeda</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Bess</surname><given-names>EN</given-names></string-name></person-group>. <article-title>Alternative pathway for dopamine production by acetogenic gut bacteria that O-Demethylate 3-methoxytyramine, a metabolite of catechol O-Methyltransferase</article-title>. <source>J Appl Microbiol</source>. <year>2022</year>;<volume>133</volume>(<issue>3</issue>):<fpage>1697</fpage>&#8211;<lpage>1708</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jam.15682</pub-id>.<pub-id pub-id-type="pmid">35737746</pub-id><pub-id pub-id-type="pmcid">PMC9544265</pub-id></mixed-citation></ref><ref id="cit0132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sweeny</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Clough</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bhamidipati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Baluom</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Grossbard</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname><given-names>DT</given-names></string-name></person-group>. <article-title>Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation</article-title>. <source>Drug Metab Dispos</source>. <year>2010</year>;<volume>38</volume>(<issue>7</issue>):<fpage>1166</fpage>&#8211;<lpage>1176</lpage>.<pub-id pub-id-type="pmid">20371637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.032151</pub-id></mixed-citation></ref><ref id="cit0133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Senizza</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rocchetti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mosele</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Patrone</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Callegari</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Morelli</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lucini</surname><given-names>L</given-names></string-name></person-group>. <article-title>Lignans and gut microbiota: an interplay revealing potential health implications</article-title>. <source>Molecules</source>. <year>2020</year>;<volume>25</volume>(<issue>23</issue>):<fpage>5709</fpage>. doi:<pub-id pub-id-type="doi">10.3390/molecules25235709</pub-id>.<pub-id pub-id-type="pmid">33287261</pub-id><pub-id pub-id-type="pmcid">PMC7731202</pub-id></mixed-citation></ref><ref id="cit0134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adlercreutz</surname><given-names>H</given-names></string-name></person-group>. <article-title>Lignans and human health</article-title>. <source>Crit Rev Clin Lab Sci</source>. <year>2007</year>;<volume>44</volume>(<issue>5&#8211;6</issue>):<fpage>483</fpage>&#8211;<lpage>525</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10408360701612942</pub-id>.<pub-id pub-id-type="pmid">17943494</pub-id></mixed-citation></ref><ref id="cit0135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sandler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karoum</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ruthven</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Calne</surname><given-names>DB</given-names></string-name></person-group>. <article-title>M-hydroxyphenylacetic acid formation from L-dopa in man: suppression by neomycin</article-title>. <source>Science</source>. <year>1969</year>;<volume>166</volume>(<issue>3911</issue>):<fpage>1417</fpage>&#8211;<lpage>1418</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.166.3911.1417</pub-id>.<pub-id pub-id-type="pmid">5350345</pub-id></mixed-citation></ref><ref id="cit0136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bokkenheuser</surname><given-names>VD</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dehazya</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>WG</given-names></string-name></person-group>. <article-title>Isolation and characterization of human fecal bacteria capable of 21-dehydroxylating corticoids</article-title>. <source>Appl Environ Microbiol</source>. <year>1977</year>;<volume>34</volume>(<issue>5</issue>):<fpage>571</fpage>&#8211;<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1128/aem.34.5.571-575.1977</pub-id>.<pub-id pub-id-type="pmid">303887</pub-id><pub-id pub-id-type="pmcid">PMC242702</pub-id></mixed-citation></ref><ref id="cit0137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morris</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Brem</surname><given-names>AS</given-names></string-name></person-group>. <article-title>Role of gut metabolism of adrenal corticosteroids and hypertension: clues gut-cleansing antibiotics give us</article-title>. <source>Physiol Genomics</source>. <year>2019</year>;<volume>51</volume>(<issue>3</issue>):<fpage>83</fpage>&#8211;<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1152/physiolgenomics.00115.2018</pub-id>.<pub-id pub-id-type="pmid">30681907</pub-id></mixed-citation></ref><ref id="cit0138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hirano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nakama</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tamaki</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Masuda</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Oda</surname><given-names>H</given-names></string-name></person-group>. <article-title>Isolation and characterization of thirteen intestinal microorganisms capable of 7 alpha-dehydroxylating bile acids</article-title>. <source>Appl Environ Microbiol</source>. <year>1981</year>;<volume>41</volume>(<issue>3</issue>):<fpage>737</fpage>&#8211;<lpage>745</lpage>. doi:<pub-id pub-id-type="doi">10.1128/aem.41.3.737-745.1981</pub-id>.<pub-id pub-id-type="pmid">7224633</pub-id><pub-id pub-id-type="pmcid">PMC243769</pub-id></mixed-citation></ref><ref id="cit0139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Devlin</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Fischbach</surname><given-names>MA</given-names></string-name></person-group>. <article-title>A biosynthetic pathway for a prominent class of microbiota-derived bile acids</article-title>. <source>Nat Chem Biol</source>. <year>2015</year>;<volume>11</volume>(<issue>9</issue>):<fpage>685</fpage>&#8211;<lpage>690</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nchembio.1864</pub-id>.<pub-id pub-id-type="pmid">26192599</pub-id><pub-id pub-id-type="pmcid">PMC4543561</pub-id></mixed-citation></ref><ref id="cit0140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wells</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></string-name></person-group>. <article-title>Identification and characterization of a bile acid 7alpha-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces</article-title>. <source>Appl Environ Microbiol</source>. <year>2000</year>;<volume>66</volume>(<issue>3</issue>):<fpage>1107</fpage>&#8211;<lpage>1113</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.66.3.1107-1113.2000</pub-id>.<pub-id pub-id-type="pmid">10698778</pub-id><pub-id pub-id-type="pmcid">PMC91949</pub-id></mixed-citation></ref><ref id="cit0141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guzior</surname><given-names>DV</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Review: microbial transformations of human bile acids</article-title>. <source>Microbiome</source>. <year>2021</year>;<volume>9</volume>(<issue>1</issue>):<fpage>140</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40168-021-01101-1</pub-id>.<pub-id pub-id-type="pmid">34127070</pub-id><pub-id pub-id-type="pmcid">PMC8204491</pub-id></mixed-citation></ref><ref id="cit0142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mythen</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Devendran</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>M&#233;ndez-Garc&#237;a</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cann</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ridlon</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Targeted synthesis and characterization of a gene cluster encoding NAD(P)H-Dependent 3&#945;-, 3&#946;-, and 12&#945;-hydroxysteroid dehydrogenases from Eggerthella CAG: 298, a gut metagenomic sequence</article-title>. <source>Appl Environ Microbiol</source>. <year>2018</year>;<volume>84</volume>(<issue>7</issue>):<fpage>e02475</fpage>&#8211;<lpage>02417</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.02475-17</pub-id>.<pub-id pub-id-type="pmid">29330189</pub-id><pub-id pub-id-type="pmcid">PMC5861830</pub-id></mixed-citation></ref><ref id="cit0143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Crnkovic</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Won</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Orjala</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname><given-names>H</given-names></string-name></person-group>. <article-title>Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites</article-title>. <source>Drug Metab Dispos</source>. <year>2019</year>;<volume>47</volume>(<issue>3</issue>):<fpage>194</fpage>&#8211;<lpage>202</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.118.084772</pub-id>.<pub-id pub-id-type="pmid">30598508</pub-id><pub-id pub-id-type="pmcid">PMC6367689</pub-id></mixed-citation></ref><ref id="cit0144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jourova</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Anzenbacher</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Matuskova</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Vecera</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Strojil</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kolar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nobilis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hermanova</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hudcovic</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kozakova</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Gut microbiota metabolizes nabumetone in vitro: consequences for its bioavailability in vivo in the rodents with altered gut microbiome</article-title>. <source>Xenobiotica</source>. <year>2019</year>;<volume>49</volume>(<issue>11</issue>):<fpage>1296</fpage>&#8211;<lpage>1302</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00498254.2018.1558310</pub-id>.<pub-id pub-id-type="pmid">30794062</pub-id></mixed-citation></ref><ref id="cit0145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Larsen</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Cysteine conjugate beta-lyase in the gastrointestinal bacterium Eubacterium limosum</article-title>. <source>Mol Pharmacol</source>. <year>1986</year>;<volume>29</volume>(<issue>1</issue>):<fpage>97</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">3945231</pub-id></mixed-citation></ref><ref id="cit0146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cooper</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Krasnikov</surname><given-names>BF</given-names></string-name>, <string-name name-style="western"><surname>Niatsetskaya</surname><given-names>ZV</given-names></string-name>, <string-name name-style="western"><surname>Pinto</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Callery</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Villar</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Artigues</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bruschi</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Cysteine S-conjugate &#946;-lyases: important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents</article-title>. <source>Amino Acids</source>. <year>2011</year>;<volume>41</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00726-010-0552-0</pub-id>.<pub-id pub-id-type="pmid">20306345</pub-id><pub-id pub-id-type="pmcid">PMC2898922</pub-id></mixed-citation></ref><ref id="cit0147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shu</surname><given-names>YZ</given-names></string-name>, <string-name name-style="western"><surname>Kingston</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Van Tassell</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Wilkins</surname><given-names>TD</given-names></string-name></person-group>. <article-title>Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria</article-title>. <source>Xenobiotica</source>. <year>1991</year>;<volume>21</volume>(<issue>6</issue>):<fpage>737</fpage>&#8211;<lpage>750</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498259109039513</pub-id>.<pub-id pub-id-type="pmid">1949905</pub-id></mixed-citation></ref><ref id="cit0148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gingell</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bridges</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>RT</given-names></string-name></person-group>. <article-title>The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat</article-title>. <source>Xenobiotica</source>. <year>1971</year>;<volume>1</volume>(<issue>2</issue>):<fpage>143</fpage>&#8211;<lpage>156</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498257109044386</pub-id>.<pub-id pub-id-type="pmid">5173017</pub-id></mixed-citation></ref><ref id="cit0149"><label>149.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Choi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fenando</surname><given-names>A</given-names></string-name></person-group>. <source>Sulfasalazine. StatPearls</source>. <publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls Publishing. Copyright &#169; 2024, StatPearls Publishing LLC</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="cit0150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peppercorn</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>P</given-names></string-name></person-group>. <article-title>The role of intestinal bacteria in the metabolism of salicylazosulfapyridine</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1972</year>;<volume>181</volume>(<issue>3</issue>):<fpage>555</fpage>&#8211;<lpage>562</lpage>.<pub-id pub-id-type="pmid">4402374</pub-id></mixed-citation></ref><ref id="cit0151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ito</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nakanishi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Sasaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zenno</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Saigo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kitade</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tanokura</surname><given-names>M</given-names></string-name></person-group>. <article-title>Three-dimensional structure of AzoR from Escherichia coli. An oxidereductase conserved in microorganisms</article-title>. <source>J Biol Chem</source>. <year>2006</year>;<volume>281</volume>(<issue>29</issue>):<fpage>20567</fpage>&#8211;<lpage>20576</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M513345200</pub-id>.<pub-id pub-id-type="pmid">16684776</pub-id></mixed-citation></ref><ref id="cit0152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ryan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Laurieri</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Westwood</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sim</surname><given-names>E</given-names></string-name></person-group>. <article-title>Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases</article-title>. <source>Protein Cell</source>. <year>2010</year>;<volume>1</volume>(<issue>8</issue>):<fpage>780</fpage>&#8211;<lpage>790</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13238-010-0090-2</pub-id>.<pub-id pub-id-type="pmid">21203919</pub-id><pub-id pub-id-type="pmcid">PMC4875192</pub-id></mixed-citation></ref><ref id="cit0153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chan</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Pope</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Gilbert</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Sacra</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Baron</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Lennard-Jones</surname><given-names>JE</given-names></string-name></person-group>. <article-title>Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide</article-title>. <source>Dig Dis Sci</source>. <year>1983</year>;<volume>28</volume>(<issue>7</issue>):<fpage>609</fpage>&#8211;<lpage>615</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF01299921</pub-id>.<pub-id pub-id-type="pmid">6345112</pub-id></mixed-citation></ref><ref id="cit0154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wadworth</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Fitton</surname><given-names>A</given-names></string-name></person-group>. <article-title>Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease</article-title>. <source>Drugs</source>. <year>1991</year>;<volume>41</volume>(<issue>4</issue>):<fpage>647</fpage>&#8211;<lpage>664</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003495-199141040-00009</pub-id>.<pub-id pub-id-type="pmid">1711964</pub-id></mixed-citation></ref><ref id="cit0155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sousa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Zann</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Borde</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abrahamsson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Basit</surname><given-names>AW</given-names></string-name></person-group>. <article-title>On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid</article-title>. <source>J Pharm Sci</source>. <year>2014</year>;<volume>103</volume>(<issue>10</issue>):<fpage>3171</fpage>&#8211;<lpage>3175</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jps.24103</pub-id>.<pub-id pub-id-type="pmid">25091594</pub-id></mixed-citation></ref><ref id="cit0156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zahran</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Ali-Tammam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hashem</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Aziz</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>AE</given-names></string-name></person-group>. <article-title>Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>5508</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-019-41894-8</pub-id>.<pub-id pub-id-type="pmid">30940826</pub-id><pub-id pub-id-type="pmcid">PMC6445285</pub-id></mixed-citation></ref><ref id="cit0157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rogers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sychterz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Talley</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bershas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Serabjit-Singh</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Investigations of hydrazine cleavage of eltrombopag in humans</article-title>. <source>Drug Metab Dispos</source>. <year>2011</year>;<volume>39</volume>(<issue>9</issue>):<fpage>1747</fpage>&#8211;<lpage>1754</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.111.040188</pub-id>.<pub-id pub-id-type="pmid">21646438</pub-id></mixed-citation></ref><ref id="cit0158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mercier</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chalansonnet</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Orenga</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gilbert</surname><given-names>C</given-names></string-name></person-group>. <article-title>Characteristics of major Escherichia coli reductases involved in aerobic nitro and azo reduction</article-title>. <source>J Appl Microbiol</source>. <year>2013</year>;<volume>115</volume>(<issue>4</issue>):<fpage>1012</fpage>&#8211;<lpage>1022</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jam.12294</pub-id>.<pub-id pub-id-type="pmid">23795903</pub-id></mixed-citation></ref><ref id="cit0159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Antila</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huuskonen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nevalainen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kanerva</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Vanninen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lehtonen</surname><given-names>L</given-names></string-name></person-group>. <article-title>Site dependent bioavailability and metabolism of levosimendan in dogs</article-title>. <source>Eur J Pharm Sci</source>. <year>1999</year>;<volume>9</volume>(<issue>1</issue>):<fpage>85</fpage>&#8211;<lpage>91</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0928-0987(99)00048-2</pub-id>.<pub-id pub-id-type="pmid">10494001</pub-id></mixed-citation></ref><ref id="cit0160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rold&#225;n</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Reinado</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Moreno-Vivi&#225;n</surname><given-names>C</given-names></string-name></person-group>. <article-title>Reduction of polynitroaromatic compounds: the bacterial nitroreductases</article-title>. <source>FEMS Microbiol Rev</source>. <year>2008</year>;<volume>32</volume>(<issue>3</issue>):<fpage>474</fpage>&#8211;<lpage>500</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1574-6976.2008.00107.x</pub-id>.<pub-id pub-id-type="pmid">18355273</pub-id></mixed-citation></ref><ref id="cit0161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elmer</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Remmel</surname><given-names>RP</given-names></string-name></person-group>. <article-title>Role of the intestinal microflora in clonazepam metabolism in the rat</article-title>. <source>Xenobiotica</source>. <year>1984</year>;<volume>14</volume>(<issue>11</issue>):<fpage>829</fpage>&#8211;<lpage>840</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498258409151481</pub-id>.<pub-id pub-id-type="pmid">6506755</pub-id></mixed-citation></ref><ref id="cit0162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Takeno</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sakai</surname><given-names>T</given-names></string-name></person-group>. <article-title>Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction</article-title>. <source>Teratology</source>. <year>1991</year>;<volume>44</volume>(<issue>2</issue>):<fpage>209</fpage>&#8211;<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1002/tera.1420440209</pub-id>.<pub-id pub-id-type="pmid">1925980</pub-id></mixed-citation></ref><ref id="cit0163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rafii</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sutherland</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>EB</given-names><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Cerniglia</surname><given-names>CE</given-names></string-name></person-group>. <article-title>Reduction of nitrazepam by clostridium leptum, a nitroreductase-producing bacterium isolated from the human intestinal tract</article-title>. <source>Clin Infect Dis</source>. <year>1997</year>;<volume>25</volume>(<issue>Suppl 2</issue>):<fpage>S121</fpage>&#8211;<lpage>122</lpage>. doi:<pub-id pub-id-type="doi">10.1086/516204</pub-id>.<pub-id pub-id-type="pmid">9310649</pub-id></mixed-citation></ref><ref id="cit0164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>LinWu</surname><given-names>S-W</given-names></string-name>, <string-name name-style="western"><surname>Syu</surname><given-names>C-J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y-L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>AHJ</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>F-C</given-names></string-name></person-group>. <article-title>Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines</article-title>. <source>Biochemical Pharmacol</source>. <year>2009</year>;<volume>78</volume>(<issue>1</issue>):<fpage>96</fpage>&#8211;<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bcp.2009.03.019</pub-id>.<pub-id pub-id-type="pmid">19447228</pub-id></mixed-citation></ref><ref id="cit0165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Merkel</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Steers</surname><given-names>E</given-names></string-name></person-group>. <article-title>Relationship between chloramphenicol reductase activity and chloramphenicol resistance in Escherichia coli</article-title>. <source>J Bacteriol</source>. <year>1953</year>;<volume>66</volume>(<issue>4</issue>):<fpage>389</fpage>&#8211;<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jb.66.4.389-396.1953</pub-id>.<pub-id pub-id-type="pmid">13096493</pub-id><pub-id pub-id-type="pmcid">PMC317399</pub-id></mixed-citation></ref><ref id="cit0166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Erwin</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Kline</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Unrath</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Weber</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Howald</surname><given-names>WN</given-names></string-name></person-group>. <article-title>Chloramphenicol is a substrate for a novel nitroreductase pathway in Haemophilus influenzae</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2007</year>;<volume>51</volume>(<issue>8</issue>):<fpage>2820</fpage>&#8211;<lpage>2829</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00087-07</pub-id>.<pub-id pub-id-type="pmid">17526758</pub-id><pub-id pub-id-type="pmcid">PMC1932534</pub-id></mixed-citation></ref><ref id="cit0167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crofts</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Sontha</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Biddy</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Zanolli</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gaumnitz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dantas</surname><given-names>G</given-names></string-name></person-group>. <article-title>Discovery and characterization of a nitroreductase capable of conferring bacterial resistance to chloramphenicol</article-title>. <source>Cell Chem Biol</source>. <year>2019</year>;<volume>26</volume>(<issue>4</issue>):<fpage>559</fpage>&#8211;<lpage>570.e6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chembiol.2019.01.007</pub-id>.<pub-id pub-id-type="pmid">30799223</pub-id><pub-id pub-id-type="pmcid">PMC6474809</pub-id></mixed-citation></ref><ref id="cit0168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Basit</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Newton</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Lacey</surname><given-names>LF</given-names></string-name></person-group>. <article-title>Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora</article-title>. <source>Int J Pharm</source>. <year>2002</year>;<volume>237</volume>(<issue>1&#8211;2</issue>):<fpage>23</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0378-5173(02)00018-2</pub-id>.<pub-id pub-id-type="pmid">11955801</pub-id></mixed-citation></ref><ref id="cit0169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Basit</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Lacey</surname><given-names>LF</given-names></string-name></person-group>. <article-title>Colonic metabolism of ranitidine: implications for its delivery and absorption</article-title>. <source>Int J Pharm</source>. <year>2001</year>;<volume>227</volume>(<issue>1&#8211;2</issue>):<fpage>157</fpage>&#8211;<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0378-5173(01)00794-3</pub-id>.<pub-id pub-id-type="pmid">11564550</pub-id></mixed-citation></ref><ref id="cit0170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Teng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ju</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hua</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mu</surname><given-names>X</given-names></string-name></person-group>. <article-title>Combined antitumor activity of the nitroreductase/CB1954 suicide gene system and &#947;-rays in HeLa cells in vitro</article-title>. <source>Mol Med Rep</source>. <year>2016</year>;<volume>14</volume>(<issue>6</issue>):<fpage>5164</fpage>&#8211;<lpage>5170</lpage>. doi:<pub-id pub-id-type="doi">10.3892/mmr.2016.5917</pub-id>.<pub-id pub-id-type="pmid">27840931</pub-id><pub-id pub-id-type="pmcid">PMC5355654</pub-id></mixed-citation></ref><ref id="cit0171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Emptage</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Knox</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Danson</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Hough</surname><given-names>DW</given-names></string-name></person-group>. <article-title>Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation</article-title>. <source>Biochem Pharmacol</source>. <year>2009</year>;<volume>77</volume>(<issue>1</issue>):<fpage>21</fpage>&#8211;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bcp.2008.09.010</pub-id>.<pub-id pub-id-type="pmid">18840409</pub-id></mixed-citation></ref><ref id="cit0172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mitchell</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Minchin</surname><given-names>RF</given-names></string-name></person-group>. <article-title>E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2</article-title>. <source>Cancer Gene Ther</source>. <year>2008</year>;<volume>15</volume>(<issue>11</issue>):<fpage>758</fpage>&#8211;<lpage>764</lpage>. doi:<pub-id pub-id-type="doi">10.1038/cgt.2008.47</pub-id>.<pub-id pub-id-type="pmid">18600257</pub-id></mixed-citation></ref><ref id="cit0173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Williams</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Little</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Mowday</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Rich</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Chan-Hyams</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Copp</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Smaill</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Patterson</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Ackerley</surname><given-names>DF</given-names></string-name></person-group>. <article-title>Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility</article-title>. <source>Biochem J</source>. <year>2015</year>;<volume>471</volume>(<issue>2</issue>):<fpage>131</fpage>&#8211;<lpage>153</lpage>. doi:<pub-id pub-id-type="doi">10.1042/BJ20150650</pub-id>.<pub-id pub-id-type="pmid">26431849</pub-id></mixed-citation></ref><ref id="cit0174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lavrijsen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>van Dyck</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>van Houdt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hendrickx</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Monbaliu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Woestenborghs</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Meuldermans</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Heykants</surname><given-names>J</given-names></string-name></person-group>. <article-title>Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans</article-title>. <source>Drug Metab Dispos</source>. <year>1995</year>;<volume>23</volume>(<issue>3</issue>):<fpage>354</fpage>&#8211;<lpage>362</lpage>.<pub-id pub-id-type="pmid">7628301</pub-id></mixed-citation></ref><ref id="cit0175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jaworski</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Hawes</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Hubbard</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>McKay</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Midha</surname><given-names>KK</given-names></string-name></person-group>. <article-title>The metabolites of chlorpromazine N-oxide in rat bile</article-title>. <source>Xenobiotica</source>. <year>1991</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1451</fpage>&#8211;<lpage>1459</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498259109044395</pub-id>.<pub-id pub-id-type="pmid">1763519</pub-id></mixed-citation></ref><ref id="cit0176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Powis</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ames</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Kovach</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Metabolic conversion of indicine N-oxide to indicine in rabbits and humans</article-title>. <source>Cancer Res</source>. <year>1979</year>;<volume>39</volume>(<issue>9</issue>):<fpage>3564</fpage>&#8211;<lpage>3570</lpage>.<pub-id pub-id-type="pmid">476682</pub-id></mixed-citation></ref><ref id="cit0177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dajani</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Gorrod</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Beckett</surname><given-names>AH</given-names></string-name></person-group>. <article-title>Reduction in vivo of (&#8722;)-nicotine-1&#8242;-N-oxide by germ-free and conventional rats</article-title>. <source>Biochemical Pharmacol</source>. <year>1975</year>;<volume>24</volume>(<issue>5</issue>):<fpage>648</fpage>&#8211;<lpage>650</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0006-2952(75)90189-6</pub-id>.<pub-id pub-id-type="pmid">1125066</pub-id></mixed-citation></ref><ref id="cit0178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Atawodi</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Richter</surname><given-names>E</given-names></string-name></person-group>. <article-title>Bacterial reduction of N-oxides of tobacco-specific nitrosamines (TSNA</article-title>. <source>Hum Exp Toxicol</source>. <year>1996</year>;<volume>15</volume>(<issue>4</issue>):<fpage>329</fpage>&#8211;<lpage>334</lpage>. doi:<pub-id pub-id-type="doi">10.1177/096032719601500409</pub-id>.<pub-id pub-id-type="pmid">8845223</pub-id></mixed-citation></ref><ref id="cit0179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gillani</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Rawling</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>M</given-names></string-name></person-group>. <article-title>Cytochrome P450-mediated biotransformation of sorafenib and its N-Oxide metabolite: implications for cell viability and human toxicity</article-title>. <source>Chem Res Toxicol</source>. <year>2015</year>;<volume>28</volume>(<issue>1</issue>):<fpage>92</fpage>&#8211;<lpage>102</lpage>. doi:<pub-id pub-id-type="doi">10.1021/tx500373g</pub-id>.<pub-id pub-id-type="pmid">25489883</pub-id></mixed-citation></ref><ref id="cit0180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boonhai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bootdee</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Saisorn</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Takkavatakarn</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sitticharoenchai</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tungsanga</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tiranathanagul</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Leelahavanichkul</surname><given-names>A</given-names></string-name></person-group>. <article-title>TMAO reductase, a biomarker for gut permeability defect induced inflammation, in mouse model of chronic kidney disease and dextran sulfate solution-induced mucositis</article-title>. <source>Asian Pac J Allergy Immunol</source>. <year>2023</year>;<volume>41</volume>(<issue>2</issue>):<fpage>168</fpage>&#8211;<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.12932/AP-100321-1084</pub-id>.<pub-id pub-id-type="pmid">34284591</pub-id></mixed-citation></ref><ref id="cit0181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cotter</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Gunsalus</surname><given-names>RP</given-names></string-name></person-group>. <article-title>Oxygen, nitrate, and molybdenum regulation of dmsABC gene expression in Escherichia coli</article-title>. <source>J Bacteriol</source>. <year>1989</year>;<volume>171</volume>(<issue>7</issue>):<fpage>3817</fpage>&#8211;<lpage>3823</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jb.171.7.3817-3823.1989</pub-id>.<pub-id pub-id-type="pmid">2544558</pub-id><pub-id pub-id-type="pmcid">PMC210130</pub-id></mixed-citation></ref><ref id="cit0182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shamat</surname><given-names>MA</given-names></string-name></person-group>. <article-title>The role of the gastrointestinal microflora in the metabolism of drugs</article-title>. <source>Int J Pharm</source>. <year>1993</year>;<volume>97</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0378-5173(93)90121-U</pub-id>.</mixed-citation></ref><ref id="cit0183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sousa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Paterson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Carlsson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abrahamsson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Basit</surname><given-names>AW</given-names></string-name></person-group>. <article-title>The gastrointestinal microbiota as a site for the biotransformation of drugs</article-title>. <source>Int J Pharm</source>. <year>2008</year>;<volume>363</volume>(<issue>1&#8211;2</issue>):<fpage>1</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijpharm.2008.07.009</pub-id>.<pub-id pub-id-type="pmid">18682282</pub-id></mixed-citation></ref><ref id="cit0184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marshall</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>GF</given-names></string-name></person-group>. <article-title>Complete denitration of nitroglycerin by bacteria isolated from a washwater soakaway</article-title>. <source>Appl Environ Microbiol</source>. <year>2001</year>;<volume>67</volume>(<issue>6</issue>):<fpage>2622</fpage>&#8211;<lpage>2626</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.67.6.2622-2626.2001</pub-id>.<pub-id pub-id-type="pmid">11375172</pub-id><pub-id pub-id-type="pmcid">PMC92916</pub-id></mixed-citation></ref><ref id="cit0185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>White</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Snape</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Nicklin</surname><given-names>S</given-names></string-name></person-group>. <article-title>Bacterial biodegradation of glycerol trinitrate</article-title>. <source>Int Biodeterior &amp; Biodegrad</source>. <year>1996</year>;<volume>38</volume>(<issue>2</issue>):<fpage>77</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0964-8305(96)00028-5</pub-id>.<pub-id pub-id-type="pmcid">PMC1388782</pub-id><pub-id pub-id-type="pmid">16535244</pub-id></mixed-citation></ref><ref id="cit0186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lundberg</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Weitzberg</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gladwin</surname><given-names>MT</given-names></string-name></person-group>. <article-title>The nitrate&#8211;nitrite&#8211;nitric oxide pathway in physiology and therapeutics</article-title>. <source>Nat Rev Drug Discov</source>. <year>2008</year>;<volume>7</volume>(<issue>2</issue>):<fpage>156</fpage>&#8211;<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd2466</pub-id>.<pub-id pub-id-type="pmid">18167491</pub-id></mixed-citation></ref><ref id="cit0187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kitamura</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sugihara</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kuwasako</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tatsumi</surname><given-names>K</given-names></string-name></person-group>. <article-title>The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide</article-title>. <source>J Pharm Pharmacol</source>. <year>1997</year>;<volume>49</volume>(<issue>3</issue>):<fpage>253</fpage>&#8211;<lpage>256</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.2042-7158.1997.tb06790.x</pub-id>.<pub-id pub-id-type="pmid">9231340</pub-id></mixed-citation></ref><ref id="cit0188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname><given-names>JS</given-names></string-name></person-group>. <article-title>A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors</article-title>. <source>Int Clin Psychopharmacol</source>. <year>1995</year>;<volume>10</volume>(<issue>1</issue>):<fpage>19</fpage>&#8211;<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00004850-199503000-00003</pub-id>.<pub-id pub-id-type="pmid">7542676</pub-id></mixed-citation></ref><ref id="cit0189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butzbach</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Stockham</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Kobus</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Sims</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Byard</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Lokan</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>GS</given-names></string-name></person-group>. <article-title>Bacterial degradation of risperidone and paliperidone in decomposing blood</article-title>. <source>J Forensic Sci</source>. <year>2013</year>;<volume>58</volume>(<issue>1</issue>):<fpage>90</fpage>&#8211;<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1556-4029.2012.02280.x</pub-id>.<pub-id pub-id-type="pmid">22994980</pub-id></mixed-citation></ref><ref id="cit0190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Renwick</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Sweatman</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Cumberland</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>CF</given-names></string-name></person-group>. <article-title>The role of the gut flora in the reduction of sulphinpyrazone in the rat</article-title>. <source>Biochemical Pharmacol</source>. <year>1982</year>;<volume>31</volume>(<issue>16</issue>):<fpage>2649</fpage>&#8211;<lpage>2656</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0006-2952(82)90713-4</pub-id>.<pub-id pub-id-type="pmid">7138558</pub-id></mixed-citation></ref><ref id="cit0191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davis</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Guenthner</surname><given-names>LE</given-names></string-name></person-group>. <article-title>Sulindac oxidation/reduction by microbial cultures; microbial models of mammalian metabolism</article-title>. <source>Xenobiotica</source>. <year>1985</year>;<volume>15</volume>(<issue>10</issue>):<fpage>845</fpage>&#8211;<lpage>857</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498258509045036</pub-id>.<pub-id pub-id-type="pmid">4072250</pub-id></mixed-citation></ref><ref id="cit0192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Strong</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Renwick</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>The reduction of sulphinpyrazone and sulindac by intestinal bacteria</article-title>. <source>Xenobiotica</source>. <year>1987</year>;<volume>17</volume>(<issue>6</issue>):<fpage>685</fpage>&#8211;<lpage>696</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00498258709043976</pub-id>.<pub-id pub-id-type="pmid">3630204</pub-id></mixed-citation></ref><ref id="cit0193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Renwick</surname><given-names>AG</given-names></string-name></person-group>. <article-title>Sulphoxide reduction by rat intestinal flora and by Escherichia coli in vitro</article-title>. <source>Biochem Pharmacol</source>. <year>1995</year>;<volume>49</volume>(<issue>11</issue>):<fpage>1567</fpage>&#8211;<lpage>1576</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0006-2952(95)00093-F</pub-id>.<pub-id pub-id-type="pmid">7786297</pub-id></mixed-citation></ref><ref id="cit0194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Etienne</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Resnick</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sagher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brot</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Weissbach</surname><given-names>H</given-names></string-name></person-group>. <article-title>Reduction of sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2003</year>;<volume>312</volume>(<issue>4</issue>):<fpage>1005</fpage>&#8211;<lpage>1010</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2003.10.203</pub-id>.<pub-id pub-id-type="pmid">14651971</pub-id></mixed-citation></ref><ref id="cit0195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kappler</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Nasreen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McEwan</surname><given-names>A</given-names></string-name></person-group>. <article-title>New insights into the molecular physiology of sulfoxide reduction in bacteria</article-title>. <source>Adv Microb Physiol</source>. <year>2019</year>;<volume>75</volume>:<fpage>1</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">31655735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.ampbs.2019.05.001</pub-id></mixed-citation></ref><ref id="cit0196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yamashita</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Furuno</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kawasaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gomita</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Metabolism of omeprazole by gut flora in rats</article-title>. <source>J Pharm Sci</source>. <year>1995</year>;<volume>84</volume>(<issue>4</issue>):<fpage>516</fpage>&#8211;<lpage>517</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jps.2600840425</pub-id>.<pub-id pub-id-type="pmid">7629748</pub-id></mixed-citation></ref><ref id="cit0197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Hyun</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Shim</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Kobashi</surname><given-names>K</given-names></string-name></person-group>. <article-title>The role of intestinal bacteria in the transformation of sodium picosulfate</article-title>. <source>Jpn J Pharmacol</source>. <year>1992</year>;<volume>59</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1254/jjp.59.1</pub-id>.<pub-id pub-id-type="pmid">1507649</pub-id></mixed-citation></ref><ref id="cit0198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaysser</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Eitel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tanino</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Siebenberg</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Matsuda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ichikawa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gust</surname><given-names>B</given-names></string-name></person-group>. <article-title>A new arylsulfate sulfotransferase involved in liponucleoside antibiotic biosynthesis in streptomycetes</article-title>. <source>J Biol Chem</source>. <year>2010</year>;<volume>285</volume>(<issue>17</issue>):<fpage>12684</fpage>&#8211;<lpage>12694</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M109.094490</pub-id>.<pub-id pub-id-type="pmid">20157116</pub-id><pub-id pub-id-type="pmcid">PMC2857076</pub-id></mixed-citation></ref><ref id="cit0199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gallego-Hern&#225;ndez</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez-Lucas</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>De la Cruz</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Olvera</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Morett</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Medina-Aparicio</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ram&#237;rez-Trujillo</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>V&#225;zquez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez-Mora</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Calva</surname><given-names>E</given-names></string-name></person-group>. <article-title>Transcriptional regulation of the assT-dsbL-dsbI gene cluster in Salmonella enterica serovar typhi IMSS-1 depends on LeuO, H-NS, and specific growth conditions</article-title>. <source>J Bacteriol</source>. <year>2012</year>;<volume>194</volume>(<issue>9</issue>):<fpage>2254</fpage>&#8211;<lpage>2264</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.06164-11</pub-id>.<pub-id pub-id-type="pmid">22343301</pub-id><pub-id pub-id-type="pmcid">PMC3347046</pub-id></mixed-citation></ref><ref id="cit0200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mill&#225;n</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes</article-title>. <source>Purinergic Signal</source>. <year>2006</year>;<volume>2</volume>(<issue>2</issue>):<fpage>335</fpage>&#8211;<lpage>341</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11302-005-5435-6</pub-id>.<pub-id pub-id-type="pmid">18404473</pub-id><pub-id pub-id-type="pmcid">PMC2254479</pub-id></mixed-citation></ref><ref id="cit0201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jancova</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Anzenbacher</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Anzenbacherova</surname><given-names>E</given-names></string-name></person-group>. <article-title>Phase II drug metabolizing enzymes</article-title>. <source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source>. <year>2010</year>;<volume>154</volume>(<issue>2</issue>):<fpage>103</fpage>&#8211;<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.5507/bp.2010.017</pub-id>.<pub-id pub-id-type="pmid">20668491</pub-id></mixed-citation></ref><ref id="cit0202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maloj&#269;i&#263;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Owen</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Glockshuber</surname><given-names>R</given-names></string-name></person-group>. <article-title>Structural and mechanistic insights into the PAPS-Independent sulfotransfer catalyzed by bacterial aryl sulfotransferase and the role of the DsbL/DsbI system in its folding</article-title>. <source>Biochemistry</source>. <year>2014</year>;<volume>53</volume>(<issue>11</issue>):<fpage>1870</fpage>&#8211;<lpage>1877</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bi401725j</pub-id>.<pub-id pub-id-type="pmid">24601529</pub-id></mixed-citation></ref><ref id="cit0203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shaw</surname><given-names>WV</given-names></string-name></person-group>. <article-title>Chloramphenicol acetyltransferase: enzymology and molecular biology</article-title>. <source>CRC Crit Rev Biochem</source>. <year>1983</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.3109/10409238309102789</pub-id>.<pub-id pub-id-type="pmid">6340955</pub-id></mixed-citation></ref><ref id="cit0204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dull</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Salata</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>P</given-names></string-name></person-group>. <article-title>Role of the intestinal flora in the acetylation of sulfasalazine metabolites</article-title>. <source>Biochem Pharmacol</source>. <year>1987</year>;<volume>36</volume>(<issue>21</issue>):<fpage>3772</fpage>&#8211;<lpage>3774</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0006-2952(87)90034-7</pub-id>.<pub-id pub-id-type="pmid">2890356</pub-id></mixed-citation></ref><ref id="cit0205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Delom&#233;nie</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fouix</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Longuemaux</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brahimi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bizet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Picard</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Denamur</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dupret</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid</article-title>. <source>J Bacteriol</source>. <year>2001</year>;<volume>183</volume>(<issue>11</issue>):<fpage>3417</fpage>&#8211;<lpage>3427</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.183.11.3417-3427.2001</pub-id>.<pub-id pub-id-type="pmid">11344150</pub-id><pub-id pub-id-type="pmcid">PMC99640</pub-id></mixed-citation></ref><ref id="cit0206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Westwood</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Holton</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues-Lima</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Dupret</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Bhakta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Noble</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Sim</surname><given-names>E</given-names></string-name></person-group>. <article-title>Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase</article-title>. <source>Biochem J</source>. <year>2005</year>;<volume>385</volume>(<issue>Pt 2</issue>):<fpage>605</fpage>&#8211;<lpage>612</lpage>. doi:<pub-id pub-id-type="doi">10.1042/BJ20041330</pub-id>.<pub-id pub-id-type="pmid">15447630</pub-id><pub-id pub-id-type="pmcid">PMC1134735</pub-id></mixed-citation></ref><ref id="cit0207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>XC</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>FJ</given-names></string-name></person-group>. <article-title>N-Hydroxyarylamine O-Acetyltransferases catalyze acetylation of 3-amino-4-hydroxyphenylarsonic acid in the 4-hydroxy-3-nitrobenzenearsonic acid transformation pathway of Enterobacter sp. Strain CZ-1</article-title>. <source>Appl Environ Microbiol</source>. <year>2020</year>;<volume>86</volume>(<issue>2</issue>). doi:<pub-id pub-id-type="doi">10.1128/AEM.02050-19</pub-id>.<pub-id pub-id-type="pmcid">PMC6952230</pub-id><pub-id pub-id-type="pmid">31676473</pub-id></mixed-citation></ref><ref id="cit0208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quinn</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Melnik</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Vrbanac</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Patras</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Christy</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Bodai</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Belda-Ferre</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tripathi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>LK</given-names></string-name>, et al</person-group>. <article-title>Global chemical effects of the microbiome include new bile-acid conjugations</article-title>. <source>Nature</source>. <year>2020</year>;<volume>579</volume>(<issue>7797</issue>):<fpage>123</fpage>&#8211;<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2047-9</pub-id>.<pub-id pub-id-type="pmid">32103176</pub-id><pub-id pub-id-type="pmcid">PMC7252668</pub-id></mixed-citation></ref><ref id="cit0209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gentry</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Panitchpakdi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Belda-Ferre</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Carrillo Terrazas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H-H</given-names></string-name>, <string-name name-style="western"><surname>Zuffa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Avila-Pacheco</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Reverse metabolomics for the discovery of chemical structures from humans</article-title>. <source>Nature</source>. <year>2023</year>;<volume>626</volume>(<issue>7998</issue>):<fpage>419</fpage>&#8211;<lpage>426</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-023-06906-8</pub-id>.<pub-id pub-id-type="pmid">38052229</pub-id><pub-id pub-id-type="pmcid">PMC10849969</pub-id></mixed-citation></ref><ref id="cit0210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nugent</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rampton</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DF</given-names></string-name></person-group>. <article-title>Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs</article-title>. <source>Gut</source>. <year>2001</year>;<volume>48</volume>(<issue>4</issue>):<fpage>571</fpage>&#8211;<lpage>577</lpage>. doi:<pub-id pub-id-type="doi">10.1136/gut.48.4.571</pub-id>.<pub-id pub-id-type="pmid">11247905</pub-id><pub-id pub-id-type="pmcid">PMC1728243</pub-id></mixed-citation></ref><ref id="cit0211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Horrocks</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>OG</given-names></string-name>, <string-name name-style="western"><surname>Yip</surname><given-names>AYG</given-names></string-name>, <string-name name-style="western"><surname>Marques</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>McDonald</surname><given-names>JAK</given-names></string-name></person-group>. <article-title>Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization</article-title>. <source>Microbiol (Read)</source>. <year>2023</year>;<volume>169</volume>(<issue>8</issue>). doi:<pub-id pub-id-type="doi">10.1099/mic.0.001377</pub-id>.<pub-id pub-id-type="pmcid">PMC10482380</pub-id><pub-id pub-id-type="pmid">37540126</pub-id></mixed-citation></ref><ref id="cit0212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Selmer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Andrei</surname><given-names>PI</given-names></string-name></person-group>. <article-title>P-hydroxyphenylacetate decarboxylase from Clostridium difficile. A novel glycyl radical enzyme catalysing the formation of p-cresol</article-title>. <source>Eur J Biochem</source>. <year>2001</year>;<volume>268</volume>(<issue>5</issue>):<fpage>1363</fpage>&#8211;<lpage>1372</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1432-1327.2001.02001.x</pub-id>.<pub-id pub-id-type="pmid">11231288</pub-id></mixed-citation></ref><ref id="cit0213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peng</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Keerthisinghe</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>M</given-names></string-name></person-group>. <article-title>Gut microbial metabolite p-cresol alters biotransformation of bisphenol A: enzyme competition or gene induction?</article-title><source>J Hazard Mater</source>. <year>2022</year>;<volume>426</volume>:<fpage>128093</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhazmat.2021.128093</pub-id>.<pub-id pub-id-type="pmid">34952505</pub-id></mixed-citation></ref><ref id="cit0214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clayton</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lindon</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Everett</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Nicholson</surname><given-names>JK</given-names></string-name></person-group>. <article-title>Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2009</year>;<volume>106</volume>(<issue>34</issue>):<fpage>14728</fpage>&#8211;<lpage>14733</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0904489106</pub-id>.<pub-id pub-id-type="pmid">19667173</pub-id><pub-id pub-id-type="pmcid">PMC2731842</pub-id></mixed-citation></ref><ref id="cit0215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Desgranges</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Razaka</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>De Clercq</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Herdewijn</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Balzarini</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Drouillet</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bricaud</surname><given-names>H</given-names></string-name></person-group>. <article-title>Effect of (e)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice</article-title>. <source>Cancer Res</source>. <year>1986</year>;<volume>46</volume>(<issue>3</issue>):<fpage>1094</fpage>&#8211;<lpage>1101</lpage>.<pub-id pub-id-type="pmid">3943086</pub-id></mixed-citation></ref><ref id="cit0216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nishiyama</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ogura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Okuda</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Suda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Watabe</surname><given-names>T</given-names></string-name></person-group>. <article-title>Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (e)-5-(2-bromovinyl)uracil in the presence of NADPH</article-title>. <source>Mol Pharmacol</source>. <year>2000</year>;<volume>57</volume>(<issue>5</issue>):<fpage>899</fpage>&#8211;<lpage>905</lpage>.<pub-id pub-id-type="pmid">10779372</pub-id></mixed-citation></ref><ref id="cit0217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ogura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nishiyama</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Takubo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Okuda</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Arakawa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fukushima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nagayama</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kawaguchi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Watabe</surname><given-names>T</given-names></string-name></person-group>. <article-title>Suicidal inactivation of human dihydropyrimidine dehydrogenase by (e)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine</article-title>. <source>Cancer Lett</source>. <year>1998</year>;<volume>122</volume>(<issue>1&#8211;2</issue>):<fpage>107</fpage>&#8211;<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0304-3835(97)00377-7</pub-id>.<pub-id pub-id-type="pmid">9464498</pub-id></mixed-citation></ref><ref id="cit0218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Okuda</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ogura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Takubo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Watabe</surname><given-names>T</given-names></string-name></person-group>. <article-title>A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1998</year>;<volume>287</volume>(<issue>2</issue>):<fpage>791</fpage>&#8211;<lpage>799</lpage>.<pub-id pub-id-type="pmid">9808711</pub-id></mixed-citation></ref><ref id="cit0219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>R&#228;tz Bravo</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Hofer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kr&#228;henb&#252;hl</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ludwig</surname><given-names>C</given-names></string-name></person-group>. <article-title>Fatal drug-drug interaction of brivudine and capecitabine</article-title>. <source>Acta Oncol</source>. <year>2009</year>;<volume>48</volume>(<issue>4</issue>):<fpage>631</fpage>&#8211;<lpage>633</lpage>. doi:<pub-id pub-id-type="doi">10.1080/02841860802660502</pub-id>.<pub-id pub-id-type="pmid">19165642</pub-id></mixed-citation></ref><ref id="cit0220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Z</given-names></string-name></person-group>. <article-title>The influence of the gut microbiota on the bioavailability of oral drugs</article-title>. <source>Acta Pharmaceutica Sin B</source>. <year>2021</year>;<volume>11</volume>(<issue>7</issue>):<fpage>1789</fpage>&#8211;<lpage>1812</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apsb.2020.09.013</pub-id>.<pub-id pub-id-type="pmcid">PMC8343123</pub-id><pub-id pub-id-type="pmid">34386321</pub-id></mixed-citation></ref><ref id="cit0221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pavlovi&#263;</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Golo&#269;orbin-Kon</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>&#208;ani&#263;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stanimirov</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Al-Salami</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Stankov</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mikov</surname><given-names>M</given-names></string-name></person-group>. <article-title>Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles</article-title>. <source>Front Pharmacol</source>. <year>2018</year>;<volume>9</volume>:<fpage>1283</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2018.01283</pub-id>.<pub-id pub-id-type="pmid">30467479</pub-id><pub-id pub-id-type="pmcid">PMC6237018</pub-id></mixed-citation></ref><ref id="cit0222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Degraeve</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Haufroid</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Loriot</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gatto</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Andries</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vereecke</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Elens</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bindels</surname><given-names>LB</given-names></string-name></person-group>. <article-title>Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1</article-title>. <source>Microbiome</source>. <year>2023</year>;<volume>11</volume>(<issue>1</issue>):<fpage>138</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40168-023-01578-y</pub-id>.<pub-id pub-id-type="pmid">37408070</pub-id><pub-id pub-id-type="pmcid">PMC10324113</pub-id></mixed-citation></ref><ref id="cit0223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varma</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Rotter</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Chupka</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Whalen</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Duignan</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Litchfield</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goosen</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>El-Kattan</surname><given-names>AF</given-names></string-name></person-group>. <article-title>pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1</article-title>. <source>Mol Pharm</source>. <year>2011</year>;<volume>8</volume>(<issue>4</issue>):<fpage>1303</fpage>&#8211;<lpage>1313</lpage>. doi:<pub-id pub-id-type="doi">10.1021/mp200103h</pub-id>.<pub-id pub-id-type="pmid">21710988</pub-id></mixed-citation></ref><ref id="cit0224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Spanogiannopoulos</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pieper</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Chien</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Khuri</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pottel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vora</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tsakalozou</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>(<issue>27</issue>):<fpage>16009</fpage>&#8211;<lpage>16018</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1920483117</pub-id>.<pub-id pub-id-type="pmid">32571913</pub-id><pub-id pub-id-type="pmcid">PMC7355017</pub-id></mixed-citation></ref><ref id="cit0225"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fusco</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lorenzo</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Cintoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Porcari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rinninella</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kaitsas</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lener</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mele</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Gasbarrini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Collado</surname><given-names>MC</given-names></string-name>, et al</person-group>. <article-title>Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota</article-title>. <source>Nutrients</source>. <year>2023</year>;<volume>15</volume>(<issue>9</issue>):<fpage>2211</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu15092211</pub-id>.<pub-id pub-id-type="pmid">37432351</pub-id><pub-id pub-id-type="pmcid">PMC10180739</pub-id></mixed-citation></ref><ref id="cit0226"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hara</surname><given-names>H</given-names></string-name></person-group>. <article-title>Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability</article-title>. <source>Br J Nutr</source>. <year>2008</year>;<volume>100</volume>(<issue>2</issue>):<fpage>297</fpage>&#8211;<lpage>305</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0007114508888733</pub-id>.<pub-id pub-id-type="pmid">18346306</pub-id></mixed-citation></ref><ref id="cit0227"><label>227.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pohl</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Moodley</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dhanda</surname><given-names>A</given-names></string-name></person-group>. <article-title>The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: a systematic review</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2022</year>;<volume>37</volume>(<issue>8</issue>):<fpage>1498</fpage>&#8211;<lpage>1506</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jgh.15899</pub-id>.<pub-id pub-id-type="pmid">35612373</pub-id><pub-id pub-id-type="pmcid">PMC9545839</pub-id></mixed-citation></ref><ref id="cit0228"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Drawz</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bonomo</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Three decades of beta-lactamase inhibitors</article-title>. <source>Clin Microbiol Rev</source>. <year>2010</year>;<volume>23</volume>(<issue>1</issue>):<fpage>160</fpage>&#8211;<lpage>201</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00037-09</pub-id>.<pub-id pub-id-type="pmid">20065329</pub-id><pub-id pub-id-type="pmcid">PMC2806661</pub-id></mixed-citation></ref><ref id="cit0229"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>LoGuidice</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Bendel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Redinbo</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Boelsterli</surname><given-names>UA</given-names></string-name></person-group>. <article-title>Pharmacologic targeting of bacterial &#946;-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2012</year>;<volume>341</volume>(<issue>2</issue>):<fpage>447</fpage>&#8211;<lpage>454</lpage>. doi:<pub-id pub-id-type="doi">10.1124/jpet.111.191122</pub-id>.<pub-id pub-id-type="pmid">22328575</pub-id><pub-id pub-id-type="pmcid">PMC3336811</pub-id></mixed-citation></ref><ref id="cit0230"><label>230.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wallace</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lane</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Orans</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Koo</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Venkatesh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jobin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yeh</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Mani</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Alleviating cancer drug toxicity by inhibiting a bacterial enzyme</article-title>. <source>Science</source>. <year>2010</year>;<volume>330</volume>(<issue>6005</issue>):<fpage>831</fpage>&#8211;<lpage>835</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1191175</pub-id>.<pub-id pub-id-type="pmid">21051639</pub-id><pub-id pub-id-type="pmcid">PMC3110694</pub-id></mixed-citation></ref><ref id="cit0231"><label>231.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Awolade</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Cele</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kerru</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gummidi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Oluwakemi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>P</given-names></string-name></person-group>. <article-title>Therapeutic significance of &#946;-glucuronidase activity and its inhibitors: a review</article-title>. <source>Eur J Med Chem</source>. <year>2020</year>;<volume>187</volume>:<fpage>111921</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2019.111921</pub-id>.<pub-id pub-id-type="pmid">31835168</pub-id><pub-id pub-id-type="pmcid">PMC7111419</pub-id></mixed-citation></ref><ref id="cit0232"><label>232.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chamseddine</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Ducreux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Armand</surname><given-names>J-P</given-names></string-name>, <string-name name-style="western"><surname>Paoletti</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Satar</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Paci</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mir</surname><given-names>O</given-names></string-name></person-group>. <article-title>Intestinal bacterial &#946;-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity</article-title>. <source>Pharmacol &amp; Ther</source>. <year>2019</year>;<volume>199</volume>:<fpage>1</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.03.002</pub-id>.<pub-id pub-id-type="pmid">30831128</pub-id></mixed-citation></ref><ref id="cit0233"><label>233.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>H-Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C-Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>T-C</given-names></string-name>, <string-name name-style="western"><surname>Yeh</surname><given-names>L-F</given-names></string-name>, <string-name name-style="western"><surname>Hsieh</surname><given-names>W-C</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Burnouf</surname><given-names>P-A</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>B-M</given-names></string-name>, <string-name name-style="western"><surname>Hsieh</surname><given-names>T-J</given-names></string-name>, <string-name name-style="western"><surname>Dashnyam</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>Entropy-driven binding of gut bacterial &#946;-glucuronidase inhibitors ameliorates irinotecan-induced toxicity</article-title>. <source>Commun Biol</source>. <year>2021</year>;<volume>4</volume>(<issue>1</issue>):<fpage>280</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-021-01815-w</pub-id>.<pub-id pub-id-type="pmid">33664385</pub-id><pub-id pub-id-type="pmcid">PMC7933434</pub-id></mixed-citation></ref><ref id="cit0234"><label>234.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mahdy</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Azmy</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Dishisha</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mohamed</surname><given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Hassan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Aidy</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>El-Gendy</surname><given-names>AO</given-names></string-name></person-group>. <article-title>Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate irinotecan-associated toxicity</article-title>. <source>BMC Microbiol</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>53</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12866-023-02791-3</pub-id>.<pub-id pub-id-type="pmid">36864380</pub-id><pub-id pub-id-type="pmcid">PMC9979425</pub-id></mixed-citation></ref><ref id="cit0235"><label>235.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name></person-group>. <article-title>Drug-microbiota interactions: an emerging priority for precision medicine</article-title>. <source>Signal Transduct Targeted Ther</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>386</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41392-023-01619-w</pub-id>.<pub-id pub-id-type="pmcid">PMC10560686</pub-id><pub-id pub-id-type="pmid">37806986</pub-id></mixed-citation></ref><ref id="cit0236"><label>236.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kanamitsu</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Ito</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Okuda</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ogura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Watabe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Muro</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (e)-5-(2-Bromovinyl)uracil</article-title>. <source>Drug Metab Dispos</source>. <year>2000</year>;<volume>28</volume>(<issue>4</issue>):<fpage>467</fpage>&#8211;<lpage>474</lpage>.<pub-id pub-id-type="pmid">10725316</pub-id></mixed-citation></ref><ref id="cit0237"><label>237.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Whitcher-Johnstone</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tweedie</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase</article-title>. <source>Drug Metab Dispos</source>. <year>2012</year>;<volume>40</volume>(<issue>6</issue>):<fpage>1130</fpage>&#8211;<lpage>1137</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.111.044362</pub-id>.<pub-id pub-id-type="pmid">22393121</pub-id></mixed-citation></ref><ref id="cit0238"><label>238.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yu so</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>CTY</given-names></string-name>, <string-name name-style="western"><surname>Savidge</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>M</given-names></string-name></person-group>. <article-title>The role of gut microbial &#946;-glucuronidase in drug disposition and development</article-title>. <source>Drug Discov Today</source>. <year>2022</year>;<volume>27</volume>(<issue>10</issue>):<fpage>103316</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drudis.2022.07.001</pub-id>.<pub-id pub-id-type="pmid">35820618</pub-id><pub-id pub-id-type="pmcid">PMC9717552</pub-id></mixed-citation></ref><ref id="cit0239"><label>239.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thiele</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Clancy</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Heinken</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>RMT</given-names></string-name></person-group>. <article-title>Quantitative systems pharmacology and the personalized drug&#8211;microbiota&#8211;diet axis</article-title>. <source>Curr Opin Syst Biol</source>. <year>2017</year>;<volume>4</volume>:<fpage>43</fpage>&#8211;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coisb.2017.06.001</pub-id>.<pub-id pub-id-type="pmid">32984662</pub-id><pub-id pub-id-type="pmcid">PMC7493425</pub-id></mixed-citation></ref><ref id="cit0240"><label>240.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maier</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pruteanu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zeller</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Telzerow</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Brochado</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Dose</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mori</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Extensive impact of non-antibiotic drugs on human gut bacteria</article-title>. <source>Nature</source>. <year>2018</year>;<volume>555</volume>(<issue>7698</issue>):<fpage>623</fpage>&#8211;<lpage>628</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature25979</pub-id>.<pub-id pub-id-type="pmid">29555994</pub-id><pub-id pub-id-type="pmcid">PMC6108420</pub-id></mixed-citation></ref><ref id="cit0241"><label>241.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zimmermann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wegmann</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>AL</given-names></string-name></person-group>. <article-title>Separating host and microbiome contributions to drug pharmacokinetics and toxicity</article-title>. <source>Science</source>. <year>2019</year>;<volume>363</volume>(<issue>6427</issue>). doi:<pub-id pub-id-type="doi">10.1126/science.aat9931</pub-id>.<pub-id pub-id-type="pmcid">PMC6533120</pub-id><pub-id pub-id-type="pmid">30733391</pub-id></mixed-citation></ref><ref id="cit0242"><label>242.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vich Vila</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Collij</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Sanna</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sinha</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Imhann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bourgonje</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Mujagic</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jonkers</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Masclee</surname><given-names>AAM</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Impact of commonly used drugs on the composition and metabolic function of the gut microbiota</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>362</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-14177-z</pub-id>.<pub-id pub-id-type="pmid">31953381</pub-id><pub-id pub-id-type="pmcid">PMC6969170</pub-id></mixed-citation></ref><ref id="cit0243"><label>243.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagata</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nishijima</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Miyoshi-Akiyama</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kojima</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kimura</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aoki</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ohsugi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ueki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Iwata</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome</article-title>. <source>Gastroenterology</source>. <year>2022</year>;<volume>163</volume>(<issue>4</issue>):<fpage>1038</fpage>&#8211;<lpage>1052</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.gastro.2022.06.070</pub-id>.<pub-id pub-id-type="pmid">35788347</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>